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With nearly 1,350 complete genome sequences available our understanding of 
biology at the molecular level has never been more complete. A consequence of these 
sequencing projects was the discovery of large functionally unannotated segments of 
each genome. The genes (and proteins they encode) found in these unannotated regions 
are considered “hypothetical proteins”. Current estimates suggest between 12%-50% of 
the known gene sequences are functionally unannotated. Incomplete functional 
annotation of the various genomes significantly limits our understanding of biology.  
Pragmatically, identifying the functions of these proteins could lead to new therapeutics; 
making functional annotation of paramount importance.   
This dissertation describes the development of new methods for protein functional 
annotation independent of homology transfer. The hypothesis is proteins with similar 
function have significantly similar active sites. Nuclear magnetic resonance ligand 
affinity screening was employed to identify and define protein active sites. The methods 
developed were tested on a series of functionally diverse, annotated proteins including, 
serum albumins (H. sapiens, B. taurus),  and amylases (B. licheniformis, A. oryzae, B. 
amyloliquefaciens H. vulgare, I. batatas), primase C-terminal domain (S. aureus), 
nuclease (S. aureus) and the type three secretion system protein PrgI (S. typhirium).   
  
 
  
 
 Functional annotation using protein active sites require a high-resolution three-
dimensional structure of the protein.  In addition to method development, this dissertation 
describes the NMR solution structure of Staphylococcus aureus primase carboxy-
terminal domain (CTD). The primase CTD is essential for bacterial DNA replication and 
distinctly different from eukaryotes. With the rapid rise in antibiotic resistance, the 
primase CTD of S. aureus is an attractive antibiotic target.  The methods used for 
functional annotation were used to screen S. aureus primase CTD to identify the 
compound acycloguanosine as a binding ligand to primase CTD.   
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“Evolution is an obstacle course not a freeway….” S.J Gould 
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CHAPTER 1:  
 
GENERAL INTRODUCTION 
 
 
1.1 General introduction to functional genomics. Protein science has a long 
history inevitably intertwined with the advancements in chemistry, biology and physics.  
The term “protein” was initially used by Jöns Jakob Berzelius and Gerhardus Johannes 
Mulder who performed the first elemental analysis of a protein in 1839.
1
  Surprisingly, all 
proteins Berzelius and Mulder studied contained the general empirical formula; 
C400H620N100O120.
1
  
 Nearly a century after Mulder‟s work, Jensen et. al. discovered the first amino 
acids in a protein.
2
  This discovery eventually lead to the first complete amino acid 
sequence of a protein elucidated by F. Sanger in 1955.
3, 4
  Sanger followed up his work 
on protein sequencing with developing techniques for DNA sequencing
5, 6
 and 
successfully completed the first entire sequenced genome in 1977.
7
  Twenty-two years 
later, Haemophilus influenzae became the first living organism to have its entire genome 
sequenced.
8
  The following 6 years uncovered the complete genome sequences for 
Escherichia coli
9
, Drosophila melanogaster
10
, and in 2001 Homo sapiens.
11
  
Since the first published genome in 1977
7
 there has been an explosion in the 
number of complete genome sequences (figure 1.1).  As of August 2010, a total of 1350 
genomes have been completed and published representing all branches in the tree of life 
with nearly 6500 additional sequencing projects currently in progress.
12
 In addition to 
individual species sequencing efforts, the technological advances in genome sequencing 
and relative low cost have help push the development of metagenomics.  Metagenomics 
is the sequencing of samples collected directly from their environment.  This has led to 
2 
 
 
  
the complete sequencing of the human gut “microbiome”13 and the identification of 
various soil
14
 and ocean
15, 16
 microbes that could not be cultured in a laboratory setting.  
 
 
Figure 1.1 The rapid increase in sequenced genomes.  Since the first genome of a 
living organism was sequenced in 1995 there has been a dramatic increase in the total 
number of completed genomes.  The data was collected from the current status of the 
GOLD database
12
 (August 2010) which listed a total of 1350 completed genomes.   
 
A consequence of these sequencing projects was the discovery of large 
functionally unannotated segments of each genome.  The genes (and proteins they 
encode) found in these unannotated regions are considered “hypothetical proteins”. The 
term hypothetical protein is synonymous with novel gene product, unknown protein, non-
characterized protein or putative uncharacterized gene product. Current estimates suggest 
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the percent of unannotated proteins found in all sequenced genomes is between 12%-
50%.
17-19
 For example, an estimated 50% of the genes in the Escherichia coli genome 
have not been experimentally annotated.
20, 21
   
The large number of hypothetical proteins initially suggested these proteins were 
adaptations to specific environmental niches and therefore species specific.
22
 Considering 
the large degree of biodiversity this seemed like a reasonable assumption.
22, 23
  However, 
most hypothetical proteins are not species specific, but rather found in a range of 
phylogenetic distributions generating families of “conserved hypothetical proteins”.24  
For example the E. coli hypothetical protein yrdC is a member of a hypothetical protein 
family.  Homologous sequences to yrdC are also found in Bacillus subtilis, yeast, and 
humans.
24
   Proteins such as yrdC are annotated as conserved hypothetical proteins 
because no member in the family is completely functionally annotated.
24, 25
 
The most accurate and manually edited source for indentifying conserved 
hypothetical protein families, the Cluster of Orthologous Groups database (COG),
26
 
reports 2143 uncharacterized, putative or predicted orthologous families in bacteria.
25, 27
 
The large number of hypothetical and conserved hypothetical proteins significantly limits 
our understanding of biology.   From a pragmatic viewpoint, identifying the functions of 
these proteins could lead to new therapeutics; making functional annotation of these 
proteins of paramount importance.    
1.2 Introduction to protein functional annotation. The most basic level of 
functional annotation involves associating experimental evidence for a particular 
biochemical, biological process, or interaction to a specific gene.  A number of 
experimental methods exist to annotate protein function.  These include various 
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enzymatic assays,
28, 29
 protein-protein interaction hybrid assays,
30, 31
 knockout studies,
32, 
33
 gene silencing methods using antisense oligodeoxynucleotides,
34
 ribozymes
35
 or RNA 
interference  
36-38
 and recently metabolomic data.
39-41
    
While powerful and direct, often a single biochemical method cannot fully 
annotate a gene.  For example, with knockout and gene silencing studies a function is 
inferred from the change in observed phenotype between the wild-type and knockout 
organsim.
42
  Knockout studies of essential genes are relatively straightforward with the 
appropriate control experiments because if the gene is no longer active the cell dies.
43
  
However, these studies only prove the knockout gene is essential for survival.  These 
studies do not suggest a molecular function.  For knockout studies of non-essential genes 
the issue becomes even more problematic. If multiple different genes carry out a 
particular function the knockout of gene may give no change in phenotype.  Often this 
happens when a redundant gene compensates for the knockout.
44
   
Functional annotations from enzymatic assays generally describe the substrate 
used in the study or reaction mechanism.  For example, the general function ascribed to 
the enzyme responsible for catalyzing the oxidation of ethanol to acetaldehyde using 
nicotinamide adenine dinucleotide (NAD+) as a coenzyme, is alcohol dehydrogenase.
45
  
In humans, the alcohol dehydrogenase family consists of 7 unique genes each bind a 
range of alcohol substrates.
45
 The problem becomes, if a gene has multiple in vitro 
functions, which one is the “correct” in vivo function? For alcohol dehydrogenase this 
problem is even larger with multiple genes binding a range of substrates. 
The enzyme classification (EC) scheme attempts to standardize functional 
annotation from experimental methods.
46
 The enzyme classification scheme annotates 
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proteins based on 6 broad functional classes (oxidoreductases, transferases, hydrolases, 
lyases isomerases and ligases).  The functional annotation of the enzyme is further 
refined based on substrate and reaction chemistry. For the alcohol dehydrogenase 
example, all 7 genes in human are classified with the EC number of E.C 1.1.1.1 with each 
number designating a specific level of functional annotation (scheme 1.1) 
 
Scheme 1.1. Example of enzyme classification (EC) nomenclature. 
EC 1.1.1.1 Alcohol dehydrogenase  
 E.C 1.-.-.-    Oxidoreductases 
 E.C 1.1.-.-  Acting on the CH-OH group of donors 
 E.C 1.1.1.-  With NAD(+) or NADP(+) as acceptor 
 E.C 1.1.1.1  Alcohol dehydrogenase 
 
The EC method provides a concise method to annotate experimental functions 
down to specific reaction chemistry.  However, the problem becomes, what level of 
enzyme activity (Km, Vmax etc…) is needed to assign an EC number?  Additionally, for 
Escherichia coli, only 30% of the genome encodes for enzymes, the remaining 70% 
encodes for transport proteins, response regulators, structural proteins, and other non-
enzyme functions.
47
 
The sheer number of unannotated proteins significantly limits complete 
biochemical analysis of every gene within an organism.  A search of the NCBI protein 
sequence database for the term “hypothetical” retrieves nearly 1.5 million hits (August 
2010). Correspondingly, nearly 2730 unique structures deposited in the Protein Data 
Bank (PDB) are annotated as hypothetical (August 2010).  The large number of 
unannotated proteins makes pure experimental work impractical and supports the 
necessity of bioinformatics and hybrid bioinformatic/experimental methods.
21
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   Since the early stages of protein and gene sequencing, it was shown sequences 
directly relate to the evolution of a protein and in some instances the organism.
48-51
 This 
triggered the development of many sequence comparison methods attempting to 
accurately measure sequence relatedness.
52-59
  Today, multiple sequence alignments 
(MSA) are routinely used to identify sequence similarity, build phylogenetic 
relationships, and to measure evolutionary clocks.
60-65
   In addition to sequence based 
approaches, the three dimensional structure of a protein is related to molecular and 
organism evolution.  A number of reports have shown a protein structure can also 
generate structure based phylogenetic trees
66-70
 and protein domain complexity scales 
with organism complexity.
71
  Mapping the evolutionary relationship between proteins is 
fundamental to current automatic functional annotation methods. 
Current bioinformatic methods for functional annotation rely on gene and protein 
sequence, structure or hybrid sequence/structure similarity searches to automatically 
annotate protein function.
72
   These methods use the evolutionary conservation of a 
protein to infer a generalized function; „inheritance through homology‟.73-75  Homology is 
a hypothesis of the evolutionary relatedness between two or more proteins based on 
relative sequence or structure similarities.
76, 77
   The degree sequence similarity needed to 
infer homology is still being debated.  However, for highly similar sequences (≥ 70%) 
this method is effective at annotating function.
78
  
Functional annotation using homology transfer is the standard method of 
automated functional prediction. Many databases exist for automated functional 
prediction including, PFAM,
79
 Gene Ontology,
80-82
 UniProt/RefSeq/Swiss-Prot,
83
 
ProFunc,
84
 and STRING.
85
  Similarly, the COG/KOG
26
 and eggNOG
17
 databases often 
7 
 
 
  
get used for functional prediction because they contain large sets of orthologous genes. 
These databases and others have been reviewed in depth previously.
86
  Each database 
uses different methods of protein representation, different algorithms for comparison and 
different scoring functions, in the majority of cases the result is a generalized functional 
annotation.   
These automated functional annotation tools are necessary for managing the large 
volume of sequence data and remain the most popular.
87
 However, these methods often 
lead to spurious annotations because homology does not necessarily imply conservation 
of function.
88
  Additionally, these methods are often error prone and based on a small set 
of experimentally annotated proteins.
87, 89-92
 The maximum reported error rate for 
automatic functional annotation is 63% for all unannotated genes.
87, 91
  For enzymes 
approximately 30% of current automatic functional annotations are incorrect.
90
  
Differences in protein active site structure leading to different ligand specificities and 
enzyme efficiencies are suspected to be a major source of errors in automatic functional 
annotations.
78, 90, 93
   
In addition to the problems stated above, many of the automatic function 
prediction methods have reached an apparent maximum effectiveness.
94
 Essentially, (i) 
proteins with known function become overly populated in the databases so no new 
information is reported, or (ii) hypothetical proteins only match other hypothetical 
proteins.  Figure 1.2 shows a structure based similarity search of the protein Bcl-xL, 
which only retrieves other Bcl-xL proteins. Alternatively, a search of a hypothetical 
protein YtfP from E. coli only retrieves other proteins of unknown function.  Similar 
results are obtained using sequence similarity. 
8 
 
 
  
 
 
 
 
 
9 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Structure based similarity searching to predict protein function. (A) The 
anti-apoptosis protein Bcl-xL (1YSN) was compared to the Dali FSSP database
95-98
 to 
identify potential new functions.  The only significant hits (Z>2.0) were redundantly 
solved protein structures of the same sequence or Bcl-2 homologs.  (B)  The structure of 
the hypothetical protein YtfP (1XHS) was compared to the same database with the most 
significant hits having no known function or a range of predicted functions.  This 
example highlights two common problems with current structure based database 
searches: (i) a protein with known function is overly populated so no new information is 
reported, or (ii) hypothetical proteins only match other hypothetical proteins. 
10 
 
 
  
1.3 Annotation of function using ligand binding.   A major source of error in 
automatic function prediction is differences in active site structure and ligand specificity. 
Could using active site information increase functional annotation? Proteins interact with 
biological molecules including other proteins, DNA, RNA or small molecule ligands.  
Therefore, the active site of a protein must be intrinsically linked to the function of the 
protein.
99
   
Active site similarity tools for functional prediction and annotation are a rapidly 
growing trend.
100-106
  Using ligands to probe protein function is an evolutionary 
independent method to predict protein function.  This should reduce the error rate of 
traditional homology based methods because active site annotations are not limited to 
correct ortholog detection.
107
 Additionally, traditional homology based methods do not 
account for post-translational modifications or the occurrence of gene sharing.  Both of 
which have dramatic biological significance.
108-110
   
A corollary to function prediction using ligand binding is using similar functions 
to predict off-target side effects of drugs.
105, 106, 111, 112
  Recent observations of potential 
drug leads binding a range of protein targets with similar function further support the idea 
of using ligand binding to predict protein function.  Attempts have been made to relate 
ligand binding to sequence or structure similarity with minimal success.
113
 To date only a 
handful of studies have attempted to relate ligand binding with protein function.
106, 114-117
   
 The work reported in this dissertation uses this most basic definition of protein 
function to establish a uniform method for identifying functional similarity.  The 
hypothesis is proteins with similar function will bind to a set of similar biologically 
relevant small molecules at a specific active site. The hypothesis is supported by reports 
11 
 
 
  
showing functional regions of a protein are more stable relative to the remainder of the 
protein sequence undergoing random drift.
118, 119
 The correlation between ligand binding 
sites, ligand structure and protein function has also been demonstrated by a network of 
ligand binding-site.
120
 A variety of computational methods have attempted to exploit the 
stability of functional regions by identifying ligand binding sites as a method to predict 
function.
121, 122
 Unfortunately, the combined requirements of predicting the ligand, the 
binding site, and a similarity to an annotated proteins leads to a high level of ambiguity.  
This dissertation will discuss the development of high-throughput screening 
methods to detect ligand binding and discovery protein active sites.  There is an inherent 
similarity between the methods used to detect ligand binding for functional annotation 
and drug discovery.  In this dissertation the high-throughput NMR screening method to 
detect ligand binding were originally developed to identify binding ligands and protein 
active sites for attractive drug targets.  
Drug discovery is a uniquely complex problem in science and medicine.
123, 124
  
This is further complicated by the fact that each disease is distinct and requires its own 
efficient strategy to successfully develop safe therapeutics.
125
  A central theme in drug 
discovery research is attempting to identify highly specific ligands (nM-pM KD) that bind 
a biological target.  Therefore, the methods used to detect ligand binding in drug 
discovery research are also amenable to identifying binding ligands for functional 
annotation. In this dissertation, the techniques developed for high-throughput NMR 
screening were used to identify binding ligand to a number of functionally diverse 
proteins including, serum albumins (H. sapiens, B. taurus),  and amylases (B. 
licheniformis, A. oryzae, B. amyloliquefaciens H. vulgare, I. batatas), primase C-terminal 
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domain (S. aureus), nuclease (S. aureus) and the type three secretion system protein PrgI 
(S. typhirium).   
1.4 General principles of high-throughput nuclear magnetic resonance 
screening.  From target selection to pre-clinical trials, nuclear magnetic resonance 
(NMR) has established itself as an invaluable tool for the chemist working in the drug 
discovery industry.
126, 127
 The flexibility provided by NMR comes from various 
molecular probes that include chemical shifts, relaxation parameters (T1, T2), spatial 
information (nuclear Overhauser effects, NOE), and diffusion rates. Each parameter is 
uniquely sensitive to the local chemical and physical environment of a sample and 
provides structural information at atomic resolution for both small (<1000 Da) and large 
(> 1000 Da) biological molecules. Additionally, in recent years NMR has proven more 
valuable to the drug discovery process than simply a tool for structural studies of 
biological molecules.
126
  This is most apparent with the increase use of NMR as a critical 
component for high-throughput screening (HTS).  The current methods for NMR affinity 
screening methods are listed in table 1.1.  
NMR affinity screening methods complement structural biology efforts by 
validating chemical leads prior to initiating a structure-based drug design program.
128-133
 
Target focused screening techniques, such as SAR by NMR,
134
 RAMPED-UP NMR,
135
 
STD-NMR,
136
 and NMR-SOLVE
137
 were developed to identify ligands that bind a 
therapeutic target in a biologically relevant manner (table 1.1).  This is often done by 
observing chemical shift changes in two-dimensional 2D 
1
H-
15
N HSQC spectra of the 
protein in the presence and absence of a small molecule ligand.  Target based NMR 
screening methods provide invaluable information about the nature of a ligand binding 
13 
 
 
  
site.
134, 138-143
  However, these methods often require high concentrations (≥ 100 M) of 
expensive 
15
N isotope enriched protein and demand large amounts of data collection 
time.  Therefore target based screening methods are often better suited for secondary 
follow-up screens.
115, 144, 145
 
Unlike the target focused methods, ligand focused techniques detect binding 
events by identifying changes in the free 
1
H ligand spectrum upon the addition of a 
protein. Many ligand focused methods have been developed that exploit various NMR 
molecular probes including saturation transfer differences,
136, 146
 line-broadening 
changes,
147-150
 diffusion rate changes,
151
 
19
F NMR,
149, 152
 spin labels,
150
 and transfer 
NOEs
153
 (table 1.1).  The ligand focused methods are relatively quick (1-5 min), do not 
require 
15
N enriched samples, and are sensitive at much lower protein concentrations (≤ 5 
M). Therefore, these methods have rapidly become invaluable to high-throughput 
screening with a high success rate of identifying potential inhibitors.
154-159
 
This dissertation will focus on using and developing screening methods for high-
throughput NMR screening to functionally annotate proteins with no known function.    
The two central methods used are the 1D line broadening experiment and the 2D 
1
H-
15
N 
HSQC experiment.  These methods will be used in tandem for each screen to detect and 
confirm ligand binding.  The tiered approach to NMR screening maximizes the total 
number of hits identified while reducing the overall sample and data collection 
requirements.
144
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Table 1.1 Various NMR screening methods and the NMR parameter used to detect ligand binding.
Screening 
Technique 
NMR Parameter used to Detect Ligand Binding 
 Labeled 
Protein? 
Limited by 
Protein MW? 
Ref. 
MS/NMR 
Retention on size-exclusion column & chemical 
shift changes 
Yes Yes 
145
 
Multi-Step NMR 
Line-broadening change (T2) & chemical shift 
changes 
Yes Yes 
144
 
RAMPED-UP 
NMR 
Chemical shift changes, screening multiple proteins Yes Yes 
135
 
SAR by NMR Chemical shift changes Yes Yes 
134
 
SMILI-NMR In-cell chemical shift changes Yes Yes 
160
 
STINT-NMR In-cell chemical shift changes Yes Yes 
161, 162
 
SLAPSTIC 
Line-broadening change (T2) due to protein spin 
label 
Yes No 
150
 
AIDA-NMR 
Line-broadening change (T2) due to protein-protein 
complex formation, labeled protein or Trp reporter 
in ligand binding site 
Yes/No Yes 
147, 148
 
TINS 
Line-broadening change (T2) due to binding to an 
immobilized protein target 
No Yes 
163
 
3-FABS Chemical shift changes, requires fluorinated ligands No No 
152
 
Affinity NMR Change in translational diffusion No No 
151
 
FAXS 
Line-broadening change (T2) due to ligand 
competition, requires fluorinated ligands 
No No 
149
 
INPHARMA Transfer nuclear Overhauser effect (NOE) No No 
164
 
NOE pumping Transfer nuclear Overhauser effect (NOE) No No 
153
 
SALMON Saturation transfer difference from solvent No No 
165
 
STD NMR Saturation transfer difference from protein No No 
136
 
WaterLOGSY Saturation transfer difference from solvent No No 
146
 
1
4
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1.5 Summary of work. The challenges of functional annotation described above 
are a product of having only a limited collection of bioinformatic tools based on a small 
set of experimentally characterized proteins.  This dissertation focuses on the 
development and implementation of new experimental approaches to extend functional 
annotation of unknown proteins. First, in chapter 2 I will discuss the development of a 
technique to measure relative dissociation constants (KD) from an NMR high-throughput 
ligand affinity screen. The method is used to qualitatively select the best binding 
ligand(s) that will be used to probe the active sites of the various targets and identify a 
biological function.   
Chapters 3 and 4 will discuss the implementation and optimization of the 
Functional Annotation Screening Technology by NMR (FAST-NMR).
166
 The FAST-
NMR method is a tiered approach to high-throughput NMR affinity screening to identify 
binding ligands and proteins active sites. The protein active sites are compared to a 
database of active sites using the Comparison of Active Site Similarity (CPASS) tool.
103
 
Functional similarity is inferred through similarities in protein active sites. 
 In chapter 3 I show the utility of the FAST-NMR method by establishing a 
functional similarity between the type III secretion system (T3SS) protein PrgI from S. 
typhirium and the human apoptosis regulating protein Bcl-xL. This relationship would 
not have been identified with current methods because sequence and structure similarity 
are below the limit of acceptable homology. In chapter 4, I validate the FAST-NMR 
method by expressing, purifying and screening the S. aureus nuclease protein.  I show the 
FAST-NMR method correctly identifies the best binding ligand thyamdine-5‟-
triphosphate and active site of the protein.  Additionally, the FAST-NMR binding site 
16 
 
 
  
correctly identified a nucleotide (thymidine-3‟,5‟-diphosphate) bound nuclease structure 
(1TR5) as the best match in the CPASS search.  I will also discuss the implementation to 
two new pulse sequences and improvements to automated data collection.  These 
improvements to the screening technology dramatically increase throughput and 
flexibility of FAST-NMR. 
The FAST-NMR method was initially developed as a tool for functional 
annotation.  However, the generalized tiered approach to NMR screening used by FAST-
NMR is also valuable to drug discovery.  In chapter 5 I will discuss the structure, 
dynamics and high-throughput screening of the DnaG primase C-terminal domain from 
Staphylococcus aureus.  The C-terminal domain of primase specifically interacts with the 
DnaC helicase to initiate primer synthesis and is therefore an attractive drug target for 
antibiotic development.  Using the FAST-NMR screening methods I show 
acycloguanosine binds to the C-terminal domain of primase at the important helicase 
interaction site.  This result was used to identify a set of structurally similar compounds 
for further antibiotic development.  
A surprising result from the S. aureus primase CTD structure was the observation 
of a potential phylogenetic dependence on protein structure similarity.  In chapter 6 I 
expand on this observation by completing a thorough analysis of functionally identical 
protein structures and report a maximum sequence and structure similarity between the 
two bacterial phyla, Firmicutes and Proteobacteria.  Additionally, the results from 
chapter 6 were used to show a constant rate of structural drift during protein evolution.  
Finally, in chapter 7 I discuss a new technique for functional annotation that 
evolved from the FAST-NMR methodology, but is independent of sequence, structure or 
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evolutionary information.  The method involves the development of a robust scoring 
system to measure ligand binding profile similarities.  A ligand binding profile is defined 
as a set of ligands that bind a protein from a high-throughput ligand affinity screen using 
a standardized chemical library. Functional annotation is inferred by clustering unknown 
proteins with previously annotated proteins that share similar ligand binding profiles. The 
method was tested on two sets of control proteins, 2 serum albumins (H. sapiens, B. 
taurus) and 5 amylases (B. licheniformis, A. oryzae, B. amyloliquefaciens H. vulgare, I. 
batatas). 
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CHAPTER 2: 
 
ESTIMATING PROTEIN-LIGAND BINDING AFFINITY USING HIGH-
THROUGHPUT SCREENING BY NMR 
 
2.1 INTRODUCTION  
In chapter 1 the general principles for using NMR as a high-throughput screening 
tool were discussed in the context of functional annotation and drug discovery.   For a 
high-throughput screen to be successful a hit must efficiently alter the biological activity 
of a protein or other biological target molecule and disrupt its normal function.
1
  This is 
generally accomplished by a small molecule changing the dynamics of a protein 
2
 or 
interfering with a critical protein-protein interaction.
3
  For a small molecule hit identified 
from a high-throughput screen to become a viable drug candidate it must elicit these 
effects while simultaneously demonstrating in vivo efficacy in the absence of toxic side-
effects. Thus, an important component of the drug discovery process is the verification 
that a small molecule ligand actually binds the protein target in a selective and 
biologically relevant fashion. 
Selectively is measured by binding affinity which is governed by the equilibrium 
parameters of a binding interaction.  The equilibrium state of a binding interaction is 
described by the concentration of the free ligand [L]F, free receptor [P]F, and the receptor-
ligand complex [PL]. For single-site binding, the relative ratios of these concentrations 
are governed by the kinetic on (kon) and off (koff) rates between the free and bound forms 
as described in eq 2.1. 
                                   
[2.1]
 
43 
 
 
  
The strength of a ligand‟s binding affinity is quantified by the dissociation 
constant (KD), or simply the ratio of koff and kon rates.  
                                             
[PL]
[P][L]
k
k
K FF
on
off
D
    
[2.2] 
 The selectivity of a ligand to a particular target biological molecule is inversely 
proportional to the strength of the KD.  Highly selective compounds will have a KD in the 
pM-nM range while weaker ligands will exhibit binding in the M-mM range.  Often a 
HTS will rely on the identification of M-mM binding ligands coupled with structural 
information to develop high affinity ligands through combinatorial approaches.   
Similar to traditional measurements,
4
 NMR methods rely on the collection of 
multiple data points to accurately determine a KD for a protein-ligand interaction.  This 
approach is usually impractical in a high–throughput mode that requires a rapid method 
for characterizing and ranking binding affinities. Examples of high-throughput KD 
measurements using 1D NMR experiments have been described that use 
19
F-containing 
compounds
5, 6
 or the displacement of known low-affinity inhibitors. 
7, 8
  Unfortunately, 
these approaches are typically limited in practice because known low-affinity inhibitors 
or a large library of “drug-like” and structurally diverse 19F-containing compounds are 
not available for a wide range of protein targets.  To increase the utility and throughput of 
NMR affinity screening a rapid and universal method to determine binding affinity was 
still needed. 
This chapter discusses a new NMR screening method that can determine the 
relative ranking of binding affinities using a variation of traditional 1D 
1
H NMR line-
broadening experiments.
9, 10
  This approach correlates the ratio of NMR peak intensities 
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for free and bound ligands to the fraction of bound ligand in a protein-ligand complex. 
This method is illustrated by using human serum albumin (HSA) as a model protein.  
HSA is also an important secondary target for efficacy screening and a well-established 
system for monitoring protein-ligand interactions.
11
 
 
2.2 THEORY 
2.2.1 Single point KD measurements. Binding interactions between a protein 
(MW > 5000 Da) and a low molecular weight ligand (MW < 500 Da) can be examined 
by using the decrease in NMR peak intensity that occurs upon the addition of a protein to 
a solution with constant ligand concentration. NMR line-broadening experiments follow 
an opposite protocol from typical experiments that measure KD values, where variable 
protein concentrations are added to solutions that contain a constant ligand concentration. 
Thus, a different form for the standard Langmuir binding isotherm (eq 2.2) was required. 
Rearrangement of eq 2.2 produces the following binding isotherm, in which fB 
represents the “fractional occupancy”, or the fraction of bound ligand. 
         
B
DT
F
[PL] 1
f
K[L]
1
[P]
      [2.3] 
It is assumed in many types of binding studies the total ligand concentration [L]T 
is approximately equal to the free ligand concentration; however, this assumption is not 
applicable to the NMR line-broadening experiments used in this study because [L]T is not 
necessarily in  excess of the maximum complex concentration [PL]. Also, a direct 
measurement of the free protein concentration is not possible for the method described in 
this report. Therefore, eq 2.3 was derived to describe this situation in terms of the total 
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protein concentration [P]T and total ligand concentration [L]T that are known to be present 
in the system (see appendix 2A and 2B for definition of variables and equation derivation 
respectively).   
    
B
DT
2
T T D T T D D T
[PL] 1
f
2K[L]
1
([P] [L] K ) ([P] [L] K ) 4K [L]
   [2.4] 
Equation 2.4 can be simplified to approximate the fractional occupancy in terms 
of the total ligand concentration [L]T and total protein concentration [P]T by using a 
Taylor series expansion and the assumption that  [L]T > [P]T.  
                                             
T
B
T T D
[P][PL]
f
[L] ([L] K )
         [2.5] 
The fractional occupancy for a protein-ligand complex can be measured using a 
ratio of NMR peak intensities (1-IB/IF), where IB is the sum of ligand NMR peak 
intensities in the presence of the protein and IF is the sum of NMR peak intensities for the 
free ligand. Therefore, Bexpt (the NMR peak intensity ratio) represents an easily 
measurable response of ligand binding that can be described in terms of the fraction of 
bound ligand (fB) and the NMR linewidth for the free ( F) and bound ( B) states (see 
Appendix B for derivation). 
B
expt
BF
B
F
I 1
B =1 1
νI
1 f ( 1)
ν
        [2.6] 
Combining eq 2.5 and eq 2.6 leads to a new binding isotherm for this system, as 
shown below, 
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                 B
expt
TF
T D
I 1
B 1 1
c[P]I
1
[L] K
            where  B
F
ν
c 1
ν
  [2.7] 
The unit-less NMR linewidth ratio constant (c), as defined in eq 2.7, accounts for 
the proportional change in ligand linewidth upon binding of a ligand to a protein. Once a 
ligand is bound, the free ligand linewidth ( F) of a ligand resonance adopts the linewidth 
of the protein ( B) and the increase in linewidth produces a corresponding decrease in 
peak intensity measured by the ratio of NMR peak intensity (B).  
The dissociation equilibrium constant for a protein-ligand complex that is 
calculated using eq 2.7 is based on relative changes in NMR peak intensity by fitting the 
given binding isotherm to a complete protein titration curve. This is impractical in the 
context of an NMR high-throughput screen where only a single titration point is 
measured. However, eq 2.7 can be rearranged to solve for KD to yield an estimate for KD 
that is based on [P]T, [L]T, c and Bsingle, where Bsingle is the fractional occupancy at a 
single protein concentration. The resulting expression is shown in eq 2.8.  
           
T
D T T
single
c[P]
K c[P] [L]
B
             [2.8] 
For proteins such as HSA that possess multiple non-specific binding sites, the 
decrease in ligand signal at a relatively high protein concentration will be an average of 
specific and non-specific binding. To correct for this effect, the non-specific binding term 
n[P]T that corresponds to a linear increase in fraction bound with the addition of protein is 
simply added to eq 2.7, as shown in eq 2.9. 
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T
TF
T D
I 1
B 1 1 n[P]
c[P]I
1
[L] K
    [2.9] 
 
2.3 EXPERIMENTAL 
2.3.1 Materials. The HSA (essentially fatty acid free, ≥ 96% pure), choline 
bromide (~ 99% pure), clofibrate, furosemide, phenol red, phenylbutazone, phenytoin (~ 
99% pure), sodium salicylate, tolbutamide, uridine 5‟-monophosphate (98-100% pure) 
and warfarin (> 98% pure) were purchased from Sigma (St. Louis, MO). The 
bromophenol blue (ACS reagent grade, 95% pure), bromocresol green (ACS reagent 
grade, 95% pure), and ibuprofen were from Sigma-Aldrich (Milwaukee, WI). The 
dimethyl sulfoxide-d6 (99.9% D), deuterium oxide (99.9 atom% D) and naproxen (98% 
pure) were obtained from Aldrich (Milwaukee, WI). The 3-(trimethylsilyl)propionic-
2,2,3,3-d4 acid sodium salt (98% D) was purchased from Cambridge Isotope (Andover, 
MA). The potassium phosphate dibasic salt (anhydrous, 99.1% pure) and monobasic salt 
(crystal, 99.8% pure) were purchased from Mallinckrodt (Phillipsburg, NJ).  
2.3.2 Apparatus. All NMR spectra were collected on a Bruker 500 MHz Avance 
spectrometer (Billerica, MA) equipped with a triple-resonance, Z-axis gradient cryoprobe 
and  using a Bruker BACS-120 sample changer and IconNMR software for automated 
data collection. Spectra were collected at 298 K using 512 transients, a sweep-width of 
6009 Hz, 16 K data points and a relaxation delay of 2.0 s. The residual H2O resonance 
signal was suppressed with presaturation during the recycle delay and a composite pulse 
train prior to the 90
o
 excitation pulse.  The total experiment time, including sample 
changing for each spectrum, was approximately 33 min.  
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2.3.3 Sample Preparation. All small-molecule ligands that were used in this 
study were selected based on their previously reported KD values for HSA and their good 
solubility in an aqueous solution.
11
  The small-molecule ligand samples were individually 
prepared in 10 mL stock solutions that contained 20 µM ligand, 1% (v/v) dimethyl 
sulfoxide-d6 (DMSO-d6), 10 µM 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt 
(TSP) and pH 7.0 (uncorrected) 50 mM potassium phosphate buffer prepared in 
deuterium oxide.  
A series of ten HSA stock solutions were prepared in deuterium oxide
 
by making 
serial dilutions from a 200 μM master solution of HSA in deuterium oxide. The final 
concentrations of HSA in these stock solutions ranged from 0 µM to 200 μM and were 
prepared so that a 10 µL addition of the HSA stock solution to 490 μL of a free ligand 
solution resulted in final concentrations of 0 µM, 0.1 µM, 0.2 µM, 0.4 µM, 0.6 µM, 0.8 
µM, 1 µM, 2 µM, 3 µM, and 4 µM HSA, respectively. These mixtures were prepared 
individually for each ligand in 1.5 mL microcentrifuge tubes and then transferred to 
NMR tubes. The sample for each titration that contained 0 μM HSA was used as the 
reference for calculating the free ligand intensities (IF) and free ligand linewidths ( F).  
All binding studies performed with these solutions were conducted at 25ºC. 
2.3.4 1D 
1
H NMR binding curves. Spectra were processed with the ACD/1D 
NMR manager (Advanced Chemistry Development, Inc., Toronto, Ontario). A linear 
prediction algorithm was applied to the FID in the forward direction and the resulting 
FID was Fourier transformed. The NMR spectrum was phase-adjusted and baseline-
corrected. The residual water signal was removed for spectrum clarity by the solvent 
removal function in ACD.  This function zeros‟ the spectrum baseline at the residual 
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water signal. All ligand resonance peaks were visually selected and peak positions were 
measured relative to a TSP reference set to 0.0 ppm. Peak intensities were measured 
relative to the DMSO-d6 peak at 2.69 ppm that was normalized to an intensity of 1.00.  
The DMSO-d6 peak was completely recovered during the 1D 
1
H NMR experiment using 
a 2.0 s recycle delay. This is >3x  the T1 for DMSO in D2O at 298K (0.3-0.5 s) and is 
acceptable for complete relaxation.
12, 13
  Individual peak intensities in the aromatic region 
for each ligand were summed to obtain the free (IF) and bound (IB) intensities at each 
titration point. The peak-intensity ratios were plotted versus total protein concentration 
and fit to eq 2.9 using the program KaleidaGraph version 3.52 for Windows (Synergy 
Software., Reading, PA) to estimate the KD value for each protein-ligand complex. The 
average NMR linewidth ratio (c) for each ligand was estimated by using eq 2.7, where B 
was taken to be approximately 94.2 Hz using a previously measured correlation time for 
HSA of 41 ns.
14
  The value for F was calculated as described in the next section. The fit 
of each binding curve was constrained so that KD ≥ 0 in these studies.   
2.3.5 Measuring a free ligand NMR linewidth ( F). To measure the free ligand 
linewidth ( F) for use in eq 2.7, the NMR spectrum for each free ligand (i.e., as obtained 
in a solution containing no HSA) was processed as described above to avoid any 
distortion in linewidth resulting from processing. NMR peak linewidths were measured 
using the ACD/1D NMR manager peak fitting routine. The average peak linewidth was 
used to report F for each ligand and to calculate the NMR linewidth ratio. 
2.3.6 Simulated high-throughput screening by NMR. To simulate the outcome 
of an NMR high-throughput screening assay, a single protein concentration [P]T from the 
full titration curve was used. On average, the 0.2 M HSA titration point yielded a large 
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response for all 12 ligands without reaching saturation. The static total ligand 
concentration [L]T was 20 M. A simulated response curve was generated by fitting a 
range of KD values to a range of ideal Bsingle values calculated using eq 2.8. The measured 
Bsingle value for each ligand at the 0.2 M HSA titration point was used to calculate a 
single-point binding constant from eq 2.8 and compared to the simulated response curve. 
This simulated experiment used both the individual c values calculated for each ligand 
from the full titration experiment and an average c value calculated from the 12 NMR 
titration curves. The single-point dissociation equilibrium constant for each ligand was 
calculated using this average c value. 
 
2.4 RESULTS AND DISCUSSION  
2.4.1 Measuring KD from 1D 
1
H NMR line-broadening experiments. The 
development of NMR-based screening assays that monitor changes in chemical-shifts or 
linewidth as a means to identify or verify initial chemical leads has evolved to become an 
increasingly important component of drug discovery efforts in the biotechnology and 
pharmaceutical industry.
15, 16
  Nevertheless, the direct measurement of a binding affinity 
from a high-throughput NMR screen is generally lacking.
5, 6, 8, 17, 18
  A decrease in the 
intensity of a ligand's NMR signal in the presence of a protein is commonly used in 
NMR-based screens to monitor the formation of a protein-ligand complex. 1D 
1
H NMR 
spectra of small-molecules (MW ≤ 500 Da) usually have extremely sharp peaks due to 
slow dipole-dipole relaxation (T2).
19
  Binding to a high molecular weight agent like a 
protein induces peak broadening and a corresponding decrease in the ligand's NMR 
signal intensity because the bound ligand now experiences the shorter relaxation time of 
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the protein. This effect is illustrated in figure 2.1 using binding by the protein HSA to the 
drugs phenytoin and naproxen as examples.  
The observed increase in ligand linewidth in such an experiment will depend on a 
number of factors that include the dissociation equilibrium constant for the protein-ligand 
interaction, KD. In general, the observed change in the ligand's linewidth ( obs) for the fast 
exchange limit will follow the result shown below. 
                   obs F B B Fν ν f (ν ν )
       where    
DT
T
B
K[L]
[P]
f     [2.10] 
In eq 2.10, fB is the fraction of the bound protein-ligand complex, F is the free ligand 
NMR linewidth, and B is the linewidth for the bound state of the ligand (see the 
appendix B for an explanation regarding the above expression for fB).  Eq 2.10 shows that 
an increase in the observed ligand linewidth will be related to the free and bound ligand 
linewidths and the value of KD for the protein-ligand complex. If it is assumed the 
linewidth of the protein-ligand complex is significantly larger than that for the free 
ligand, the ratio of the ligand linewidth in the presence and absence of the protein should 
represent the remaining free ligand concentration, as indicated by eq 2.7. 
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Figure 2.1. Relative line broadening of in response to protein binding. 1D 
1
H NMR 
spectra for titration of 20 M of the drugs phenytoin (A) and naproxen (B) with 
increasing concentrations of HSA. The concentrations of HSA were as follows: (i) 0 µM, 
(ii) 0.4 µM, (iii) 1 µM, (iv) 2 µM, and (v) 4 µM. As the protein concentration increases, 
the intensity of the ligand NMR signal decreases due to the bound ligand adopting the 
shorter relaxation time of the protein. The decrease in the ratio of NMR signal intensity 
( B
F
I
1
I
) is proportional to the degree of binding such that tighter binding ligands (B) will 
relax more quickly than weaker binding ligands (A).  
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This relationship assumes there is a lack of any significant contribution of 
chemical or dynamic exchange to the observed change in linewidth. This is a reasonable 
assumption in the context of a high-throughput NMR screen against a single protein 
target. First, initial chemical leads tend to be weak binders in the fast exchange regime, 
where the linewidth change of the ligand will be dominated by the linewidth of the 
protein. Second, biologically relevant binders will interact with the same or similar 
binding sites on the protein. Under these circumstances, the ligand may experience a 
relatively constant contribution of chemical and dynamical line-broadening. Thus, the 
minimal contribution of linewidth from exchange processes should not affect the relative 
ranking of the ligand binding affinities that are obtained when using such an experimental 
approach.              
The validity of this method for high-throughput screening by NMR was examined 
by using twelve ligands with previously determined binding affinities to HSA.
11, 20-23
 
These ligands were used to examine the relationship between the estimated values for KD 
and the relative ratios of the NMR Peak intensity. Samples containing 20 M of any 
given ligand were titrated with solutions that contained 0 to 4 μM of HSA to develop full 
binding curves for each of the twelve ligands. As a control, two suspected non-binding 
ligands (i.e., choline bromide and uridine-5‟-monophosphate) were also screened in the 
presence of HSA with no observable decrease in signal (data not shown). The KD values 
that were obtained by this method (see table 2.1) were experimentally determined by 
directly fitting the resulting binding curve of each ligand to eq 2.9. These fits gave a sum 
of residuals squared that ranged between 0.977 and 0.998 over the ten concentrations of 
HSA that were tested. Figure 2.2 shows the results that were obtained for three of the 
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tested ligands, which have previously reported dissociation equilibrium constants that 
ranged from 0.7 to 36.8 M. These figures and the corresponding fits illustrate the ability 
of this approach to be used with ligands that have weak-to-moderate strength binding to 
proteins such as HSA. 
 
 
Figure 2.2. NMR ligand binding titration. Experimental fractional occupancy (Bexpt) for 
naproxen (), tolbutamide (), and phenol red () versus the total concentration of 
HSA. The best-fit lines were obtained using eq 2.9. The r
2
 for these best-fit lines are given 
in the text and the KD values that were obtained from these lines are provided in table 2.1.  
 
2.4.2 Co-variance of KD and the NMR linewidth ratio (c). Ideally, the 
dissociation equilibrium constant (KD) and the NMR linewidth ratio (c) could be 
simultaneously derived by fitting eq 2.7 to the experimental NMR binding curves. 
Unfortunately, KD and c are completely covariant. This requires an approximation for c in 
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order to calculate KD from the NMR binding curves. The linewidth of a protein ( P) may 
provide a lower estimate of B if it is assumed that B is dominated by the protein 
linewidth ( P). Estimations of P can be made from the correlation time ( c) of the protein 
by using the intramolecular dipole-dipole relaxation rate constant (T2
-1
). 
24
 
0 0
1 2
2
3
T b {3J(0) 5J(ω ) 2J(2ω )}
20
     [2.11] 
Where 
2
o
3
μ γ
b=-
4π r
h
, c
2 2
c
τ
J(ω)
1 ω τ
 and B0     [2.12] 
In these equations, J( ) is the normalized spectral density function, 
permeability, 
-1
), ħ is Plank‟s constant, B0 
is the static magnetic field strength and r is the hydrodynamic radius of the protein. In 
addition, the Stokes-Einstein equation can be used to relate c to the molecular weight 
(MW) for a globular protein,
25
 
   
3
c
4π ηr
τ
3kT  
  with, 
c
MW
τ * (ns)
2400
      [2.13] 
where T is the temperature, k is the Boltzmann constant,  is the viscosity of the solvent, 
r is the radius and  is the shape constant.  
 The reliability of eq 2.13 to approximate a protein correlation time from its 
molecular weight is illustrated from a comparison between 27 experimental c values 
26, 27
 
and correlation times predicted using eq 2.13 (figure 2.3A). A linear best-fit was obtained 
with an R
2
 of 0.81 in this case. For a high-throughput screen, p can be estimated from 
the molecular weight of a protein by using this approximation for c with a shape constant 
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of 1.32 combined with eq 2.11 and 2.12. The shape constant was determined by 
optimizing a linear fit between the experimental and predicted c values shown in figure 
2.3A by varying . The result is an approximate correlation between P and MWP, as 
shown in eq 2.14.  
P Pν 1.26 MW          [2.14] 
This dependency of linewidth on the size and shape of a protein is plotted in 
figure 2.3B. For HSA (MW, 66 kDa), the correlation time (41 ns) has previously been 
measured using time-resolved fluorescence.
14
  This correlation time was used to calculate 
the  value used for P, which was 94.2 Hz. 
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Figure 2.3. Approximation of protein linewidth based on molecular weight. (A) 
Comparison of 27 experimental protein correlation times determined using NMR 
dynamics data with correlation times predicted from protein MW using eq 2.13 and a 
shape constant of 1.32. A best-fit line is shown with a slope of 1 and an R
2
 of 0.81. (B) A 
plot of linewidth versus protein molecular weight based on eq 2.13 for spherical proteins 
with  of 1 (solid line) and elliptical proteins with  of 1.32 (dashed).  
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The free ligand linewidth ( F) can be measured directly from the NMR spectra of 
the free ligand using an average ligand linewidth. Average F values measured from the 
free ligand NMR spectra are reported in table 2.1. However, for large and diverse 
chemical libraries it may not be feasible to measure an accurate linewidth for each 
compound. Alternatively, F is generally between 1 and 2 Hz for many small-molecules 
(MW, 500 < Da), which provides a reasonable estimate for F to calculate an average 
value for c. 
   2.4.3 Sensitivity of KD and NMR linewidth Ratio (c). A closer examination of 
eq 2.7 indicates the NMR linewidth ratio (c) acts as a scaling factor in the calculation of 
KD, with a larger c value resulting in a proportionally larger KD value. Unfortunately, 
small variations or errors in the measurement of F will result in proportionally larger 
variations in both c and KD. In the context of high-throughput screening by NMR, an 
incorrect estimate of c will result in a systematic underestimation or overestimation of 
KD. However, the relative ranking of the ligand binding affinities will be maintained. In 
addition, a lower limit to c is inherently defined by eq 2.7. 
2.4.4 Comparison of estimated KD values with literature values. Table 2.1 
shows the dissociation equilibrium constants that were measured for twelve ligands 
known to bind HSA by using the 1D 
1
H NMR line-broadening method that is described 
herein. Previously reported KD values from the literature are also listed for these twelve 
ligands.
20-22, 28-52
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Table 2.1. Comparison of KD values determined by NMR and reported in the literature under similar conditions 
Ligand Literature KD (µM) Line width (Hz) c 
Measured KD 
(µM) 
Ibuprofen 
0.3
50
 0.33
45
 0.37
49
 0.5
45
 0.52
34
 1.0
47
 1.25
30
 1.26
40
 1.74
41
 1.89
33
 2.08
30
 
2.8
35
 4.76
41
 5.56 
35
 5.68
38
 8.33
33
 7.17
29
 18.2
50
  23.81
53
 25.64
53
 
2.3 ± 0.2 41.5 0.5 ± 1.0 
Naproxen 0.83
42
 1.25
47
 7.09
39
 10.6
46
 23.7
44
 1.8 ± 0.6 51.3 0.7 ± 1.2 
Clofibrate 1.32
47
 1.7 ± 0.1 54.3 1.7 ± 3.4 
Bromophenol Blue 0.67
43
 2.5 ± 0.4 37.8 3.0 ± 2.3 
Furosimide 5.26
36
 52.63
28
 1.5 ± 0.8 57.6 3.4 ± 3.0 
Warfarin 1.61
39
 2.17
37
 2.27
37
 2.94
36
 3.03
37
 3.4
31
 3.7
46
 3.85
32
  4.76
37
 5.3
31
 6.8
31
 2.3 ± 0.9 41.7 4.0 ± 2.8 
Phenylbutazone 0.67
36
 1.9
31
 5.43
32
 8.4
31
 11
31
 15.13
34
 3.7 ± 0.6 25.2 6.5 ± 2.9 
Salicylate 5.26
36
 15.15
37
 32.15
37
 35.71
37
 141
46
 1.4 ± 0.8 63.6 7.2 ± 2.9 
Bromocresol Green 0.63
48
 1.43
43
 2.7 ± 0.3 35.1 7.4 ± 2.1 
Tolbutamide 25
36
 31.25
39
 2.7 ± 0.4 34.9 10.2 ± 1.2 
Phenol Red 35.7
43
 1.6 ± 0.5 58.7 36.8 ± 6.5 
Phenytoin 
50
20
 58.8
20
 62.5
20
 71.43
53
 96.15
20
 111
20
 1342.3
20
 153.85
20
 211
20
 
244
20
 568.2
20
  
2.0 ± 0.6 46.8 131.6 ± 12.5 
6
0
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In general, there is good agreement between the KD values that were estimated by 
NMR and those values reported in the literature. Variations in temperature, pH or buffer 
conditions may partly explain the range of KD values observed in the literature. There 
may have also been differences in the fatty acid content of the HSA preparations, which 
can affect the reported KD values. Thus, 1D 
1
H NMR line-broadening measurements 
appear to provide reliable preliminary estimates for binding affinities as part of a high-
throughput screening assay.      
One limitation of the model that was used for this analysis is the assumption of 
only a single site interaction between the ligand and protein. There are many cases for 
which multisite binding or other effects (e.g., allosteric interactions) are present that give 
rise to more complex binding models.
11, 19
 Multisite binding also contributes to the 
relatively large range of KD values reported in the literature for HSA ligands. In these 
situations, the KD values listed in table 2.1 (for both the NMR and literature results) 
should be regarded as weighted averages and as measures of the global affinity for a 
particular ligand with HSA. This averaging effect may be more pronounced for the NMR 
method than for other techniques because of the practical limit in ligand concentration 
that could be used to provide a measurable signal. There is also a practical limit to the 
number of concentrations and data points that could be sampled to give a binding curve. 
This effect may explain why the NMR-derived KD values tend to be lower than the 
literature values, because the use of higher concentrations for the NMR studies would 
give a higher weight and likelihood to the detection of weaker interactions between the 
ligand and protein.  
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A number of other practical limitations also need to be considered in the use of 
NMR for these binding studies. For instance, the NMR resonances that are specifically 
involved with protein binding have been shown to exhibit the most dramatic changes in 
linewidth.
9, 10
  Therefore, there are inherent errors caused by summing all peak intensity 
and selectively excluding ligand peaks due to an overlap with buffer and protein 
resonances. In addition, errors in the measurement of peak intensity might arise at lower 
ligand concentrations due to the difficulty of accurately identifying and selecting peaks 
under these conditions. The result could be either a low or high estimate for KD, 
depending on the disparity in linewidth changes and on which peaks are excluded. Using 
overlapping peaks would introduce an alternative error because the observed intensity is 
the sum of multiple peaks that cannot be easily de-convoluted. Also, the analysis of 
hundreds to thousands of NMR spectra in a high-throughput screening assay precludes a 
manual inspection to selectively determine which peaks to include or exclude.  
2.4.5 Estimating KD based on single-point 1D 
1
H NMR line-broadening 
Measurements. Since NMR-based screens are a common component of the drug 
discovery process in the pharmaceutical industry, single-point estimates of ligand binding 
affinities could be an extremely valuable tool to initially rank and prioritize chemical 
leads. During the iterative drug optimization process, it is typical to focus on a small set 
(i.e., 3-5 compounds) of structurally distinct chemical classes that are amenable to 
synthetic modification and that exhibit drug-like characteristics.
54
 For this work, an NMR 
screen could be used to verify the presence of a specific and biologically-relevant 
interaction involving a protein target and to rank the relative binding affinity of the 
screened ligands to simplify the selection of promising lead compounds. This approach 
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was illustrated in this study by simulating NMR high-throughput screening results for the 
twelve compounds that were used in the previous binding study.  
First, using an average c value of 45.7 ±11.6 and an HSA concentration of 0.2 
M, single point KD values were calculated for a range of Bsingle values using eq 2.8. The 
results of this calculation are shown in figure 2.4. Superimposed on the single point curve 
in figure 2.4A are the KD values reported in table 2.1 plotted versus the experimental B 
values at 0.2 M HSA. Superimposed on the single point curve in figure 2.4B are the KD 
values from table 2.1, where the corresponding c values were used to determine a best-fit 
to eq 2.9. This represents the typical protocol that would be used in a high-throughput 
screen and shows that an average value of c is acceptable for use when individual 
estimates of c may not be practical.  A comparison of figure 2.4B with the theoretical 
curve based on eq 2.8 indicates the single-point method can provide a reasonable 
approximation for KD.  
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Figure 2.4. Use of NMR in a single-point binding analysis for several small-molecule 
ligands with known interactions with the protein HSA. The curves in (A) and (B) 
represents the ideal single-point KD values calculated from eq 2.8 with 0.2 M HSA and 
an average c value of 45.7 ± 11.6. (A) The KD values and errors reported in table 2.1 are 
superimposed on the ideal fit. The KD values are based on the best-fit to eq 2.9 using the 
c values determined for each individual compound. (B) The KD for each compound was 
re-calculated based on the best-fit to eq 2.9 using the c values from table 2.1. The error 
bars in B represent the range of KD values measured from the range of c values with the 
error in the free ligand linewidth, F, propagated.   
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For the twelve compounds that were considered in figure 2.4B, all compounds 
gave single-point estimates that agreed within a range of one standard deviation over the 
range of binding affinities and concentrations that were tested. All twelve compounds had 
experimental and single-point estimates for KD that agreed within two standard 
deviations. A higher deviation was observed in figure 2.4A for ligands with higher KD 
values. This occurs because of differences between the individual c values and the 
average c values. Also, eq 2.9 is more sensitive to small changes in c at these high KD 
values. This occurs because, at high KD values, vanishingly small differences in NMR 
intensities correspond to large differences in KD. In other words, this method is reaching 
a practical limit of detection since KD rapidly approaches infinity as NMR peak intensity 
changes approach zero. 
The relative ranking of the KD values were also the same for results that were 
obtained by the single-point calculations or the full titration method. These results 
indicate the single-point method can, at least in cases such as these, provide a preliminary 
estimate of KD values and binding affinities that can be used in the context of a high-
throughput screening assay. At a minimum, the relative changes in linewidth provide a 
rapid and efficient mechanism to prioritize NMR screening leads for further evaluation. 
However, it is still recommended that a more robust approach for measuring binding 
affinities for promising leads follow the NMR ligand affinity screen. This precaution 
follows, in part, from the fact that the accuracy of the KD values that are measured from 
the single-point 
1
H NMR line-broadening experiments will be strongly dependent on 
having a reasonable estimate for the value of NMR linewidth ratio (c) in such a study.   
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Appendix A: Glossary of terms found in chapter 2 
L  small-molecule ligand 
[L]T  total ligand concentration  
[L]F  free ligand concentration  
P  protein target 
[P]T  total protein concentration  
[P]F  free protein concentration  
[PL]  protein-ligand complex concentration 
IB   NMR peak height of bound ligand  
IF  NMR peak height of free ligand 
KD  dissociation equilibrium constant for a protein-ligand complex 
c  NMR linewidth ratio constant  
B  NMR signal response dependent on fraction of bound ligand 
Bsingle NMR signal response dependent on fraction of bound ligand at a single  
F  linewidth of the free ligand 
B  linewidth of the bound protein-ligand complex 
P  linewidth of the protein 
obs  observed linewidth change upon addition of protein or ligand 
fB  fraction bound complex in solution 
fF  fraction of free ligand in solution 
T2
-1
  dipole-dipole relaxation constant 
c  correlation time 
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J( )  normalized density function of T2
-1 
Bo  static magnetic field strength 
Larmor frequency 
MWP molecular weight of a protein target 
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Appendix B: Derivation of equations for rapid KD method found in chapter 2 
The binding of a protein (P) with a single small ligand (L) can be represented by the 
following reaction. 
[PL]  [P] + [L]             [B1] 
The dissociation equilibrium constant for this system is described by the expression in eq 
B2, where the concentrations [P]F, [L]F and [PL] represent the concentration of free 
protein, free ligand, and protein-ligand complex, respectively. 
F F
D
[P] [L]
K =
[PL]     
          [B2] 
Based on mass balance, eq B3 can be used to express [L]F and [PL] in terms of the total 
ligand concentration and other concentrations in this system. 
[P]T [P]F [PL]  [L]T [L]F   [L]F [L]T [P]T [P]F        [B3] 
Substitution of these relationships into eq B2 gives eq B4. 
F T T F
D
T F
[P] [L] -[P] +[P]
 K =
[P] -[P]
            [B4] 
Eq B4 can now be rearranged into the following form,  
D T F F T T F
2
F T T D F D T
 K [P] -[P] =[P] [L] -[P] +[P]
[P] + [L] -[P] +K [P] -K [P] =0
                     [B5] 
which makes it possible to solve for [P]F by using the quadratic formula, as indicated in 
eq B6, where only the positive root has any meaning in a real protein-ligand system. 
2
T T D T T D D T
F
- [L] -[P] +K ± [L] -[P] +K +4K [P]
[P] =   
2
        [B6] 
The bound fraction of ligand fB is next defined as given in eq B7. 
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B
DF
F
[PL] 1
f = =
K[PL]+[L]
1+
[P]
   
         [B7] 
If we substitute the positive root of eq B6 into eq B7, the result is eq B8. 
B
D
2
T T D T T D D T
-1
D D T
2
T T D T T D
1
f =
2K
1+
- [L] -[P] +K + [L] -[P] +K +4K [P]
1
=
2K 4K [P]
1+ 1+ -1
[L] -[P] +K [L] -[P] +K
        [B8] 
A further simplification of eq B8 can be accomplished by expanding the square root as a 
power series where D T
2
T T D
4K [P]
x=
[L] -[P] +K
about x = 0. This approach is valid as long as the 
ligand is in considerable excess relative to the protein. The power series that is used here 
is shown below.  
2x x
1+x=1+ - +...
2 8
        
 [B9] 
If eq B9 is truncated at the second term, this allows the square root term in eq B8 to be 
written in the approximate form that is given in eq B10. 
D T D T
2 2
T T D T T D
4K [P] 2K [P]
1+ 1+
[L] -[P] +K [L] -[P] +K
     [B10] 
The overall result of this simplification is that eq B8 converts to the expression shown 
below, there the fraction of bound ligand fB is now described in terms of only KD, the 
total ligand concentration and the total protein concentration. 
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T
B
T T D T D
T
[P]1
f =
[L] -[P] +K [L] +K
1+
[P]
          [B11] 
If it is assumed the observed free and bound NMR linewidths are represented by F and 
B, respectively, and that exchange occurs between free and bound states, the general 
solution to the NMR lineshape is bilorentzian. In the slow limit, the spectrum is 
obviously just a sum of the spectra of free and bound species, weighted by their relative 
abundances. If exchange rates become comparable to the inverse linewidths, then a 
conventional solution of the pair of coupled linear differential equations, including auto 
and cross relaxation terms but neglecting any chemical-shift difference between the 
states, gives a time domain (free induction decay): 
f (t) c e c e   [B12.a] 
with  
e exp t
 
 [B12.b] 
c c2
c1
  [B12.c] 
c1
1
4
K11 2K 21 K 22 ML 0 K11 2K12 K 22 MPL 0  [B12.d] 
c2
1
2
ML 0 MPL 0   [B12.e] 
K11 K 22
2
2
K12 K 21
 
 [B12.f] 
K11
1
T2, f
k1 P   [B12.g] 
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K22
1
T2,b
k 1   [B12.h] 
K12 k 1   [B12.i] 
K21 k1 P   [B12.j] 
where ML and MPL are the magnetization of the free and bound species, respectively. In 
the fast exchange limit, the solution is still formally biexponential, but the coefficient c– 
goes to zero, and the free induction decay signal, normalized to unity at zero time, 
becomes 
f (t) exp
1
T2, f
[L]
[L] [PL]
1
T2,b
[PL]
[L] [PL]
exp
f f
T2, f
fb
T2,b
 [B13] 
Fourier transforming, the fast exchange NMR signal height can be written as shown in eq 
B14: 
F F
B
F F B B
I
I =
f +f
                 [B14] 
where IF is the height of the ligand signal in the absence of protein and IB is the observed 
peak height of the bound complex. This is exactly the same as the height of the free 
ligand signal in extreme slow exchange!  Rearranging eq B14 explains the observed 
decrease in NMR peak signal for a free small-molecule ligand upon its binding to a 
protein. The relative ratio of NMR peak height ( B
F
I
I
) is now in terms of the fraction of 
free ligand (fF) and the fraction of bound ligand (fB) and is dependent on the observed 
increase in NMR linewidth upon the binding of a ligand to a protein. 
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B F
F F F B B F B B F B B B F
B
B
F
I 1 1
1- 1 1 1
I f f f f 1 f f
1
1
1 f 1
     [B15] 
Inserting B11 into B15 provides a measure of the dissociation equilibrium constant for 
the protein-ligand complex by relating the fraction of bound ligand to the observed 
change in NMR peak height. 
B
T B TF
T D F T D
I 1 1
B 1- 1 1
[P] c[P]I
1 ( 1) 1
[L] +K [L] +K
    where    c = B
F
-1  [B16] 
The NMR linewidth ratio, c, is then measured by using the free ligand NMR spectrum 
and by assuming the linewidth of the bound complex approximates the linewidth of the 
protein.  
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CHAPTER 3:  
 
STRUCTURAL AND FUNCTIONAL SIMILARITY BETWEEN THE 
BACTERIAL TYPE III SECRETION SYSTEM NEEDLE PROTEIN PRGI AND 
THE EUKARYOTIC APOPTOSIS BCL-2 PROTEINS 
 
 
3.1 INTRODUCTION 
The previous chapter discussed the development of a high-throughput screening 
methodology to measure and rank relative binding affinities.  One of the primary reasons 
for developing such a method was for the use in the Functional Annotation Screening 
Technology by NMR (FAST-NMR).
1
  The FAST-NMR method is a multi-step approach 
to high-throughput screening using nuclear magnetic resonance (NMR).  A target protein 
is screened with a library of biologically functional compounds to identify which 
compounds bind to the target protein, known as a “hit”.  The first step in the FAST-NMR 
approach is a 1D 
1
H line broadening experiment, similar to the experiments described in 
chapter 2.   
The 1D 
1
H line broadening experiment is a ligand focused experiment in which 
the response of the free ligand is compared to a sample with the target protein added.   
For FAST-NMR, the 1D 
1
H line broadening step is used to identify potential hits as an 
initial screen.  The method developed in chapter 2 is then used to prioritize which ligand-
protein interactions are further studied using a secondary target focused 2D 
1
H-
15
N 
HSQC screen based on relative binding affinity. The 2D 
1
H-
15
N HSQC monitors the 
changes in the protein spectrum upon addition of the binding ligands. FAST-NMR also 
utilizes the Comparison of Protein Active Site Structures (CPASS) software and database 
to identify similar sequence and structure characteristics between experimentally 
identified ligand binding sites for proteins of known and unknown function.
2
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Functional regions of a protein are more stable relative to the remainder of the 
protein sequence undergoing random drift.
3, 4
 The correlation between ligand binding 
sites, ligand structure and protein function has also been demonstrated by a network of 
ligand binding-site similarity described by Park & Kim.
5
 A variety of computational 
methods have attempted to exploit the stability of functional regions by identifying ligand 
binding sites as a method to predict function.
6, 7
 Unfortunately, the combined 
requirements of predicting the ligand, the binding site, and a similarity to an annotated 
proteins leads to a high level of ambiguity. The FAST-NMR approach attempts to 
experimentally identify ligand binding sites to annotate proteins of unknown function.
7-9
 
Applying the FAST-NMR method to previously annotated systems also enables 
experimental ligand binding site data to identify functional relationships that otherwise 
would not be recognized based solely on global sequence and structure similarity.  
The type three secretion system (T3SS) is composed of 20-25 different proteins, 
which are assembled in a highly choreographed mechanism similar to the assembly of 
flagella.
10-12
 In Salmonella typhimurium, the needle complex is responsible for puncturing 
a host‟s cell membrane to allow effector proteins (SipB, SipC, SipD) from S. 
typhimurium to enter the host.
13
 Many of these effectors can activate bacterial induced 
apoptosis of a hosts‟ cell by interacting with capsase-114 in a mechanism similar to 
apoptosis in eukaryotic cells.
15
 The needle complex is a large homomultimer composed 
of ~120 repeated copies of the monomeric protein PrgI, a small helical protein of 83 
amino acids.
16
 The monomeric form of PrgI is a helix-turn-helix motif with two 
symmetrically charged surfaces and a conserved loop region, PxxP domain, which are 
important for needle assembly.
16-18
 The charged surfaces of PrgI responsible for needle 
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assembly also provide a potential binding site for small molecule ligands. This makes 
PrgI an attractive drug target to disrupt the formation of the needle complex and prevent 
infection by S. typhimurium. However, to date there has been no reported ligands that 
bind to either region of this protein-protein interaction site.  
The PrgI needle complex protein from S. typhimurium T3SS was screened in our 
FAST-NMR assay, which resulted in the identification of a functional similarity between 
the ligand binding sites of PrgI and the anti-apoptosis protein Bcl-xL. Additionally, Dali
19
 
and T-Coffee
20
 analysis found regions of structure and sequence similarity between the 
two proteins consistent with the FAST-NMR results. The predicted active-site similarity 
between PrgI and Bcl-xL was also used to experimentally verify that chelerythrine,
21
 a 
ligand known to inhibit Bcl-xL and induce apoptosis, also binds PrgI. These results 
provide experimental evidence that suggest a functional relationship between the 
bacterial type III secretion systems and apoptosis. This is consistent with a general 
conservation in function between PrgI and the Bcl-2 family of proteins that includes Bcl-
xL; both form membrane pores through oligomerization using a conserved helix-turn-
helix motif to release effectors to stimulate cell death.  
 
3.2 EXPERIMENTAL 
3.2.1 FAST-NMR screen of PrgI.   The Salmonella typhimurium type three 
secretion protein (T3SS) PrgI was screened with a functional library 
22
 using the FAST-
NMR assay.
7, 8
 Unlabeled and 
15
N labeled monomeric PrgI was graciously provided by 
Dr. Roberto DeGuzman (University of Kansas) along with the assigned 2D 
1
H-
15
N 
HSQC spectrum. Sample preparation and experimental parameters for the NMR screen 
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were executed in the same manner as described previously 
8
.  Briefly, each ligand 
mixture was screened at 100 M/ligand concentration with 25 M protein in a 99.99% 
D2O buffered solution of 20 mM d19-bis-Tris at pH 7.0 with 5% DMSO-d6 to maintain 
ligand solubility and 11.1 M 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt as a 
chemical shift reference.  1D 
1
H NMR spectra for each sample was collected using a 
presaturation pulse sequence with 64 real transients, 8 dummy transients with 8 k data 
points, a sweep width of 11.0 ppm and a recycle delay of 2.0 s.  Data was Fourier 
transformed, auto-phase and baseline corrected. Each 1D 
1
H NMR spectrum were 
compared to the corresponding free ligand mixture reference spectrum and visually 
analyzed to identify binding ligands.  A binding event was identified by the decrease in 
ligand intensity of the nuclease-mixture relative to the free ligand mixture. Total data 
collection time including sample changing was approximately 10 min/spectrum. All 1D 
1
H NMR spectra were collected on a Bruker 500 MHz Avance spectrometer (Billercia, 
MA) equipped with a triple resonance, Z-axis gradient cryoprobe and using a Bruker 
BACS-120 sample changer and IconNMR software for automated data collection.  All 
spectra were collected at 298 K. 
All 2D 
1
H-
15
N HSQC spectra were collected at 298K using the same 
instrumentation with the standard 2D 
1
H-
15
N HSQC (hsequetf3gp) pulse sequence 
implemented in Bruker TopSpin 1.3 with optimized sample specific 90
o
 pulse lengths.  A 
total of 16 real scans and 128 dummy scans were collected with 2 k data points  with a 
sweep width of 9.5 ppm in the 
1
H dimension and 128 data points with a sweep width of 
28.0 ppm in the 
15
N dimension.  A ligand free 2D 
1
H-
15
N HSQC spectrum was collected 
using the same buffer conditions with 95% H2O/5% D2O to ensure the protein was 
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properly folded prior to addition of ligands. Total experiment time was approximately 1.5 
hrs/spectrum. 
A total of 113 1D 
1
H NMR line-broadening spectra were collected to identify 5 
binding ligands from the functional chemical library of 437 compounds. Measurement of 
binding dissociation constants were completed as described in chapter 2 and as described 
previously.
23
 Secondary 2D 
1
H-
15
N HSQC NMR experiments were collected only for the 
5 compounds identified as binders in the line-broadening experiments. Chemical shift 
perturbations (CSPs) (eq 3.1) from the 2D 
1
H-
15
N HSQC NMR  experiments were used 
to identify the PrgI ligand binding site, where only residues with a CSP greater than one 
standard deviation from the mean were used 
               [3.1] 
where NH is the difference between free and bound 
1
H amide chemical shifts (ppm) and 
15N is the difference between free and bound 
15
N chemical shifts (ppm).  
 A rapid approach to determine a ligand binding orientation was employed to 
determine a PrgI co-structure in the same manner as described previously.
24
 The CSPs 
minimize the search space by using a significantly reduced AutoDock 3D grid. AutoDock 
4.0 was used to generate 100 docked PrgI-ligand co-structures using the Lamarckian 
search algorithm with a population size of 300 and 500,000 energy evaluations.
25
 The 
AutoDockFilter (ADF) program then uses an NMR energy function based on the 
magnitude of CSPs to select the best ligand conformation.  
    [3.2] 
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where ADF calculates a pseudo-distance (dCSP) based on the magnitude of the NH CSP, 
which is then compared to the shortest distance (dS) between any atom in the residue that 
incurred an NH CSP and any atom in each docked ligand conformer. Comparison of 
these CSP-directed and selected ligand-docked structures with experimental x-ray and 
NMR structures has yielded an overall average rmsd  of 1.17 ± 0.74 Å.
24
 
A co-structure of the lipid derivative didecyldimethylammonium bromide 
(DDAB) bound to PrgI was uploaded to the CPASS database (http://cpass.unl.edu) to 
identify proteins with similar ligand binding sites by maximizing an rmsd weighted 
BLOSUM62
26, 27
 scoring function (Sab).  
     [3.3] 
where active site a contains n residues and is compared to active site b from the CPASS 
database which contains m residues, pi,j is the BLOSUM62 probability for amino-acid 
replacement for residue i from active site a with residue j from active site b, i,j is a 
corrected root-mean square difference in the C  coordinate positions between residues i 
and j, and dmin/di is the ratio of the shortest distance to the ligand among all amino-acids 
in the active site compared to the current amino-acid‟s shortest distance to the ligand. Sab 
is only summed over the optimal alignment for residue i from active site a with residue j 
from active site b. It is not summed over all possible combinations of i and j. If the 
number of residues are not identical between active sites a and b (n ≠ m), then the 
additional residues will not have a corresponding match. Each residue can only be used 
once in the alignment. If active site a contains unmatched residues, then no contribution 
is made to Sab which effectively reduces the maximal possible score that can be achieved 
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for active site a. At the time of this study (May 2008), there were ~35,000 protein-ligand 
structures in the CPASS database. CPASS was run on a 16 node Beowulf Linux cluster, 
requires approximately 40 sec for each pair-wise comparison and took ~24 hrs to 
complete a full search against the entire database.  
3.2.2 Structure similarity searching Native protein structures for PrgI (PDB ID: 
2JOW) 
16
 and Bcl-xL (PDB ID: 1YSN)
28
 were uploaded to the DaliLite
29
 web server 
(http://www.ebi.ac.uk/DaliLite/) to identify regions of structure homology between the 
two proteins. To identify structure similarity and possible homology with other proteins 
within the PDB, the structures were also uploaded to the full Dali
19
 web server 
(http://www.ebi.ac.uk/dali/). A truncated version of the Bcl-xL structure was generated 
by identifying the amino acids within regions of structure similarity and removing these 
residues from the native PDB file. The truncated PDB file was searched for regions of 
similarity using the DaliLite web server (http://www.ebi.ac.uk/Tools/dalilite/index.html).  
3.2.3 Sequence similarity searching using BLAST and T-Coffee. Sequences 
from the T3SS and apoptosis regulation were downloaded from the NCBI server 
(http://www.ncbi.nlm.nih.gov/) and included PrgI (gi|16766179), InvJ (gi|16766198) and 
InvG (gi|474941) from S. typhimurium,  and Bcl-xL, (gi|510901), Bak1 (gi|82571458), 
Bid (gi|4557361) and Bax (gi|231632) from Homo sapiens respectively. A full BLAST 
search was completed using these sequences associated with both systems as queries.
30
 
All BLAST sequence searches used default settings. In addition, the sequences and 
structures for Bcl-xL (PDB-ID: 1YSN), S. typhimurium PrgI (PDB-ID: 2JOW), B. 
pseudomallei BsaL (PDB-ID: 2GOU) and S. flexneri MxiH (PDB-ID: 2CA5) obtained 
from the PDB were uploaded to the T-Coffee
20
 web server (http://www.tcoffee.org/) to 
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obtain a multiple sequence alignment using the EXPRESSO(3DCoffee) software.
31
 Only 
the sequence region of the Bcl-xL structure that contained the pore-forming domain and 
yielded the highest alignment score was used for the multiple sequence alignment. 
3.2.4 Secondary binding site similarity between Bcl-xL and PrgI. To further 
support a structural and functional similarity between Bcl-xL and PrgI,  the BindingDB
32
 
(http://www.bindingdb.org/) was searched for commercially available compounds to test 
for binding to PrgI. The free 2D 
1
H-
15
N HSQC spectrum was collected using 100 M 
15
N 
labeled PrgI in 20 mM bis-Tris buffer with 100 mM sodium chloride at pH 7.0. A second 
PrgI sample was prepared in the same manner as above with the addition of 500 M 
chelerythrine to generate the bound 2D 
1
H-
15
N HSQC spectrum. Chemical shift 
perturbations and a PrgI-chelerythrine docked co-structure were determined as described 
previously
24
 and was compared to the Bcl-xL-chelerythrine model 
33
.  
 
3.3 RESULTS 
3.3.1 Results from the FAST-NMR screen. The needle complex protein, PrgI, 
from S. typhimurium is an attractive antibacterial target because the protein is exposed to 
the cell surface and blocking this target could prevent injection of virulence factors into 
the host.
34
 The interaction of PrgI with the host membrane stimulates the delivery of 
effectors from the bacteria into the host cytosol to induce cell death. Recently an NMR 
structure was determined for a monomeric form of PrgI,
16
 which enabled the screening of 
PrgI using the FAST-NMR assay.
8
 FAST-NMR combines NMR ligand affinity 
screening
35
 using a fragment-based functional library
22
 with structural biology and 
bioinformatics
2
 to rapidly determine protein-ligand complexes
24
 and infer functional 
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relationship between proteins based on similarities in functional epitopes. Also, the 
resulting protein-ligand co-structure provides a valuable starting point for structure-based 
drug design. 
FAST-NMR applies a tiered approach to screening
35
 to minimize resources and 
increase throughput (figure 3.1). First, PrgI was screened with the functional chemical 
library using 1D 
1
H NMR line-broadening experiments. Five compounds (L-carnitine 
inner salt, didecyldimethylammonium bromide, 1-methylimidazole, methiothepin 
mesylate salt, sucrose) were found to bind PrgI by showing a significant decrease in 
1
H 
peak intensity upon addition of 25 M of PrgI. This was determined by comparing 
normalized 
1
H ligand peak intensities between the free and bound NMR spectra (figure 
3.1A). However, the secondary 2D 
1
H-
15
N HSQC
 
experiments identified the lipid 
derivative didecyldimethylammonium bromide (DDAB) as the only specific PrgI binder 
(figure 3.1B) based on the observation of a significant number of chemical shift changes 
in the spectrum. The remaining four compounds elicited no change in chemical shifts in 
the PrgI 2D 
1
H-
15
N HSQC
 
spectrum, which suggest the compounds bound non-
specifically to PrgI. PrgI was found to bind DDAB with a KD of 553 M as calculated by 
a 1D 
1
H line broadening method of chapter 2.
23
 Finding a lipid derivative that specifically 
binds to PrgI is consistent with the protein‟s function; sensing new host cells and 
signaling secretion through an interaction with the host membrane.
36
  
Chemical shift perturbations (CSPs) in the 2D 
1
H-
15
N HSQC experiments 
between free PrgI and the complex identified the PrgI residues that bind DDAB. Mapping 
these CSPs onto the PrgI surface identified the DDAB binding site as corresponding to 
residues at the bifurcation point of the two helices (figure 3.1C). Specifically, residues 
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S6, L9, S13, K15, and D17 of helix 1 and N59, V65, K66, V67, F68, K69, D70, D72, 
A73 and L76 of helix 2 showed significant CSPs in the presence of DDAB as calculated 
by eq 3.1. This ligand binding site has been shown to be important for the formation of 
the T3SS needle complex in which PrgI forms a repeating coiled-coils structure.
11
 
According to recent alanine scanning and structural studies, the surface residues in the 
region between the bifurcation point of the two helices and the conserved loop region, 
PxxP domain, are important for needle assembly.
16-18
 These residues bind to the backside 
of the bifurcation point of the two helices in a stacked N-terminus to C-terminus 
manner.
16-18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
 
  
 
93 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Identification of PrgI Binding Ligands. (A) DDAB NMR spectra in the 
absence (top) and presence (bottom) of PrgI illustrating changes in NMR intensities 
(boxed) upon binding PrgI. Both free and bound 1D 
1
H NMR spectra were normalized to 
a constant DMSO signal intensity. (B) Expanded view of the superimposed 2D 
1
H-
15
N 
HSQC
 
spectra of the free and DDAB bound PrgI NMR samples. Residues that incur a 
chemical shift perturbation are boxed. (C) Expanded view of PrgI surface rendered in 
VMD
37
 where residues that incur a chemical shift change are colored blue and DDAB is 
colored yellow. Co-structure based on NMR determined ligand binding site using 
AutoDock and our AutoDockFilter program.  
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The PrgI residues exhibiting significant CSPs upon binding DDAB were used to 
guide and filter a molecular docking simulation based on our method to rapidly determine 
protein-ligand co-structures.
24
 AutoDock 4.0
25
 was used to calculate 100 docked 
structures within a 3D grid defined by the CSPs. Our AutoDock Filter program (ADF) 
selected the best conformer based on consistency with the magnitude of chemical shift 
changes.
24
 The ligand is expected to be closest to the protein residues that incurred the 
largest CSPs. The best PrgI-DDAB docked structure is shown in figure 3.1C, where 
DDAB adopts an extended conformation that straddles both helices of PrgI.  
3.3.2 Analysis of CPASS and structure similarity results. Comparison of 
Protein Active Site Structures (CPASS) analysis of the PrgI-DDAB complex identified a 
human Bcl-2 protein family member (the anti-apoptosis regulating protein Bcl-xL (PDB-
ID:1YSN) complexed to an acyl-sulfonamide-based inhibitor (ABT-737))
28
 as the top hit 
based on a ligand binding-site CPASS similarity score of 37.7%. The CPASS alignment 
is shown in figure 3.2A and is based on maximizing the spatial orientation of similar 
residue types between the two ligand binding sites. All other proteins with a CPASS 
similarity > 30%  were also evaluated, but Bcl-xL was the only protein that gave a 
reliable CPASS score and showed some level of structure or sequence similarity to PrgI. 
It is important to note the CPASS identified similarity between PrgI and Bcl-xL was 
fundamentally dependent on the existence of a Bcl-xL-ligand complex in the PDB. 
Ligand complexes for other members of the Bcl-2 protein family (Bax, Bid) currently do 
not exist.  
While DDAB and ABT-737 are distinctly different ligands, the compounds share 
strong similarities in their mode of protein interactions. ABT-737 binds Bcl-xL edge-on 
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in an elongated conformation where a minimal number of atoms contact the hydrophobic 
binding cleft of Bcl-xL. In this manner, DDAB mimics this edge contact interaction of 
ABT-737 with the similar hydrophobic binding cleft in PrgI. Also, ABT-737 binds in a 
protein-protein binding interface similar to DDAB, where inhibiting protein interactions 
is the drugs mechanism of action in cancer cells.
28
 Thus, the PrgI and Bcl-xL ligand 
binding-sites are functionally similar. 
A pairwise structure alignment using DaliLite
29
 yielded a non-significant Z-score 
of 1.4 and only 6% sequence identity between PrgI (PDB ID:2JOW) and Bcl-xL (PDB 
ID:1YSN). Nevertheless, the helix-turn-helix structure of PrgI (residues S13-V65) 
overlaps the buried helix-turn-helix motif (N136-I182) in Bcl-xL that corresponds to 
helices 5 (residues W137-D156) and 6 (residues L162-D176) (figure 3.2B). A focused 
pairwise comparison between the full PrgI protein and the 5 and 6 helices of Bcl-xL 
gave a low but significant Z-score of 3.3 with an root-mean-square-difference (rmsd) of 
3.1Å. The sequence identity also increases from 6% to 9% between the full and focused 
pairwise alignments, respectively.  
While there is an overlap between the DaliLite alignment of PrgI with Bcl-xL and 
the protein ligand binding sites identified by CPASS, these sites are not identical. This 
arises because the CPASS similarity is not confined by the primary sequence of the two 
proteins, but simply captures the spatial orientation of conserved residues around a ligand 
binding site. This is illustrated by the non-sequential sequence alignment of the PrgI and 
Bcl-xL ligand binding sites in figure 3.2. The exclusion of the sequence connectivity as a 
constraint to determine an alignment illustrates the advantage of CPASS in identifying a 
functional relationship over global sequence and structure alignments.
29, 30
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Figure 3.2. Active Site Similarity between PrgI and Bcl-xL. (A) CPASS alignment of 
the S. typhimurium PrgI active-site complexed to DDAB with the active-site of human 
Bcl-2 protein (Bcl-xL) complexed with acyl-sulfonamide-based inhibitor. The residues 
aligned by CPASS are labeled and colored blue in the structures. The active site sequence 
alignment is also shown below the structures. The ligands are colored yellow. (B) 
Overlay of the human Bcl-2 protein (red) with S. typhimurium PrgI (turquoise) based on a 
DaliLite alignment. (C) Multiple-sequence alignment of the three known T3SS structures 
of S. typhimurium PrgI, B. pseudomallei BsaL, and S. flexneri MxiH with the human Bcl-
2 protein (Bcl-xL). The reliability of the each amino acid alignment is color-coded from 
blue (poor) to red (good) using the CORE index.
38
 The consensus alignment received a 
score of 69, where a perfect alignment receives a score of 100. 
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3.3.3 Sequence similarity results. A BLAST
30
 homology search using the PrgI 
and Bcl-xL sequences did not yield any significant information relating PrgI to Bcl-xL. 
The Bcl-xL sequence only identified homology to other Bcl-2 proteins. Similarly, the 
PrgI sequence was only aligned to other T3SS needle proteins. This is consistent with a 
ClustlW2
39
 sequence alignment between PrgI and Bcl-xL that resulted in a low 14.3% 
sequence similarity, which falls below the twilight zone of sequence similarity.
40
 Also, 
focused BLAST searches did not provide any new information. Searching microbial 
genomes using the Bcl-2 sequences or searching the human genome with T3SS 
sequences did not identify any sequence alignments with significant E-values. Thus, 
global sequence alignments did not readily result in identifying any relationship between 
T3SS and apoptosis proteins. This highlights the power of active site similarity searches 
to identify potentially new functional similarities in proteins. 
Hidden Markov model (HMM) methods
41
 provide an alternative and more robust 
approach to identify homology between distantly related proteins with low sequence 
similarity relative to traditional BLAST searches. The T-Coffee web server 
(http://www.tcoffee.org/) provides a consensus sequence alignment (M-Coffee) using 
multiple HMM protocols.
20
 A reliable alignment of conserved residues (figure 3.2C) was 
obtained between the known T3SS structures of PrgI (PDB ID: 2JOW), BsaL (PDB ID: 
2G0U) from Burkholderia pseudomallei, and MxiH (PDB ID: 2CA5) from Shigella 
flexneri with the human Bcl-xL (PDB ID: 1YSN) protein. The multiple-sequence 
alignment was obtained using EXPRESSO(3DCoffee) 
31
 that combines structural 
information with a HMM sequence alignment method. The reliability of the per residue 
alignment is color-coded using the color index,
38
 where the majority of residues where in 
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the average to good range. The alignment of Bcl-xL with the three T3SS structures 
received a score of 53, where a score of 100 results from a perfect alignment. For 
comparison, the alignment of the three known human T3SS proteins resulted in a range 
of scores from 72 to 76. Conversely, scores that range from the 20 to the 30 indicate poor 
or insignificant alignments. Thus, PrgI aligns preferentially to the other T3SS proteins, 
but its alignment to the pore forming helices in Bcl-xL is significant and reliable.  
Importantly, the sequence alignment of PrgI with Bcl-xL encompasses the same residues 
involved in the ligand binding sites identified by CPASS and the structural similarity 
identified by DaliLite.  
3.3.4 Identification of a second PrgI ligand binding site. The identification of a 
compound that binds similarly to both PrgI and Bcl-xL would further establish a 
functional relationship between these two proteins. BindingDB
32
 was used to identify 
potential inhibitors of PrgI based on the CPASS predicted active site similarity with Bcl-
xL. A total of 71 ligands were reported to bind Bcl-xL. A majority of the compounds 
were piperazine derivatives and were not readily available. Two compounds, 
chelerythrine and sanquinarine were identified as having affinity to Bcl-xL and were both 
available from commercial suppliers. Chelerythrine was selected over sanquinarine based 
on previous NMR screening and docking studies that suggested chelerythrine binds 
between 4, 5 and 6 of Bcl-xL.
33
 This region of Bcl-xL was predicted to overlap with 
PrgI based on the pairwise Dali alignment (figure 3.2B). Conversely, sanquinarine bound 
the BH3 binding cleft of Bcl-xL and thus was not selected for this secondary binding 
analysis.
33
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A comparison between the free and chelerythrine bound PrgI 2D 
1
H-
15
N HSQC 
spectra (figure 3.3A) identified a chelerythrine binding site on PrgI (figure 3.3B). The 
PrgI residues that exhibited chemical shift changes upon binding chelerythrine include 
residues A14, K15 in helix 1 and residues Y57, N59, A60, V65, K66, V67, F68, and D72 
in helix 2. The AutoDock/ADF docked structure of PrgI with chelerythrine suggests PrgI 
residues K15 and Y57 are the most important residues for chelerythrine binding based on 
a close contact with the ligand (figure 3.3B). Many of the residues that show significant 
CSPs for PrgI bound to chelerythrine overlap with the DDAB residues, however, the 
chelerythrine binding site is on the opposite face of PrgI (figure 3.4). This indicates there 
are two ligand binding sites on PrgI that is consistent with the two known protein-protein 
interaction sites for PrgI self-oligermization. The chelerythrine AutoDock docking energy 
decreased significantly compared to DDAB, -0.43 to -5.29 kcal/mol, respectively 
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Figure 3.3. Verification the Bcl-xL inhibitor chelerythrine also binds PrgI.  (A). 
Expanded overlay of the 2D 
1
H-
15
N HSQC spectra for free PrgI (black) and PrgI bound 
to chelerythrine (blue). CSPs greater than one standard deviation are boxed. (B) An 
AutoDock/ADF docked structure of PrgI complexed with chelerythrine based on the 
observed CSPs from (A). (C) The Bcl-xL region shown to bind chelerythrine is 
highlighted while the reaming protein structure is transparent. Chelerythrine is colored 
yellow and is drawn with licorice bonds. Side-chains for Y173 and V135 are shown as 
licorice bonds and colored grey.  (D) A ribbon diagram of the AutoDock/ADF docked 
PrgI-chelerythrine co-structure. The PrgI-chelerythrine binding region that overlaps with 
Bcl-xL is highlighted. Chelerythrine is colored yellow and is drawn with licorice bonds. 
Side-chains for Y57 and K15 are shown as licorice bonds and colored grey. (E) An 
expanded view of the overlay of Bcl-xL (red) with PrgI (blue) illustrating the structural 
similarity of the chelerythrine binding sites. 
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Figure 3.4. The two PrgI ligand binding sites identified using FAST-NMR. The two 
PrgI ligand binding sites are highlighted on an electrostatic potential surface (blue 
positive charge, red negative charge) calculated with the DelPhiController implemented 
in Chimera 
42
.  The didecyldimethylammonium bromide binding site (A) is found in a 
region responsible for needle formation while the chelerythrine binding site (B) is found 
on the opposite face of PrgI.  
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The binding site of chelerythrine on PrgI is nearly identical to the binding site of 
chelerythrine to Bcl-xL (figure 3.3C and 3.3D). In Bcl-xL the chelerythrine binding site 
is described as being located in the BH groove of helix 4, 5 and 6, which is 
composed of residues F131, R132, V135, Y173 and H177 (figure 3.3C).
33
 Pairwise 
structure analysis between PrgI and Bcl-xL shows that Y173 of Bcl-xL and Y57 on PrgI 
are overlapping residues and K15 from PrgI is proximal to V135 from Bcl-xL (figure 
3.3E). The primary difference between the two proteins is the lack of -helix 4 in PrgI, 
where helix 4 of Bcl-xL appears to act as a „cap‟ encasing the ligand and effecting its 
relative binding orientation. Chelerythrine binds flat in the PrgI binding site, while the 
compound points into the corresponding Bcl-xL binding site partially overlaying helix 
4. Again, both of these structures are docked models based on NMR CSPs and require a 
high-resolution x-ray or NMR structure to confirm the conformation of the chelerythrine 
binding site. It is paramount to note that this similarity in chelerythrine binding between 
the two proteins would have not been discovered if it was not for the identification of the 
initial conserved ligand binding site between PrgI and Bcl-xL using the FAST-NMR 
method in combination with the CPASS database.  
 
3. 4 DISCUSSION  
3.4.1 Ligand binding similarity of the Bcl-2 family of proteins with PrgI.  A 
structural and functional similarity between PrgI, a type three secretion system protein, 
and Bcl-xL, a member of the Bcl-2 family of proteins involved in eukaryotic apoptosis, 
was identified from a FAST-NMR ligand affinity screen in combination with a 
bioinformatic analysis. This association is fundamentally based on the similarity in ligand 
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binding sites depicted in figure 3.2A, where the conserved helix-turn-helix motif simply 
provides secondary support of a PrgI and Bcl-2 functional link. While similar active sites 
provide a measure of functional similarity, inferring homology based solely on the 
observation of a similar helix-turn-helix motif is questionable. The helix-turn-helix is a 
common motif and without a global sequence similarity, an evolutionary lineage based 
solely on active site similarity cannot be readily established. However, identifying similar 
ligand binding sites between the two proteins does provide support the proteins share a 
common function and are expected to bind similar ligands.  
The initial identification of the conserved DDAB ligand binding site between Bcl-
xL and PrgI was used to predict, test and confirm that chelerythrine binds PrgI in a 
similar manner to Bcl-xL. This further supports the structural and functional similarity 
between PrgI and Bcl-xL, but also demonstrates the utility of active site similarity as a 
predictive tool for ligand binding. Chelerythrine was only tested for PrgI binding because 
of the proposed active site similarity with Bcl-xL. Thus, these studies have identified the 
first known ligands to bind PrgI (DDAB and chelerythrine). Both ligand binding sites are 
associated with the functionally important PrgI self-oligomerization sites. Therefore, 
compounds based on either the DDAB or chelerythrine scaffold may disrupt PrgI 
oligomerization. These compounds may serve as valuable chemical leads to develop 
novel antibiotics. Additionally, since the ligands bind in separate locations on the PrgI 
surface (figure 3.4), the compounds present two distinct approaches for developing drugs 
targeting PrgI. Unfortunately, because chelerythrine also binds Bcl-xL it is reasonable to 
expect that an antibiotic designed using chelerythrine as a scaffold may produce 
undesirable off-target side effects. This issue may be minimized or eliminated by simply 
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improving the PrgI binding affinity for chelerythrine derivatives. This illustrates another 
important feature of the FAST-NMR protocol; active site similarity is a useful tool to 
predict potential side effects due to off target inhibition in addition to predicting potential 
drug leads. While computational methods for predicting potential drug toxicity
43
 are 
useful because of their speed, validation requires experimental methods such as the 
FAST-NMR approach.  
3.4.2 Functional similarity of the Bcl-2 family of proteins with PrgI.  The Bcl-
2 family of proteins are essential for eukaryotic apoptosis; where Bcl-xL is responsible 
for repressing cell death activity.
15
 The in vivo binding partners of Bcl-xL include the 
pro-apoptosis proteins Bax, Bak and Bid. It has been shown that expression levels of 
repressor (Bcl-xL) and pro-apoptosis proteins (Bax, Bak and Bid) are reciprocal in nature 
suggesting precise regulation of eukaryotic apoptosis.
44
 A combination of mutational and 
structure work has shown the BH3 binding domain of Bcl-xL is critical for binding 
interactions with  other Bcl-2 proteins and apoptosis regulation.
44
  
 The structure of Bcl-xL very closely resembles the structures of Bax, Bid, Bcl-2, 
and other members of the Bcl-2 family of proteins, which all resemble pore-forming 
domains of bacterial toxins.
45-47
 Bcl-2, Bcl-xL, Bax and the truncated active form of Bid 
(tBid) have all been shown to form pores in liposomes, but a similar cellular function has 
only been observed for Bax.
44, 48, 49
 In healthy cells, Bax is a monomer in the cytosol. 
Many different apoptotic signals result in the transfer of Bax to the outer mitochondrial 
membrane where an interaction with Bid and the lipid membrane induces Bax to form a 
supramolecular opening in the outer mitochondrial membrane.
50, 51
 This pore structure 
causes the release of pro-apoptotic factors from the mitochondria into the cytoplasm to 
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induce cell death
52
 and contains ~22 copies of Bax with a diameter of ~20 nm. The 
interaction of Bcl-xL with Bax prevents Bax induced cell death,
53
 where drugs that 
disrupt Bcl-xL interacting with Bcl-2 proteins are a promising form of cancer therapy.
54
 
Bcl-xL has been described as a dominant-negative version of Bax.
55
  
PrgI comprises the T3SS needle structure, which is formed by a PrgI 
homomultimer composed of ~ 120 copies of the protein.
10-12
 This needle structure senses 
and punctures host membranes forming a pore to transfer proteins to induce cell death in 
a mechanism similar to eukaryotic apoptosis.
13-15
 A general conservation in function 
between PrgI and the Bcl-2 protein family is thus maintained and readily apparent; both 
form membrane pores via a helix-turn-helix motif through oligomerization to release 
effectors to stimulate cell death. Additionally, PrgI requires PrgJ for oligomerization into 
the needle
11
 while Bax requires Bid to induce pore formation.
51
 Thus, a protein 
interaction with other members of the Bcl-2 family is required to either promote (Bid) or 
inhibit (Bcl-xL) Bax oligomerization. It is also interesting that PrgI was found to bind to 
a lipid analog and lipids have been found to play a role in Bax oligomerization.
51
  
Importantly, the experimentally observed ligand binding sites for both PrgI and 
Bcl-xL are functionally equivalent and within the conserved helix-turn-helix motif. Both 
sites correspond to functionally critical protein-protein interaction sites required for 
oligomerization and pore formation. The DDAB binding site on PrgI overlaps with key 
residues involved in PrgI oligomerization and needle assembly. Similarly, ABT-737 is an 
inhibitor of apoptosis and functions by inhibiting Bcl-xL protein interactions.
56
 Thus, the 
similarity in the ligand binding sites helps establish a functional link between the two 
proteins.  
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3.4.3 Structural similarity of the Bcl-2 family of proteins with PrgI. The Bax 
pore-forming domain is conserved in Bcl-xL, Bcl-2 and Bid
45, 57
 and corresponds to the 
helix-turn-helix motif (helices 5 and 6) that was identified by CPASS to be similar to 
PrgI (figure 3.2A). Also, a comparison of the Bcl-xL and PrgI structure by Dalilite 
resulted in the alignment of the PrgI structure with this conserved Bcl-2 helix-turn-helix 
motif (figure 3.2B). Additionally, a multiple sequence alignment indicated a reliable 
similarity between T3SS needle-forming proteins and the Bcl-2 pore-forming region 
(figure 3.2C). Thus, the PrgI structure can be viewed as a minimalistic version of the Bcl-
2 structure, and corresponds to the functionally essential and conserved core pore-
forming domain.    
Gene duplication along with insertion and/or deletions of sub-structures into 
variable genetic regions are known methods for the evolution of protein function.
58, 59
 
These processes may explain the evolution of the Bcl-2 family of proteins from a smaller 
PrgI-like ancestor. Since the PrgI structure overlaps with residues N136 to I182, this may 
suggest N- and C-terminal insertions generated a Bcl-2 protein from a PrgI-like ancestor. 
This is consistent with the hypothesis proposed by Aouacheria et al.,
60
 where the 
ancestral toxic pore forming domain (helices 5 and 6) required developing a means to 
prevent inappropriate apoptosis and to regulate cell death. 
Presumably, a main function of the N- and C-terminal inserts into a PrgI-like 
ancestor would be to stabilize the monomer form of Bax until an apoptotic signal occurs. 
In effect, the insertions would provide a stronger control over the pore formation process. 
This is consistent with what has been experimentally observed, both the N- terminus and 
C-terminus residues of Bax are essential to maintain the monomer form of Bax in the 
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cytosol.
47, 61, 62
 Deletion of the first 20 amino acids from the N-terminus results in Bax 
being localized to the mitochondria.
61, 62
 Similarly, the Bax structure indicates the C-
terminal hydrophobic helix 9 is bent in a hydrophobic groove, but contains some critical 
solvent exposed polar residues that are necessary to maintain solubility.
47
 In fact, a model 
for the translocation of Bax from the cytosol to the mitochondria requires a 
conformational change in Bax that opens up helix 9 and exposes the pore forming 
region composed of helices 5 and 6.
47, 63
 Deletions of 21 residues from the C-terminus, 
which includes part of helix 6, prevents oligomerization.
64
  
While Bax oligomerizes to form a circular pore structure containing ~22 copies, 
this oligomerization process does not extend to form layers like the PrgI needle structure. 
The conformational change in Bax results in the globular domain remaining in the 
cytosol and sterically prevents oligomerization perpendicular to the membrane.
65
 Thus, 
the structural insert that maintains a monomer Bax in the cytosol also prevents an 
unnecessary linear extension of the Bax oligomer out of the mitochondria membrane. 
Conversely, regulating PrgI oligomerization is not necessary since the assembly of the 
T3SS system is not detrimental to the cell. Therefore, a minimal pore-forming structure is 
all that is necessary for the T3SS system.  The length of the PrgI needle is controlled by 
the proper assembly of the inner rod (PrgJ) that requires the InvJ protein.
66
 The deletion 
of InvJ results in long non-functional needles. 
3.4.4 An evolutionary relationship between T3SS and eukaryotic apoptosis?   
Based on the observed similarity in the structure and function between PrgI and the Bcl-2 
protein family it is tempting to hypothesize the proteins share a common ancestor. The 
structural comparison of PrgI with the Bcl-2 family of proteins discussed above suggests 
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a possible evolutionary path. A common ancestral protein has been suggested for the Bcl-
2 protein family, where pore formation using helices 5 and 6 is the ancestral proteins 
predicted primary function.
60
 Similarly, T3SS are also predicted to evolve from a single 
gene
67
 that is a simple but versatile export system.
68
 Again, the helix-turn-helix is a 
common and ancient motif
69
 demonstrating both its diverse utility and evolutionary 
stability. Thus, it is plausible that a simple and ancient PrgI-like protein could be an 
evolutionary precursor to both the Bcl-2 protein family and PrgI. It also appears unlikely 
that PrgI and the Bcl-2 protein family would evolve through a convergent process since 
the helix-turn-helix is such a simple and ancient motif
69
 and essential to the function of 
both proteins. Evolving a readily available helix-turn-helix protein into either PrgI or the 
Bcl-2 protein family seems like a simpler path than the conversion of a uniquely distinct 
fold to incorporate a core helix-turn-helix motif. Also, the evolution of proteins from 
simple structural components has been previously proposed
70
 and is consistent with other 
general evolutionary trends where complex systems evolve from simpler systems.
71
 
By analogy, the sharing of a common ancestor by PrgI and the Bcl-2 family of 
proteins would imply an evolutionary relationship between the T3SS and eukaryotic 
apoptosis systems. T3SS is a prime example of a vestigial system and an important 
illustration of the stepwise evolution of the flagella machinery.
72, 73
 Therefore, it is 
reasonable to expect that other systems will be identified that share an evolutionary 
relationship with T3SS. T3SS is also an ancient system and clearly predates the origin of 
the mitochondria from prokaryote endosymbiosis.
74, 75
 -proteobacteria,
74
 which are 
close relatives of the mitochondria, are known to contain T3SS.
68, 76, 77
 Could an obsolete 
T3SS system contribute valuable components to the eukaryotic apoptosis system after 
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endosymbiosis? An evolutionary link has already been observed between a mitochondrial 
and T3SS protein.
78, 79
  Furthermore, a detailed analysis of the origin of apoptotic proteins 
suggests a pivotal role for bacterial proteins in the evolution of eukaryotic apoptosis.
80
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CHAPTER 4: 
 
OPTIMIZATION AND VALIDATION OF THE FAST-NMR METHOD 
 
 
4.1 INTRODUCTION 
The predicted functional similarity between PrgI and the Bcl-2 family of proteins 
described in chapter 3 illustrates the enhanced benefit of combining experimental data 
with bioinformatics.  The Functional Annotation Screening Technology by NMR (FAST-
NMR) is an initial step in achieving high-throughput functional analysis of proteins, 
independently of global sequence or structure homology transfer. FAST-NMR uses a 
tiered approach to NMR screening to identify protein active sites.
1, 2
  First, each protein is 
screened with a library of approximately 437 compounds distributed across 113 
mixtures.
3, 4
 Binding is detected using the 1D 
1
H NMR line broadening methods 
discussed in chapters 2 and 3.
2
  The compounds that show the tightest binding are passed 
to the second tier screening step (2D 
1
H-
15
N HSQC) to identify the protein active site.   
The experimentally identified active site is compared to a database of known protein 
active sites using the CPASS database and software.
5
  Finally, protein function is inferred 
by identifying similar active sites in the CPASS database.  
The tiered approach to screening, along with screening in mixtures, reduces the 
total amount of time and sample requirements needed to identify a protein active site.
1, 3, 4
  
However, the reduction in data collection time is relative to screening a protein with 
individual compounds.  A significant bottleneck in the process remains the large data 
collection time for screening all 113 mixtures and relatively large sample requirements 
needed in the 2D 
1
H-
15
N screening step.  
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NMR is a relatively insensitive technique that uses signal averaging to increase 
signal-to-noise.  Data collection time is directly proportional to the total number of scans 
needed and the recycle delay between each scan.  To maximize signal-to-noise and 
suppress residual solvent signal; the initial FAST-NMR 1D 
1
H screening step required 
64-128 scans with a recycle delay of 1.0-2.0 s (chapter 3).  The total time to collect an 
NMR spectrum for a mixture and move to the next sample is approximately 10-14 min 
(2-6 min data collection, 8 min sample change and set up).  This correlates to 
approximately 19-26 hrs of total 1D 
1
H experiment time for each protein screen.   
The tiered approach to NMR screening saves experimental time and protein 
sample by prioritizing which ligands from the 1D screen get passed to the 2D 
1
H-
15
N 
HSQC conformation screens.
1
   However, the average number of hits for the 4 proteins 
(PA1324, SAV1430, PrgI, and S. aureus primase CTD) screened with the initial method 
was 16.75 ± 10.75 ligands with a range between 5-30 ligands.  Using the tiered approach 
method still requires large sample concentrations and experimental time.  For the 30 
ligands identified that bound SAV1430 the total amount of 
15
N labeled protein was 
approximately 30 mgs and nearly 80 hrs of data collection (2.5 hrs/HSQC with 
8min/sample change).
2
  For PrgI, the protein with the lowest number of hits, the total 
time for the 2D 
1
H-
15
N HSQC screen was approximately 11.5 hrs (1.5 hrs/HSQC with 
8min/sample changing).
6
 Obviously, spending between 30-100 hrs of total experiment 
time and the large protein requirement significantly limits the throughput of the FAST-
NMR method.   
In this chapter I will discuss the optimization of the FAST-NMR method by 
implementing two new pulse sequences and making significant updates to the automated 
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NMR data collection.  The improvements made to the screening method decreased the 
total experimental time for the 1D 
1
H NMR screening step by approximately 8 hrs per 
protein.  Additionally, the improvements made to the 2D 
1
H-
15
N HSQC screening step 
provides a greater flexibility in data collection by reducing the total amount of sample 
needed or reducing to over experimental time.    
I evaluated the improvements to FAST-NMR screening using Staphylococcus 
aureus nuclease, a well-established model protein for NMR screening with a number of 
previously solved free and ligand-bound NMR structures.
7-9
 I demonstrate the improved 
FAST-NMR screening method can correctly identify the previously reported nuclease 
ligand binding site in a high-throughput manner.  Additionally, the binding site found by 
FAST-NMR was used by CPASS to correctly identified the reference nuclease structure 
from the CPASS ligand binding site database.
5
  
   
4.2 EXPERIMENTAL 
4.2.1 Materials. The bromocresol green (ACS reagent grade, 95% pure) was 
purchased from Sigma-Aldrich (Milwaukee, WI). The dimethyl sulfoxide-d6 (99.9% D),  
2,2-Bis(hydroxymethyl)-2,2′,2″-nitrilotriethanol-d19  (98% D), naproxen (98% pure) and  
deuterium oxide (99.9% D) was obtained from Aldrich (Milwaukee, WI). The 3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (98% D) was purchased from 
Cambridge Isotope (Andover, MA). The potassium phosphate dibasic salt (anhydrous, 
99.1% pure) and monobasic salt (crystal, 99.8% pure) were purchased from Mallinckrodt 
(Phillipsburg, NJ).  E. coli cells containing the pET28a(+) plasmid with nuclease 
sequence and kanamycin resistance gene was obtained from Dr. Greg Somerville‟s lab 
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(see appendix A for nuclease sequence).  The plasmid isolation kit, Quickclean 5M 
miniprep, was purchased from GenScript (Piscataway, NJ).  All competent cell lines were 
purchased from Stratagene (La Jolla, CA).  All unlabeled growth media components 
including tryptone, yeast extract, agar, sodium chloride, and IPTG were purchased from 
Aldrich.  Cobalt affinity resin was purchased from ClonTech (Mountain View, CA).      
4.2.2 Apparatus. Two different pulse sequences with improved solvent 
suppression were implemented to decrease sample requirements and data collection time 
in the FAST-NMR method.  All NMR spectra were collected on a Bruker 500 MHz 
Avance spectrometer (Billerica, MA) equipped with a triple-resonance, Z-axis gradient 
Cryoprobe.  All samples were tuned, matched and shimmed to optimize the observed 
signal.  All sample volumes were at a constant 600 L volume in a 178 mm long x 5 mm 
OD NMR tube rated for 500-700 MHz (NE-UL5-7 New Era Enterprise, Vineland, NJ) to 
minimize shimming between samples. All samples were collected at 298K. 1D 
1
H data 
was processed using ACD labs v. 12.0 while 2D 
1
H-
15
N HSQC data was processed using 
NMRPIPE
10
 and visualized using PIPP
11
 and CCCPNMR.
12
 
4.2.3 Optimization of automated data collection. As described in chapter 2 and 
3, the FAST-NMR method utilizes the Bruker BACS-120 sample changer and IconNMR 
software for automated data collection. To increase throughput, the automatic receiver 
gain adjustment was turned off and each sample was collected at a constant receiver gain.  
Additionally, an automatic shimming routine using a single iteration of the Bruker 
gradient shimming to optimize Z1 and Z2 field axes was developed to minimize the time 
needed to shim a sample while providing adequate line shape.  
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4.2.4 Implementation of the 1D 
1
H excitation sculpting pulse sequence. The 
1D 
1
H excitation sculpting pulse sequence
13
 came as a standard and compiled pulse 
sequence in the Bruker pulse sequence library (zgesgp).  All 
1
H 90
o
 pulse lengths were 
optimized by finding a 360
o
 spectral null at a constant power level of -4.3 dB.  The 
optimized 
1
H 90
o
 pulse length was used to calculate all 
1
H pulses used in the sequence. A 
total of 64 real transients and 8 dummy transients at 8k data points were collected with a 
recycle delay of 1.0 s. Total experiment time was approximately 1.25 min. 
The excitation sculpting pulse sequence was compared to the presaturation pulse 
sequence to examine differences in spectral quality, signal to noise and ability to measure 
a single point binding constant (chapter 2).   The presaturation sequence was executed in 
the same manner as the excitation sculpting sequence with a recycle delay of 2.0 s to 
maximize solvent suppression. Total experiment time was approximately 2.5 min. 
A free ligand solution was prepared in a 5 mL stock containing 50 M naproxen, 
5% (v/v) deuterated dimethyl sulfoxide-d6 (DMSO-d6), 11.1 M 3-
(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) and 50 mM potassium 
phosphate buffer pH 7.0 (uncorrected) in 99.98% deuterium oxide.  Five replicate 
samples were made from the 5 mL stock solution and transferred to individual NMR 
tubes.  These 5 samples were used for calculating the average free ligand intensities (IF) 
and average free ligand linewidths ( F).  Data for each sample was collected using the 
excitation sculpting sequence and presaturation sequence.  
A bound ligand solution was prepared in a 5 mL stock solution containing 50 M 
naproxen, 5 M human serum albumin (HSA), 5% (v/v) deuterated dimethyl sulfoxide-
d6 (DMSO-d6), 11.1 M 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) 
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and 50 mM potassium phosphate buffer pH 7.0 (uncorrected) in 99.98% deuterium oxide. 
Five replicate samples were made from this stock solution and transferred to individual 
NMR tubes.  These 5 samples were used to calculate the average bound ligand intensities 
(IB).   Data for each sample was collected using the excitation sculpting sequence and 
presaturation sequence. 
 4.2.5 Implementation of the 2D 
1
H -
15
N HSQC with WATERGATE and 
water flip-back for solvent suppression. The 2D 
1
H-
15
N HSQC utilizing 
WATERGATE and water flip-back pulses came as a standard and compiled pulse 
sequence in the Bruker pulse sequence library (hsqcfpf3gpphwg). All 
1
H 90
o
 pulse 
lengths were optimized in the same manner as describe above in section 4.2.2.1.  
Additionally, all 
13
C and 
15
N pulse powers were optimized using the Bruker dec90 and 
dec90F3 pulse sequences, respectively.  A 100 M 
15
N labeled S. aureus nuclease sample 
and 5 M 
15
N labeled S. aureus nuclease sample were used to test the pulse sequence.  
Both samples were prepared in a 95% H2O/5%D2O buffered solution of 50 mM KPO4 
(pH 7.0) with 300 mM NaCl. 
4.2.6 Expression of unlabeled and 
15
N labeled S. aureus nuclease. The 
pET28a(+) plasmid with the recombinant nuclease sequence and kanamycin resistance 
gene was extracted from the stock E. coli cells using the method outlined in the Genscript 
Quickclean 5M miniprep kit (appendix 4B).  The plasmid was transformed into Bl21-
DE3-pLySs and Bl21-DE3-codon+ competent E. coli cells using the method described in 
the Stratagene manual.   Transformed cells were grown at 37 
o
C for 12 hrs on LB agar 
plates containing 50 mg/L kanamycin.  Only the Bl21-DE3-codon+ cells produced any 
colonies.  
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Three different isolated colonies were selected from the agar plate, individually 
inoculated into three different centrifuge tubes containing 25 mL of LB broth and left to 
grow for 12 hrs in an incubated shaker at 37 
o
C.  A 1 mL sample from each 12 hr growth 
was inoculated into three different 25 mL cultures of LB broth and left to grow until an 
O.D of 0.6 at 600nm was reached. Protein expression was induced by the addition of 500 
mM IPTG.  Induced cells were grown for an additional three hours and expression was 
checked by running a 15% PAGE gel of the whole cells (figure 4.5A).  The colony that 
gave the best expression was used to make a 25 mL 40% glycerol stock suspension stored 
in 1 mL aliquots for future expressions as previously described.
14
  
A 1 mL glycerol stock sample was thawed and used to make a LB agar streak 
plate.  Unlabeled S. aureus nuclease was expressed by isolation of a single colony from 
the streak, growing strain BL21(DE3)codon+/pET28a(+) in 25 mL LB broth containing 
kanamycin at 50 mg/L at 37 
o
C for 12 hrs.  A 5 mL sample of the 12 hr growth was 
inoculated into 1 L cultures (2 L total) of LB broth containing kanamycin at 50 mg/L at 
37 
o
C until an absorbance of 0.67 at 600 nm was reached (~4 hrs).  Protein expression 
was induced by the addition of 500 mM IPTG to each culture and shaken for an 
additional 3.5 hrs at 37 
o
C (appendix 4C).   Cells were harvested by centrifugation at 
10,000 G and stored frozen at -80 
o
C.   
A 1 mL glycerol stock sample was thawed and used to make a LB agar streak 
plate.  
15
N-labeled S. aureus nuclease was expressed by isolation of a single colony from 
the streak, growing strain BL21(DE3)codon+/pET28a(+) in 25 mL M9 minimal media 
broth (2 mL 1M MgSO4, 100 uL 1M CaCl2, 10 mL 100x Basal Medium Eagle Vitamin 
Solution (Gibco), 1.0 g 
15
N-NH4Cl, 4 g d-glucose, 200 mL of 5xM9 salts) containing 
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kanamycin at 50 mg/L at 37 
o
C for 12 hrs.  A 5 mL sample of the 12 hr growth was 
inoculated into 1 L cultures (2 L total) of M9 minimal media broth until an absorbance of 
0.79 at 600 nm was reached (6.75 hr) (appendix 4C).  Protein expression was induced by 
the addition of 500 mM IPTG to each culture and shaken for an additional 3 hrs at 37 
o
C.   
Cells were harvested by centrifugation at 10,000 G and stored frozen at -80 
o
C.   
4.2.7 Purification of unlabeled and 
15
N-labeled S. aureus nuclease. Both 
unlabeled and 
15
N-labeled S. aureus nuclease expressions were treated the same for 
purification. Cells were thawed, re-suspend in equilibration/wash buffer (50 mM sodium 
phosphate pH 7.0 and 300 mM NaCl) in 25 mL aliquots and sonicated on ice 3 times at 
45 s intervals.  The lysate was centrifuged for 30 min at 10,000 g and incubated with 10 
mL Talon Cobalt affinity resin for 30 min at 4 
o
C.  The protein bound resin was washed 
by passing 4 column bed volumes of equilibration/wash buffer through the resin bed.  
Nuclease was eluted with 5 column bed volumes of elution buffer (50 mM sodium 
phosphate pH 7.0, 300 mM NaCl and 150 mM imidazole) and stored at 4 
o
C. 
4.2.8 FAST-NMR screening of S. aureus nuclease. A FAST-NMR screen, 
AutoDock ligand bound co-structures and CPASS analysis of the S. aureus nuclease 
ligand binding site was completed using the methods described in chapter 3 with 
additional modifications. Specifically, the FAST-NMR ligand affinity screen of nuclease 
utilized the pulse sequences and experimental parameters described above. The increase 
in solvent suppression efficiency required using less protein sample per screen due to 
aliphatic protein resonance overlap with the ligand signals.  The total protein 
concentration was reduced from 25 M in the PrgI screen to 5 M in the nuclease screen.   
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A 10 mL volume of stock nuclease was buffer exchanged with equilibration/wash 
buffer to remove residual imidazole.  Each buffer exchange involved centrifuging the 
nuclease sample at 5,000 G for 5 min to a volume of ~1 mL using a 15 mL Amicon 
Ultra-15, 10,000 MW cutoff centrifugal filter unit (Millipore, Billerica, MA).  After each 
centrifugation, 10 mL of equilibration/wash buffer was added to the Amicon Ultra-15 and 
the process was repeated 5 times.  After the final buffer exchange the nuclease sample 
was concentrated to 5 mL.  The final concentration of the sample was approximately 1 
mM nuclease in a buffered solution of 50 mM sodium phosphate pH 7.0 and 300 mM 
NaCl. 
 1D 
1
H NMR ligand affinity screening was completed in a similar manner 
described in chapter 3.  Briefly, 5 M nuclease was added to each ligand mixture (100 
M/ligand) in a 99.99% D2O buffered solution of 20 mM d19-bis-Tris at pH 7.0 with 5% 
DMSO-d6 to maintain ligand solubility and 11.1 M 3-(trimethylsilyl)propionic-2,2,3,3-
d4 acid sodium salt as a chemical shift reference.  A total of 113 mixture samples were 
prepared.  1D 
1
H NMR spectra for each sample was collected using the excitation 
sculpting sequence with 64 real scans, 8 dummy scans with 8 k data points, a sweep 
width of 12.0 ppm and a recycle delay of 1.0 s.  Data was Fourier transformed, auto-
phase and baseline corrected. The 1D 
1
H NMR spectra were compared to free ligand 
mixture reference spectra and visually analyzed to identify binding ligands.  A binding 
event was identified by the decrease in ligand intensity of the nuclease-mixture relative to 
the free ligand mixture.  Total data collection time including sample changing was 
approximately 6 min/spectrum 
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All 2D 
1
H-
15
N HSQC affinity screens were completed by the addition of 500 M 
ligand to a 100 M 
15
N labeled nuclease sample in a 95% H2O/5%D2O buffered solution 
of 20 mM bis-Tris at pH 7.0 with 5% DMSO-d6 to maintain ligand solubility.  2D 
1
H-
15
N 
HSQC spectra were collected using the WATERGATE/flip-back pulse sequence 
described in section 4.2.5 with 8 real scans, 128 dummy scans, 1 k data points in the 
1
H 
dimension and 128 data points in the 
15
N dimension.  The sweep width of the spectrum 
was 12.0 ppm in the 
1
H dimension and 30.0 ppm in the 
15
N dimension.  A recycle delay 
for the pulse sequence was set to 1.0 s.  Total data collection time was approximately 20 
min/spectrum.  Spectra were processed using the same parameters as described in section 
4.2.4.     
 
4.3 RESULTS AND DISCUSSION 
As described in chapters 2 and 3, NMR affinity screening generally involves 
collecting an NMR spectrum at a low analyte concentration in an aqueous buffer.  This 
poses a significant challenge when developing a high-throughput NMR screening 
methods.  The relative concentration of residual protons in 99.99% D2O is 1100 mM 
compared to 20-100 M for the free ligand. The ~10-50 fold intensity difference between 
solvent and analyte peaks decreases the limit of detection (figure 4.1A). A number of 
solvent suppression techniques exist to selectively irradiate the solvent peak and increase 
the detection limit. 
The initial pulse program used for the 1D 
1
H NMR affinity screening in the 
FAST-NMR method was a presaturation sequence with a composite pulse train prior to 
the 90
o
 pulse (figure 4.1B).  The presaturation pulse is a low power pulse implemented 
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during the recycle delay at the frequency of the solvent signal.  As the presaturation pulse 
length is increased there is an increase in solvent suppression.  To maximize signal, the 
recycle delay is set at 1-5 times larger than the T1 relaxation rate for the analyte. A 
recycle delay of 2.0 s (see chapter 2 and 3) is used for the presaturation method. 
132 
 
 
  
 
 
133 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Solvent suppression for low concentration experiments. (A) A 100 M 
sample of bromocresol green in an aqueous buffer prepared with 99.99% D2O.  The 
residual protons from the water (~1100 mM) squelched the bromocresol green signals 
giving one strong peak in the center of the spectrum.  (B) The presaturation with 
composite pulse water suppression technique is used to selectively suppress the solvent 
signal.  Quality of solvent suppression is dependent on the power (p19) of the 
presaturation pulse (presat) and the pulse length, which is the same as the recycle delay 
(d1).  A composite pulse (thin vertical black bars) is applied for analyte excitation to 
decrease the effect of inhomogeneities in the applied B1 field. (C) A 100 mM sample of 
bromocresol green after solvent suppression. The experiment was collected using the 
pulse program in (B) with a recycle delay of 2.0 s and 64 scans.  The time to collect one 
spectrum is approximately 2.25 min.  The residual solvent peak can be removed for 
clarity during processing, but has a baselinewidth of 117 Hz.   
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4.3.1 Optimization of automated data collection.  The largest limiting factor for 
high-throughput ligand binding studies using the FAST-NMR method is the nearly 8 min 
required for sample changing and experimental set up.  This correlates to approximately 
15 hrs of “dead time” between data collection.  A large portion of the time was tied to the 
receiver gain adjustment and shimming routine (~3 min).  The previously described 
method for FAST-NMR (chapter 3) required samples to be prepared in 500 L volumes 
to reduce sample requirements.  However, this inadvertently required a longer shimming 
routine because the sample was not uniformly covering the receiver coil.  By preparing 
samples at a larger 600 L volume that extends beyond the receiver coil, a shorter 
gradient shimming routine was implemented while maintaining good line shape and 
linewidth. Using a simple gradient shim routine saved nearly 2 min between samples.  
Additionally, setting the receiver gain to a constant value based on the first sample and 
removing the automatic receiver gain adjustment saved nearly 1 min of sample set up 
time.  A total time savings of ~3 min per sample was seen by making small adjustments 
to the automatic data collection protocols reducing the total time between samples to ~5 
min. For the FAST-NMR library of 113 mixtures this correlates to a savings of ~5.5 hrs, 
reducing the total time for sample changing and set up during a FAST-NMR screen to 9.4 
hrs.  
4.3.2 Improving 1D 
1
H NMR screening efficiency. To further increase 
throughput of the FAST-NMR screen requires using a 1D 
1
H pulse sequence that will 
give comparable or better results with a shorter recycle delay.  The excitation sculpting 
pulse sequence for solvent suppression developed by Hwang et. al,
13
 uses gradient pulses 
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to selectively irradiate the water.  This removes the dependency on the recycle delay as 
found in the presaturation sequence. 
I compared the standard FAST-NMR presaturation pulse sequence with the 
excitation sculpting sequence to determine if there were any improvements in the ligand 
binding analysis.  Specifically, I was looking for improvement in water suppression, 
increases in signal to noise and overall spectral quality.  Spectral quality was determined 
by the amount of post-processing editing required.  I was also looking for differences in 
measured single point binding dissociations constants (KD) as described in chapter 2.  
 Five replicate samples were made at two different human serum albumin (HSA) 
concentrations (0 M and 5 M) containing 50 M naproxen, 5% (v/v) deuterated 
dimethyl sulfoxide-d6 (DMSO-d6), 11.1 M 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid 
sodium salt (TSP) and 50 mM potassium phosphate buffer pH 7.0 (uncorrected) in 
99.98% deuterium oxide.  All samples at 0 M HSA were used for calculating the 
average free ligand intensities (IF) and average free ligand linewidths ( F).  All samples at 
5 M HSA were used for calculating the average bound ligand intensities (IB).  A 1D 
1
H 
NMR spectrum using the presaturation sequence and the excitation sculpting sequence 
were collected sequentially for each sample. All samples were collected under the same 
conditions at a constant receiver gain of 32.   
The excitation sculpting method efficiently suppressed the solvent signal such that 
no residual solvent signal remained (figure 4.2C&D). The resulting baseline was flat and 
did not require any baseline corrections. The presaturation sequence did not completely 
remove the residual solvent signal and required post-processing editing of the residual 
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solvent signal. Additionally, a baseline correction was needed because of a rolling edge 
near 10.0 ppm (figure 4.2A&B). 
The signal to noise ratio for both sequences was comparable at the constant 
receiver gain set to 32 with the excitation sculpting sequence S/N = 74.9 and the S/N for 
the presaturation was 68.8 compared to the methyl peak in naproxen. The presaturation 
sequence is limited to a low receiver gain because the residual water signal is still large 
relative to the analyte concentration.  However, the improved water suppression of the 
excitation sculpting method allows a larger receiver gain (1 k). This improves the S/N to 
431.6 relative to the methyl peak in naproxen.  This was a 6 fold improvement in S/N 
compared to the initial presaturation pulse sequence.   
The naproxen average linewidth for the presaturation sequence was 3.52 ± 0.5 Hz, 
where the average linewidth for the excitation sculpting sequence was to 2.52 ± 0.1 Hz.  
The differences are due to removing the residual water signal.  For example, without 
removing the residual water signal in the presaturation sequence the reference TSP peak 
has a half width of 7.79 Hz calculated by the peak fitting routine in ACD labs.  Once the 
water peak is removed the reference peak linewidth drops to 1.91 Hz.  The difference is 
caused by the automatic peak fitting routine in ACD misreading the true baseline of the 
spectrum, this is due to negative data points in the residual solvent signal (figure 4.2 A) 
and the baseline roll at the edge of the spectrum (figure 4.2 B).  The excitation sculpting 
sequence does not have these issues and therefore the average calculated linewidth is 
smaller.  
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Figure 4.2. Comparison between two water suppression techniques. (A) The 
presaturation pulse sequence of a 50 M naproxen sample in a 99.99% D2O buffer.  The 
pulse sequence does not completely suppress the residual water signal at 4.69 ppm.  (B) 
An expanded view of the presaturation spectrum. In addition to not sufficiently 
suppressing the solvent signal the presaturation sequence generates a baseline roll at the 
edge of the spectrum around 10 ppm.  These issues distort the accurate measurement of 
the free ligand linewidth and introduce significant error in the KD measurement.  (C) The 
excitation sculpting sequence efficiently suppresses the solvent signal so no post 
processing editing is required. (D) Additionally the excitation sculpting method does not 
introduce baseline roll in the spectrum. The total time to collect a spectrum using the 
excitation sculpting sequence is approximately 1.25 min compared to 2.5 min for the 
presaturation method. 
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   The difference in measured average linewidth between the two pulse programs 
has a dramatic effect on the accuracy in measuring single point binding constants (KD).  
The peak height for each spectrum was summed and then averaged to calculate Bexpt (eq 
2.7) and the single point KD (eq 2. 8) (see chapter 2 for method description).  The 
measured KD for naproxen biding to HSA was 0.36 M using the excitation sculpting 
method and   -43.7 M using the presaturation pulse.  The non-sense KD value from the 
presaturation pulse was caused by the over estimation of the free ligand linewidth.  In 
chapter 2, the average ligand linewidth using the presaturation pulse sequence was 1.8 Hz 
and the single point KD was 0.7 ± 1.2.  The data for chapter 2 was collected under 
analytical conditions with a large number of scans (512) and long experiment time of 33 
min per sample.  This is not amenable to high-throughput screening. The problem with 
accurately measuring a free ligand linewidth under high-throughput conditions severely 
limits the utility of the presaturation pulse sequence.    
The results from the excitation sculpting sequence show a significant 
improvement over the presaturation pulse for the FAST-NMR screening.  Solvent 
suppression using this sequence is not dependent on the recycle delay reducing the total 
time needed to collect a single spectrum by approximately 1.25 min.   Additionally, the 
results from an excitation sculpting sequence do not need post processing solvent filtering 
which dramatically improves the single point KD method for high-throughput NMR 
ligand affinity screens.  
 4.3.3 Improving 2D 
1
H-
15
N HSQC NMR screening efficiency. The standard 
2D 
1
H-
15
N HSQC spectrum correlates the amide proton to the amide nitrogen giving a 
single peak for each amino acid (figure 4.3).  The current method using the standard 2D 
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1
H-
15
N HSQC requires between 1.5-2.5 hrs per spectrum and is therefore a significant 
portion of the screening time for FAST-NMR.  In addition to the data collection time, the 
method requires a minimum of 100 M 
15
N labeled protein per sample equaling between 
1-30 mgs of protein depending on the number of hits from the 1D 
1
H NMR screen.  
 
 
Figure 4.3 A standard 2D 
1
H-
15
N HSQC Spectrum.  The standard 2D 
1
H-
15
N HSQC 
correlates each backbone amide proton with its corresponding backbone amide nitrogen.  
Samples are collected in 95% H2O/5%D2O buffers with a large residual solvent streak 
(5.0 ppm). The relative ratio of analyte to solvent signal reduces the overall signal to 
noise requiring larger concentrations of analyte and longer data collection times (1.5-2.5 
hrs).  The sample was 100 M PrgI in 95%H2O/5%D2O buffered solution of 20 mM bis-
Tris pH 7.0). 
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To increase the efficiency and versatility of the 2D 
1
H-
15
N HSQC screening step 
in FAST-NMR, a solvent suppressed 2D 
1
H-
15
N HSQC pulse sequence was 
implemented.  The sequence uses the WATERGATE and water flip back method for 
solvent suppression.
15
 Suppressing the residual water in 2D 
1
H-
15
N HSQC increases the 
flexibility for NMR screening.  If sample is a limiting factor, the pulse sequence can 
detect protein concentrations as low as 5 M with an extended acquisition time.  If 
sample concentration is not a limiting factor, the pulse program can be used to collect an 
NMR spectrum in approximately 20 min at 100 M protein concentration (figure 4.4).  
 A 5 M sample of 
15
N labeled S. aureus nuclease was prepared in a 95% 
H2O/5%D2O buffer with 50 mM KPO4 and 300 mM NaCl.  Data was collected using the 
WATERGATE
15
/water flip back 2D 
1
H-
15
N HSQC
16
 pulse sequence with 400 real scans, 
128 dummy scans, 1 k data points in the 
1
H dimension and 128 data points in the 
15
N 
dimension.  The sweep width of the spectrum was 17.0 ppm in the 
1
H dimension and 30.0 
ppm in the 
15
N dimension.  A recycle delay for the pulse sequence was set to 1.0 s. The 
total experiment time was 13 hrs.  A 100 M sample of 
15
N labeled S. aureus nuclease 
was prepared using the same buffer conditions. An NMR spectrum was collected similar 
to the 5 M sample, but with only 8 real scans. The total time to collect a 2D 
1
H-
15
N 
HSQC at 100 M protein concentration was approximately 20 min. There was no 
difference in peak position between the two experiments. No differences were observed 
compared to a standard 2D 
1
H-
15
N HSQC spectrum of free nuclease at 1.2 mM protein 
concentration (figure 4.5C).  The WATERGATE/water flip back 2D 
1
H-
15
N HSQC 
experiments sufficiently suppressed the residual solvent peak such that no post-
processing editing was required.    
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Figure 4.4 Concentration study of the  WATERGATE/water flip back 2D 
1
H-
15
N 
HSQC. (A) A 5 M sample of 
15
N labeled S. aureus nuclease was prepared in the a 95% 
H2O/5%D2O buffer with 50 mM KPO4 and 300 mM NaCl. NMR spectrum was collected 
with 400 scans and experiment time was approximately 13 hrs.  (B) A 100 M sample of 
15
N labeled S. aureus nuclease under the same conditions collected with 8 scans.  Total 
experiment time was approximately 20 min.  
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4.3.4 FAST-NMR screen of S. aureus nuclease. The 19 kDa protein 
Staphylococcus aureus nuclease is a well-studied NMR model system and was used to 
test the FAST-NMR optimization and validate its functional annotation.
7-9
 The goal of 
the experiment was to identify nuclease binding ligands using the FAST-NMR screening 
methods, to identify the active site of the protein, and to complete a successful CPASS 
analysis.  The hypothesis was that we would find the same binding site as previously 
reported for the nuclease- thymidine-3‟,5‟-diphosphate ligand bound co-structure.7-9 
Furthermore, we would identify a preferential similarity between this nuclease‟s ligand 
binding site and other nuclease ligand binding sites. 
Unlabeled and uniformly 
15
N labeled nuclease was expressed and purified as 
described in the experimental sections 4.2.6 and 4.2.7.  Expression was checked by 
comparing induced and non-induced samples of three growth cultures (figure 4.5A).  A 
total of 75.6 mg/L unlabeled and 23.4 mg/L 
15
N labeled purified nuclease was obtained 
from 2 L growths.  All concentrations were measured by maximum UV absorbance at 
280 nm with a molar extinction coefficient,  of 17,420 M
-1
 cm
-1
.  A 2D -
1
H-
15
N HSQC 
was collected on the purified sample of 
15
N labeled nuclease and compared to the 
reported 2D 
1
H-
15
N HSQC spectrum
7-9
 and associated assignments to check for proper 
folding of the protein (figure 4.5C).  The spectrum for the expressed nuclease was 
comparable to the reference spectrum
7-9
 with differences most likely accounted for by 
differences in buffer, temperature, spectral resolution and the slightly longer sequence of 
the expressed nuclease (9 additional N-terminal amino acids, see appendix 4A for 
comparison between expressed nuclease and reference sequence).    
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Figure 4.5 Expression and purification of S. aureus nuclease. (A) Induced cultures 
(lane 3, 5 and 7) of unlabeled nuclease from 3 randomly selected colonies of E. coli 
BL21-DE3-codon+(nuc) were compared to non-induced cultures (lane 2, 4, 6).  A dark 
band was identified in the induced cultures at approximately 19 kDa (MW lane 1).  (B) 
Purification of the culture media with a his-tag resin gave 5 isolated bands (lane 3-7) at 
the same molecular weight as in (A).  (C)  The expression and purification was repeated 
under minimal media conditions for expression of 
15
N labeled nuclease.  A 2D 
1
H-
15
N 
HSQC was collected on a sample from the purified stock solution (1.2 mM).  The protein 
spectrum was dispersed indicating a folded protein.          
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Unlabeled nuclease was screened against the compound library as described in the 
experimental section 4.2.8.  A total of 18 ligands were identified in the 1D 
1
H NMR 
screening. Table 4.1 reports the list of all nuclease-binding ligands found in our chemical 
library.  All nucleotides in the chemical library bound nuclease.  Binding of thymidine-
5‟-triphosphate was indicated by relative changes in peak height between the free and 
bound spectrum and the appearance of enzymatic turnover of the ligand (figure 6A).  
Two new peaks at 7.32 ppm and 8.3 ppm are visible when the 5 M nuclease is added to 
the sample.  
 
Table 4.1 Ligands identified to bind nuclease from a high-throughput NMR screen.  
 
Binding ligand 
Adenosine-5‟-triphosphate 
Guanosine-5‟-triphosphate 
Uracil-5‟-triphosphate 
Cytosine-5‟-triphosphate 
Thymadine-5‟-triphosphate 
3'-5'-cyclic guanosine monophosphate 
3'-5'-cyclic adenosine monophosphate 
Suramin 
Mitoxantrone dihydrochloride 
Phosphocholine 
4-Hydroxy-3-methoxyphenylglycol 
Aquocobalamin 
L-leucine 
Bepridil dihydrocholoride 
Ciprofloxacin 
Diminazene 
Lumicolchince 
Acebutolol hydrochloride 
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 Confirmation of ligand binding was completed by monitoring changes in 
15
N and 
1
H chemical shifts upon addition of 500 M thymidine-5‟-triphosphate ligand to a 100 
M 
15
N labeled nuclease sample.  Binding site residues between nuclease and thymidine-
5‟-triphosphate were identified in a similar manner as described in chapter 3.  A total of 
17 residues were identified to have greater than 1 standard deviation from the average 
chemical shift difference upon addition of the ligand.  Of these 17 residues, 6 were 
identified in the side chain amide region, 6 residues were unambiguously identified and 
the remaining 5 were either not assigned in the reference spectrum or could not be 
unambiguously identified.  Four of the unambiguously identified residues, F34, R35, 
K84, and Y113, were residues found in the active site of the reference structure (figure 
4.6B&C). The reference binding pocket is composed of 8 amino acids F34, R35, and 
L36, T82, D83, K84, Y115, V114, and Y113.  Thymidine-5‟-triphophate was the only 
ligand titrated with 
15
N labeled nuclease because thymidine-3‟,5‟-diphosphate is the 
bound ligand for the reference nuclease structure (PDB 1JOK), which was not in the 
FAST-NMR chemical library at the time of screening.   
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Figure 4.6 FAST-NMR screen of S. aureus nuclease. (A) Unlabeled nuclease was 
screened with the FAST-NMR compound library as described in chapter 2 using the new 
pulse sequences as described in section 4.2.8.  18 ligands were found to bind nuclease 
with thymidine-5‟-triphosphate (AI single, AII mixture free) showing possible enzymatic 
turnover (AIII bound) in addition to a decrease in signal.  Two new NMR resonance not 
found in the free mixture (AII) are observed in the complex (AIII).  The assignment of 
these peaks is not clear, but most likely correspond to  the formation of thymidine-5‟-
diphosphate from thymidine-5‟-triphosphate.  The non-binding compounds in the mixture 
include biotin and acetylsalicylic acid.  (B) 17 peaks significantly changed in a 2D 
1
H-
15
N HSQC spectrum upon the addition of 500 M thymidine-5‟-triphophate to a 100 M 
sample of 
15
N labeled nuclease.  For clarity, an example of the relative change upon 
ligand binding for two residues (F34 and R35) is shown (black free nuclease, red ligand 
bound nuclease).  (C) The residues identified in the 2D 
1
H-
15
N HSQC spectrum are 
highlighted on the protein structure (1JOK) and used to generate a ligand bound co-
structure.   Structure images were generated with VMD
17
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A ligand bound co-structure of nuclease with thymidine-5‟-triphosphate was 
generated in the same manner as described in detail in chapter 3.   The residues identified 
in the 2D 
1
H-
15
N HSQC spectrum binding study that overlapped with the known binding 
site were used to define the grid search space for AutoDock. The Autodock Filter 
program
18
 was run to select the best conformation.  Finally, the ligand bound co-structure 
was uploaded to CPASS.
5
  
The best hit for the nuclease-thymidine-5‟-triphosphate docked co-structure was a 
Staphylococcus nuclease protein (PDB 1TR5) bound to thymidine-3,-5‟-diphosphate.  
The active site similarity score was 47.47% with an average rmsd of 0.69 ± 0.3 Å for the 
overlapping active site residues.   CPASS did not find the structure used to generate the 
ligand bound structure (PDB 1JOK) because the program filters out proteins with ≥ 95% 
sequence similarity and/or ligand binding sites with ≥ 80% sequence similarity.  
However, recent updates to the CPASS database and software now allow for pairwise 
active site comparisons.  The pairwise comparison between the docked nuclease co-
structure and the experimental co-structure bound to thymidine-3‟,5‟-diphosphate had a 
pairwise active site similarity score of 48.1% with and an average rmsd of 0.76 ± 0.3 Å 
for the overlapping active site residues.  
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Figure 4.7 CPASS analysis of S. aureus nuclease. (A) The ligand bound co-structure 
for nuclease complexed with thymidine-5‟-triphosphate (yellow) was uploaded to the 
CPASS database. (B) The best match was the Staphylococcus nuclease protein (PDB 
1TR5) bound to thymidine-3,-5‟-diphosphate (yellow). (C) An overlay of the two active 
sites (1JOK blue, 1TR5 red) gave an overall rmsd of 0.69± 0.3 Å and a CPASS similarity 
score of 47.47%. The sequence alignment of the two ligand binding sites is shown below 
the figures, where the aligned residues are colored blue in A and B. Structure images 
were generated with VMD.
17
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Appendix 4A.  Sequence of S. aureus nuclease.  A ClustalW sequence alignment with 
the sequence of the expressed nuclease (dNuclease) is shown with the reference nuclease 
sequence (refNuclea).  The reference nuclease sequence was reported from the PDB ID 
1JOK
7-9
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Appendix 4B. Comparison of the standard pET-28a(+) and nuclease inserted pET-
28a(+)–nuc plasmids used for the nuclease expression.  (A) Standard pET-28a(+) 
plasmid (B) nuclease inserted plasmid. (C) 1% agarose gel of the isolated pET-28a(+)-
nuc plasmid (lane2), digested plasmid (lane 3) and control pET-28a(+) plasmid (lane 4).   
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Appendix 4C.  Growth curves for nuclease expression. (A) Expression of unlabeled 
nuclease with IPTG induction at 3.5hrs OD600nm 0.67.  (B) Expression of 
15
N labeled 
nuclease with IPTG induction at 6.75 hrs OD600nm 0.79.  The difference in growth rates 
was caused by the difference in growth media.   
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CHAPTER 5:  
THE STRUCTURE, DYNAMICS AND LIGAND SCREENING OF THE 
PRIMASE C-TERMINAL DOMAIN (CTD) FROM STAPHYLOCOCCUS AUREUS 
 
 
5.1 INTRODUCTION 
 
  Bacterial primase (DnaG) is a conserved and essential enzyme responsible for the 
synthesis of Okazaki fragments during DNA replication.
1
  The protein is composed of 
three domains; N-terminal domain responsible for DNA binding, the catalytic core 
responsible for synthesis of Okazaki fragments, and the C-terminal domain (CTD) 
responsible for the interaction between primase and bacterial helicase (DnaB).
2, 3
 Full 
length primase is conserved among all organisms and exhibits relatively large sequence 
similarity.
1, 4, 5
 However, the sequence conservation is limited to the N-terminus and 
catalytic core.
1
 The C-terminal domain (primase CTD) is highly variable; even among 
similar species.
1, 4, 5
 The functional consequence of the low sequence conservation of the 
C-terminal domain is still unclear, but it could play a role in regulating species-specific 
DNA replication.
6
   
The solution structures of primase CTD shows significant variability between 
Geobacillus stearothermophilus (PDB 1Z8S) and Escherichia coli (PDB 2HAJ).
4, 7
  
Generally, the primase CTD structure is composed of two sub-domains, an N-terminal 
six-helix bundle (sub-domain C1) that is essential for DnaB activity and correct primer 
length and a helical hairpin (sub-domain C2) that mediates binding to DnaB.
4, 8
  The two 
solution structures share significant structure similarity at the N-terminal bundle (C1 sub-
domain) but show a sharp difference in the corresponding C2 sub-domain.
4, 7, 8
  In E. coli 
primase CTD is composed of 7 helices with the two sub-domains connected through a 
long ridged helix 6.
7
  In G. stearothermophilus the helix linking the two sub-domains is 
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kinked at a Pro556 residue forming two distinct helices (helix 6 and 7).
4
  The recent 
structure of the DnaG-DnaB complex shows that both the C1 and C2 sub-domains are 
important for binding to helicase.
9
  
The discrepancy in the DnaG CTD structures has yet to be fully resolved.   
However, it has been shown that primer synthesis is only carried out when primase CTD 
and helicase N-terminal domain (NTD) interact.
6
  The differences in sequence and 
structure of the primase CTD between the two organisms suggest a species-specific 
method of replication regulation.
6
  The S. aureus sequence (see appendix 5A) for primase 
CTD is more similar to the G. stearothermophilus sequence with 20% sequence identity 
and 58% sequence similarity.  However the sequence similarity between S. aureus 
sequence and the E. coli sequence (57% similarity and only 10% sequence identity) is 
comparable to the sequence similarity between S. aureus and G. stearothermophilus. The 
comparable sequence similarities make direct homology modeling challenging because 
either structure is a possible model for S. aureus. But, by comparing the sequence 
similarities of the loop region between helix 6 and 7, the proline residue (Pro556) that 
forms the kink in the linking helix in G. stearothermophilus is replaced with a glycine in 
S. aureus (appendix 5A).  Glycine has the second largest propensity (second to proline) to 
be found in a loop region.
10, 11
 Conversely, the E. coli sequence contains a methionine in 
the corresponding position consistent with a rigid helix 6. This single amino acid 
substitution between the three proteins suggests the S. aureus primase structure is more 
likely to be similar to the G. stearothermophilus structure.   
The rapid rise in community acquired antibiotic resistance, particularly to S. 
aureus, requires the rapid identification of new antibiotic targets and potential drugs.
12
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The primase-helicase interaction is an attractive antibiotic target because it is functionally 
conserved in bacteria, essential for DNA replication and the bacterial DnaG-DnaB 
interaction is distinctly different from that of eukaryotes.
1, 6
  Additionally, the high degree 
of sequence variability and differences in structure suggest a possible means to tailor 
antibiotic development to a specific organism.   
As described in chapter 1, the 1D 
1
H and 2D 
1
H-
15
N HSQC screening methods 
used for FAST-NMR was originally developed for high-throughput drug discovery.  
However, to specifically find an active site for structure based drug discovery, the 
complete backbone resonance assignments and a high-resolution, three-dimensional (3D) 
structure are required. In this chapter, I will discuss the NMR determination of the 
solution structure for S. aureus primase CTD. I will examine a potential phylum 
dependency on the two sub-domain structures using sequence and structure similarities.  I 
will also report protein dynamics for the conformation of a loop region between the two 
sub-domains.  Finally, I will discuss the discovery of a potential lead compound that 
binds to the C2 sub-domain of primase CTD. 
 
5.2 EXPERIMENTAL 
 
5.3.1 Materials. For the DnaG primase CTD  structure determination, NMR 
dynamics analysis of the structure, and the NMR ligand affinity screens, purified and 
uniformly 
13
C, 
15
N labeled [U-
13
C, 
15
N] DnaG primase CTD and 
5
N labeled [U-
15
N] 
DnaG primase CTD  was purchased from Nature Technologies (Lincoln, NE) (see figure 
5.1A for gel).  The dimethyl sulfoxide-d6 (99.9% D) and deuterium oxide (99.9% D) 
were obtained from Aldrich (Milwaukee, WI). The 3-(trimethylsilyl)propionic-2,2,3,3-d4 
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acid sodium salt (98% D) was purchased from Cambridge Isotope (Andover, MA). The 
potassium phosphate dibasic salt (anhydrous, 99.1% pure) and monobasic salt (crystal, 
99.8% pure) were purchased from Mallinckrodt (Phillipsburg, NJ).  All compounds used 
for screening were obtained as described in chapters 3, 4 and elsewhere.
13
  Briefly, the 
compound library is composed of 437 known biologically active compounds distributed 
across 113 mixtures with 3-4 compounds in each mixture. 
 5.3.2 Apparatus. All NMR experiments used for the protein backbone 
assignments of DnaG primase CTD were collected at 298 K on a five channel 600 MHz 
Bruker Avance spectrometer equipped with a 5 mm TXI probe. NMR experiments used 
for the protein side chain resonances and distance constraints were collected at the Rocky 
Mountain Regional 900 MHz NMR Facility on a four channel 900 MHz Varian INOVA 
spectrometer equipped with a 5 mm HCN probe.   Assignments of the backbone and side 
chain resonances were obtained from the following spectra: 2D 
1
H-
15
N-HSQC, 2D 
1
H-
13
C-HSQC, HNCO, HNCA, CBCACONH, CBCANH, HNHA, HBHACONH, 
CCCONH, HCCCONH and H(CCH)-COSY (collected on 900MHz).
14
 Distance 
constraints were obtained from 3D 
15
N-edited NOESY and 3D 
13
C-editied NOESY 
(collected at 900 MHz).
14
  
 Hydrogen bond constraints were determined using the (CLEANEX-PM)-FHSQC 
experiment.
15
 A total of 2048 data points were collected in the 
1
H dimension and 128 data 
points were collected in the 
15
N dimension. The spectrum was collected with 16 
transients and a sweep width of 8012.82 Hz in the 
1
H dimension and 1613.424 Hz in the 
15
N dimension. The mixing time was set to 100 ms with a CLEANEX spinlock power of 
2 KHz.  
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All NMR experiments for protein dynamics analysis were collected on a Bruker 
500 MHz Avance spectrometer (Billercia, MA) equipped with a triple resonance, Z-axis 
gradient Cryoprobe.  Experiments used for dynamics study have been described 
previously
16-18
 and included a 2D 
1
H
-15
NN HSQC experiment (hsqct1etf3gpsi)designed 
to measure T1 relaxation rates with delay times of 0.0 ms, 5.39 ms, 53.92 ms, 134.80 ms, 
269.60 ms, 404.40 ms, 539.20 ms, 674.00 ms and 1078.40 ms, a 2D 
1
H-
15
N HSQC 
experiment (hsqct2etf3gpsi) designed to measure T2 relaxation rates with delay times of 
0.0 ms, 17.6 ms, 35.2 ms, 52.8 ms, 70.4 8 ms, 105.6 ms,  123.2 ms, 140.8 ms, 158.4 ms, 
176.0 ms, and a 2D 
1
H-
15
N HSQC experiment  (hsqcnoef3gpsi) designed to measure 
NOE enhancements.   
The relaxation rates (T1,T2) for each DnaG primase CTD amino acid was 
calculated by fitting the intensity of each peak to the intensity decay curve (appendix 5B) 
(eq 5. 1) where It is the intensity of each peak at the delay time t, I0 is the initial steady 
state intensity  
           [5.1] 
The NOE values were determined by the ratio of peak intensity between the 
saturated (Isat) and unsaturated (Iunsat) spectra 
                                                         [5.2] 
All T1, T2 and NOE data measurements were used to calculate an overall 
correlation time ( r), order parameters (S
2
), internal motion ( e) or chemical exchange 
(Rex) using the Lipari-Szabo model free method
19
 implemented by FAST-MODEL 
FREE.
20
   
All NMR experiments used for the ligand binding screen were collected on a 
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Bruker 500 MHz Avance spectrometer (Billercia, MA) equipped with a triple resonance, 
Z-axis gradient cryoprobe and using a Bruker BACS-120 sample changer and IconNMR 
software for automated data collection. All 1D 
1
H NMR spectra were collected at 298K 
using the pulse sequence described in chapter 3.  To increase throughput, only 64 
transients were signal averaged for each spectrum with 8k data points.  All 2D 
1
H-
15
N 
HSQC spectra were collected at 298K using the standard pulse sequence implemented in 
Bruker TopSpin 1.3 with optimized sample specific 90
o
 pulse lengths.   
All multidimensional experiments were processed using NMRpipe,
21
 analyzed 
using PIPP
22
 or CCPNMR.
23
 All 1D 
1
H NMR spectra were processed with the ACD/1D 
NMR manager v. 12.0 (Advanced Chemistry Development, Inc., Toronto, Ontario).   All 
ligand protein docking studies were completed as described in chapter 3 and 4.  
 5.3.3 Sample preparation.  For NMR backbone assignment experiments, 
uniformly 
13
C, 
15
N labeled [U-
13
C, 
15
N] DnaG primase CTD was concentrated to 1.2 mM 
in a 95% H2O/5% D2O buffered solution of 100 mM NaCl, 25 mM KPO4 pH 6.64 
(uncorrected) using an Amicon ultra centricon (MW cutoff 10 000 Da). 50 mM arginine 
and 50 mM glutamine was added to the NMR sample for long term stability. For side 
chain experiments uniformly 
13
C, 
15
N labeled [U-
13
C, 
15
N] DnaG primase CTD was 
concentrated to 1.4 mM in the same buffer conditions used for the NMR backbone 
assignment experiments.   
 NMR dynamics data was collected using a uniformly 
15
N labeled [U-
15
N] sample 
of DnaG primase CTD concentrated to 1.2 mM in a 95% H2O/5% D2O buffered solution 
of 100 mM NaCl, 25 mM KPO4 pH 6.64 (uncorrected) using an Amicon ultra centricon 
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(MW cutoff 10 000 Da). 50 mM arginine and 50 mM glutamine was added to the NMR 
sample for long term stability.   
Sample preparation and experimental parameters for the NMR ligand affinity 
screen were executed in the same manner as described previously
24
 and in chapter 3.  
Briefly, each ligand mixture (113 total) was screened using 1D 
1
H NMR at 100 M 
ligand concentration with 25 M protein in a 99.99% D2O buffered solution of 20 mM 
d19-bis-Tris at pH 7.0 (uncorrected) with 2% DMSO-d6 to maintain ligand solubility and 
11.1 µM 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt as a chemical shift 
reference.  1D 
1
H NMR spectra for each sample was collected using a pre-saturation 
pulse sequence with 64 real transients, 8 dummy transients with 8 K data points, a sweep 
width of 11.0 ppm and a recycle delay of 2.0 s.  Data was Fourier transformed, auto-
phase and baseline corrected. Each 1D 
1
H NMR spectrum were compared to the 
corresponding free ligand mixture reference spectrum and visually analyzed to identify 
binding ligands.  A binding event was identified by the decrease in ligand intensity of the 
nuclease-mixture relative to the free ligand mixture.  Total data collection time including 
sample changing was approximately 10 min/spectrum 
Additionally, a ligand free 2D 
1
H-
15
N HSQC spectrum was collected using the 
same buffer conditions with 95% H2O/5% D2O to ensure the protein was properly folded 
prior to addition of each ligand.  
5.3.4 NMR Structure calculations and refinement. NOE assignments were 
obtained by using 3D 
15
N-edited NOESY and 3D 
13
C-edited NOESY experiments. NOE 
intensities were sorted visually into four classes: strong (1.8–2.5), medium (1.8–3.0), 
weak (1.8–4.0), very weak (3.0–5.0). Upper limits for distances involving methyl protons 
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and nonstereospecifically assigned methylene protons were corrected appropriately for 
center averaging.
 
 Initial NOE assignment was completed by the program Autostructure
25
 
which identified 1055 intra-residue, 173 sequential, 312 medium range (1 ≥ 5) and 73 
long range (5 >) NOEs.   Due to significant peak overlap, even at a high magnetic field 
(900 mHz), manual refinement was needed to complete NOE assignment. All torsion 
angle constraints were obtained by chemical shift analysis using the TALOS
26
 software 
program, and measured coupling constants from an HNHA experiment.
27
 
Hydrogen bond constraints were determined using the (CLEANEX-PM)-FHSQC 
experiment.
15
 The (CLEANEX-PM)-FHSQC spectrum was compared with the 2D 
1
H-
15
N HSQC spectrum, where amides with missing peaks were assigned hydrogen bond 
constraints. These residues were selected because the (CLEANEX-PM)-FHSQC 
spectrum identifies amide residues with fast water exchange rates. The hydrogen bond 
distance constraints were set at 2.8 Å between the carboxyl oxygen and the amide 
nitrogen, and 1.8 Å between the carboxyl oxygen and the amide proton. Carboxyl groups 
within 2.5 Å of the slowly exchanging amide groups were selected to be involved in a 
hydrogen bond. 
The structures were refined using the hybrid distance geometry dynamical-
simulated annealing method
28
 with minor modifications
29
 using the program XPLOR-
NIH
30
 adapted to incorporate pseudopotentials for 
3
J(HN-Hα) coupling constants,31 
secondary 
13Cα/13Cβ chemical shift constraints,32 and a conformational database 
potential.
33-35
 A total of 1000 structures were calculated. The 20 lowest energy structures 
were then subjected to further energy minimization with CNS using explicit water 
solvation that included Lennard-Jones and electrostatic potentials using a modification of 
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the procedure and forcefield of Nilges.
36, 37
  An average DnaG primase CTD structure 
was calculated from these 20 structures. 
The target function that is minimized during restrained minimization and 
simulated annealing comprises quadratic harmonic terms for covalent geometry, 
3
J(HN-
Hα) coupling constants, and secondary 13Cα/13Cβ chemical shift constraints, square-well 
quadratic potentials for the experimental distance and torsion angle constraints, and a 
quadratic van der Waals term for nonbonded contacts. The force constant for the 
conformational database was kept relatively low (0.5–1.0 kcal/mol) throughout the 
simulation to allow the experimental distance and torsion angle constraints to 
predominately influence the resulting structures. The force constant for the NOE and 
dihedral constraints were 30 times and 10 times stronger than the force constants used for 
the conformational database.
38
 All peptide bonds were constrained to be planar and trans. 
There were no hydrogen-bonding, electrostatic, or 6–12 Lennard-Jones empirical 
potential energy terms in the target function. 
 
5.3 RESULTS AND DISCUSSION 
 5.3.1 NMR assignments and secondary structure prediction of primase C-
terminal domain from Staphylococcus aureus.  The backbone resonance assignments 
were completed using the NMR experiments described above (
1
H-
15
N HSQC, HNCO, 
HNCA, HNCOCA, CBCACONH, CBCANH, HNHA, HBHACONH and the 
1
H-
15
N 
HSQC edited NOESY) and manually analyzed using PIPP
22
 and CCPNMR.
23
 The 
backbone resonance assignment was 85% complete with 139 amino acids of the 163 
unambiguously assigned in the 
1
H-
15
N HSQC (figure 5.1).  Unassigned residues in the 
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1
H-
15
N HSQC include M1-H13, D19, E28, H37, L38, M9, T58, R94, E95, E101, P109, 
and Y110.  The majority of the unassigned residues correlate to the engineered N-
terminal sequence (MGHNHNHNHNHNHNGGDDDD) for purification, residues M1-
H13 correlated with the N-terminal his-tag, and residue D19 is part of an engineered 
proteolytic cleavage site.   Excluding the purification tag the backbone assignments were 
94% complete. The ten amino acids found in the primase sequence that were not assigned 
were primarily found in unstructured loop regions, turns between two helices or at the 
edge of a helix.   Residues H37-M39 were in a turn region between helix 1 and 2, residue 
T58 was in an unstructured loop region between helix 2 and helix 3 and residues E101, 
P109 and Y110 were in an unstructured loop region between helix 5 and helix 6.  
Residues R94 and E95 are the second and third residues of helix 5. An exhaustive 
analysis of the NMR data set was unable to yield an assignment for these residues, 
suggesting the end of the helix may undergo partial unfolding and exchange broadening.   
Aliphatic side chain carbon chemical shift assignments were completed using the 
CCCONH experiment correlating the preceding (i-1) residue to the following (i) 
backbone amide chemical shift.   Aliphatic side chain proton chemical shifts were 
completed with the HCCH-COSY and HCCCONH experiments. Aromatic side chain 
assignments were completed using the 3D 
13
C-edited NOESY experiment.  The statistics 
for resonance assignment include, 139/163 HN, 139/201 N, 139/163 C , 134/168 H , 
128/141 C , 148/181 H , 85/92 C , 89/160 H C , 49/64 
C C H and 132/143 CO.  All assignments will be 
uploaded to the BMRB.
39
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Figure 5.1 Assigned 2D 
1
H-
15
N HSQC spectrum of S. aureus primase CTD.   (A) 
Purification of S. aureus primase CTD, lane 1 MW marker, lane 2 shows the expressed 
and purified 
13
C/
15
N labeled S. aureus primase CTD used for all studies in this work. (B) 
Complete backbone 
1
H and 
15
N assignments of the DnaG primase CTD from S. aureus.  
The spectrum was fully assigned with the exception of one peak at 
1
H 7.90 ppm and 
15
N 
120.4 ppm. The peak is large and broad relative to other peaks in the spectrum and is 
likely the remaining unassigned his tag residues. 
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  Secondary structure prediction using the difference in backbone ∆13C /13C  
carbon chemical shifts between the assigned residues and random coil chemical shifts 
predict an all -helical protein with 8 helices (figure 5.2A).  Helical structures in primase 
CTD include Helix 1 Arg26-Lys36, Helix 2 Asp41-Glu50, Helix 3 Gln60-Glu75, Helix 4 
Ile81-Tyr87, Helix 5 Asn91-Gln102, Helix 6 Try110-Lys124, Helix 7 Ile129-Arg141, 
Helix 8 Glu146-Glu161. The C1 sub-domain of primase CTD includes Helix 1-6 and the 
C2 sub-domain includes Helix 7-8 (figure 5.3B). This is consistent with the S. aureus 
DnaG primase CTD homology modeling predicted from the Geobacillus 
stearothermophilus structure
4
 and the secondary structure prediction server NetSurfP 
(figure 5.2B).
40
   
Of particular interest are the residues between the predicted helices 6 and 7 
(residues K124-T128). This region is significantly different in G. stearothermophilus 
primase CTD compared to E. coli primase CTD solution structures (PDB 1Z8S and 
2HAJ, respectively).
7
   In G. stearothermophilus, this region is a loop forming two 
distinct sub-domains (C1, C2) of primase CTD.  In E. coli, the region is a long and rigid 
 helix.  For S. aureus, the experimental secondary structure 
13
C  and 
13
C  chemical 
shift differences suggest that region is similar to the G. stearothermophilus structure with 
an extend loop region starting at residue Gly125 (figure 5.2).  The 
13
C  and 
13
C  
chemical shifts for residues in this region are near random coil chemical shift values. 
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Figure 5.2. Secondary structure prediction for S. aureus primase CTD based on 
13
C  and 
13
C  chemical shifts.  (A) secondary structures in S. aureus primase CTD are predicted based on 
differences in measured 
13
C  and 
13
C  chemical shifts compared to random coil chemical shift 
values. For ∆13C  positive regions represent  helical structure. For ∆13C negative values 
indicate helix.  The secondary structures are overlaid onto the results showing regions of  
helix.  (B) The predicted secondary structures in S. aureus primase CTD measured by 
NetSurfP.
40
  Positive regions are the probability of the sequence stretch adopting  helix 
secondary structure. Both experimental and predicted secondary structure analysis suggest a loop 
region between helix 6 and 7 starting at residue G125.  
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5.3.2 Structure calculation and analysis of primase C-terminal domain (CTD) from 
Staphylococcus aureus.  The solution structure of S. aureus primase CTD was calculated using 
1823 distance restraints, 280 dihedral restraints measured by TALOS
26
, 256 
13Cα/13Cβ carbon 
chemical shift restraints and 82 
3
JNH  coupling constant restraints.  A complete list of the 
restraints used for the structure calculation is described in table 5.1.  A total of 1000 structures 
were calculated from 10 individual sets of 100 structures using XPLOR-NIH
30
 scripts described 
previously.
41
  The lowest energy structures from each set were consolidated to generate a set of 
20 low energy structures which were further refined in a water bath using the RECOORD 
scripts
37
 implemented with CNS.
42, 43
 
The resulting S. aureus primase CTD structures are consistent with the NMR data as 
evident by the relatively low rms deviations from experimental distance, dihedral, 
13Cα/13Cβ 
chemical shift and 
3
J(HN-Hα) coupling constant constraints (figure 5.3A). Also there are no 
distance violations > 0.5 Å or dihedral angle violations > 5°. The average root-mean square 
deviation (RMSD) of the 20 lowest energy structures about the mean coordinate positions is 0.97 
± 0.16 Å for all backbone atoms and 1.73 ± 0.39 Å for all heavy atoms with  aligned residues 26-
35, 40-49, 60-75, 82-85, 92-100 and 112-124.  The final restrained minimized average structure 
of S. aureus primase CTD has an RMSD about the mean coordinate positions of 0.19 Å for all 
backbone atoms and 0.49 Å for all heavy atoms.  
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Table 5.1: Structural Statistics and Atomic rms Differencesa 
A. Structural Statistics 
 <SA>             (SA )r 
rms deviations from experimental distance restraints (Å) 
 all (1823) 0.046 ±  0.008 0.079 
 interresidue sequential (|i-j| = 1) (460) 0.038 ± 0.008             0.096 
 interresidue short range (1 <|i-j|  5) (446) 0.058 ± 0.010  0.074 
 interresidue long-range (|i-j| > 5) (140) 0.074±0.016                 0.180 
 intraresidue (663) 0.003±0.008                0.004 
 H-bonds (114)b 0.072±0.030                0.040 
rms deviation from exptl dihedral restraints (deg) (280)c,d 1.644±0.754                 0.611 
rms deviation from exptl C  restraints (ppm) (130) 1.12 ± 0.05                    1.08  
rms deviation from exptl C restraints (ppm) (126) 1.06 ± 0.02                    1.02 
rms deviation from 
3
JNH  restraints (Hz) (82) 0.83 ± 0.06                    1.02 
FNOE (kcal mol-1)d 212 ± 84.6                 602.59 
Ftor (kcal mol-1)d 36 ± 45                        6.36 
Frepel (kcal mol-1)e 65.63 ± 24                   26.38 
FL-J (kcal mol-1)f  -553.91 ± 29           -1212.10 
deviations from idealized covalent geometry 
 bonds (Å) (2684) 0.003±0.0                     0.002 
 angles (deg) (04795) 0.504 ± 0.045 0.035 
 impropers (deg) (1468)g 0.441±0.069                 0.344 
PROCHECKh 
 Overall G-Factor -0.13 ± 0.03                  -0.19 
 % Residues in most favorable region of Ramachandran plot 80.2 ± 3.1 85.5 
 H-bond energy 0.41 ± 0.41   0.45 
 Number of bad contacts/100 residues
 
25 ± 5.3
   
0.0
 
 
 
1
7
3
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B. Atomic rms Differences (Å) 
  C1 Domain (residues 26-124) secondary structurei    
 backbone atoms  all atoms  backbone atoms   all atoms  
<SA> vs SA   1.2 ± 0.1.7 2.00 ± 0.17 0.70 ± 0.44 2.4 ± 2.40   
<SA> vs (SA)r 1.37 ± 0.19 2.32 ± 0.25 0.58 ± 0.22 1.52 ± 0.6   
(SA)r vs SA   1.02 1.67 0.52 ± 0.33 1.21 ± 0.58  
1
7
4
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aThe notation of the structures is as follows: <SA> are the final 20 
simulated annealing structures and (SA )r is the restrained minimized mean 
structure obtained by restrained minimization of the mean structure SA  . 
The number of terms for the various restraints is given in parentheses.  
bFor backbone NH-CO hydrogen bond there are two restraints: rNH-O = 
1.5-2.3 Å and rN-O = 2.5 - 3.3 Å.  All hydrogen bonds involve slowly 
exchanging NH protons inferred from calculated structures and CLEANX 
fast-exchange experiment.
15
  cThe torsion angle restraints comprise 140  
and 140 .  dThe values of the square-well NOE (FNOE) and torsion angle 
(Ftor) potentials (cf. eqs 2 and 3 in 
44
) are calculated with force constants of 
50 kcal mol -1 Å-2 and 200 kcal mol-1 rad-2, respectively.  
e
The value of 
the quadratic van der Waals repulsion term (Frep) (cf. eq 5 in 
45
) is 
calculated with a force constant of 4 kcal mol -1 Å-4 with the hard-sphere 
van der Waals radius set to 0.8 times the standard values used in the 
CHARMM 
46
 empirical energy function. 
28, 46, 47
 fEL-J is the Lennard-
Jones-van der Waals energy calculated with the CHARMM empirical 
energy function and is not included in the target function for simulated 
annealing or restrained minimization.  gThe improper torsion restraints 
serve to maintain planarity and chirality.  hThese were calculated using the 
PROCHECK program. iThe residues in the regular secondary structure are: 
, 40-49( , 60-75( , 82-85( 4) 92-100( 5 , 112-124 ( 6 , 
128-143( 7  and 146-162( 8  rmsd values were measured by aligning each 
secondary structure element individually and calculating an average and 
standard deviation. 
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The quality of the S. aureus primase CTD NMR structure was analyzed using 
PROCHECK. The results for the average minimized structure (figure 5.3B) show that S. 
aureus primase CTD has an overall G-Factor of -0.13 ± 0.03 with no bad contacts, which 
are all consistent with a good quality structure. Also, all non-glycine dihedral angles lie 
within the expected region of the Ramachandran plot, where 85.5% of the backbone 
dihedral residues lie within the most favorable region with 100% of the residues falling in 
the allowed region.  The PROCHECK analysis of the average minimized structure was 
completed with the removal of the N-terminal his-tag. The consistency of the dihedral 
angles further illustrates the quality of the structure. The 20 lowest energy structures and 
the restrained-minimized average structure will be deposited into the PDB.
48
 
The S. aureus primase CTD structure is composed of 8 helices.   Helical 
structures in primase CTD include Helix 1 Arg26-Lys36, Helix 2 Asp41-Glu50, Helix 3 
Gln60-Glu75, Helix 4 Ile81-Tyr87, Helix 5 Asn91-Gln102, Helix 6 Try110-Lys124, 
Helix 7 Ile128-Arg141, Helix 8 Glu146-Glu161. The C1 sub-domain of primase CTD 
includes Helix 1-6 and the C2 sub-domain includes Helix 7-8 (figure 5.3B).  
Conformation of the loop region between the two sub-domains was established by the 
lack of sequential NH-NH NOEs in the 2D 
1
H-
15
N HSQC edited NOESY and the 
presence of exchange peaks for each residue (G125, Q126 and E127) in the CLEANX 
experiment.
15
  The results of the CLEANX experiment suggest these residues are 
undergoing exchange with the solvent and therefore not protected by hydrogen bonding; 
indicative of a loop structure. 
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Figure 5.3 Comparison of the ensemble overlay and average minimized structure.  
(A) An overlay of the backbone trace of the 20 low energy, water refined structures 
aligned with residues 26-35, 40-49, 60-75, 82-85, 92-100 and 112-124 from the N-
terminal C1 sub-domain.  (B) A ribbon diagram of the average water refined structure 20.   
The two sub-domains are labeled C1 and C2.  The C1 sub-domain is composed of helices 
1-6 and the C2 sub-domain is composed of helices 7-8.  Both structures are colored 
according to the secondary structure: red, α-helix; green, loop both images were 
generated with VMD.
49
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Figure 5.4. Ensemble overlay aligned to either sub-domain C1 or C2.  (A) An overlay 
of the backbone trace of the 20 low energy structures aligned with residues 26-35, 40-49, 
60-75, 82-85, 92-100 and 112-124 from the N-terminal C1 sub-domain.    (B) An overlay 
of the backbone trace of the 20 low energy structures aligned with residues 128-141 and 
146-161from the C-terminal C2 sub-domain. Both structures are colored according to the 
secondary structure: red, α-helix; green, loop both images were generated with VMD.49 
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The overall resolution of the protein structure was lower than what is generally 
possible with current NMR techniques. This lower resolution is an indication of the 
severe peak overlap in the NMR spectra, even at 900 MHz resolution.  Figure 5.5A is the 
resulting 2D 
1
H-
13
C HSQC slice of the aliphatic 3D 
13
C-edited NOESY experiment 
collected at the Rocky Mountain Regional 900 MHz NMR Facility.  The spectrum was 
folded to increase resolution with the blue peaks representing the proton-carbon peaks for 
the H -C , H -C , H -C , H -C side chain resonances.  The orange peaks correspond 
to the proton-carbon peaks for the H -C  backbone resonances (for absolute C  
chemical shift add 35.804 ppm to each 
13
C resonance).  As an example of the severe peak 
overlap, the resolved H -C  peaks in figure 5.5A only represent about half of the 163 
possible assignments. The remaining peaks are buried in the broad and significantly 
intense region between 4.5 ppm 
1
H and 15.0 ppm 
13
C.   
The severe peak overlap is also seen in the 2D 
1
H-
1
H slice of the aliphatic 3D 
13
C-
edited NOESY experiment (figure 5.5B). This is particularly problematic in the region 
1.0-2.0 
1
H and 1.0-2.0 
1
H corresponding to the H  and H  side chain resonances of 
lysine, leucine, isoleucine and H  of valine. These 4 amino acids compose nearly 25% of 
the total amino acid composition of S. aureus primase CTD.  
The severe peak overlap significantly complicated the complete side chain 
assignments with only 56% of H  assigned and 76% H  assigned.  The corresponding 
number of long range (>5) NOEs was lower than anticipated (only 140) for a protein of 
19.6 kDa; the main cause of the lower structure resolution.  Peak overlap was also caused 
by degenerate chemical shifts due to an all  helical protein and by broader peaks due to 
protein dynamics (see section 5.3.5)   
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Figure 5.5. 3D 
1
H-
13
C HSQC edited NOESY of S. aureus primase CTD at 900 MHz. (A) The 
2D 
1
H-
13
C plane of the 3D 
13
C-edited NOESY spectrum of S. aureus primase CTD shows 
significant peak overlap, specifically in the H -C  region (orange, note spectrum is folded add 
35.804 ppm to all orange peaks for absolute chemical shift).  A number of broad and intense 
peaks at 15.0 ppm 
13
C and ~4.5 ppm 
1
H show severe degeneracy in chemical shifts.  (B) The 2D 
1
H-
1
H plane of the 3D 
13
C-edited NOESY spectrum showing significant peak overlap in the H  
and H  regions (1.5 ppm 
1
H and 1.5 ppm 
1
H)     
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5.3.3 Comparison between the three bacterial DnaG primase CTD 
structures. In E. coli, the primase CTD is composed of 7 helices with a long helix 6 
connecting the C-terminus helix to the N-terminal bundle (figure 5.6 C).
7
  The G. 
stearothermophilus structure is composed of 8 helices with the long helix 6 of E. coli 
broken into two helices forming two sub-domains (C1, C2) (figure 5.6B).  A flexible loop 
region between helix 6 and 7 separates the two sub-domains in G. stearothermophilus.
4
  
The structure of S. aureus primase CTD is also composed of 8 helices with two sub-
domains (C1, C2) separated by a flexible loop region between helix 6 and 7 (figure 
5.6A).   Figure 5.6 shows a side-by-side comparison for all three bacterial primase CTD 
structures.  The residues found in the loop region between helix 6 and 7 are highlighted 
on figure 5.6. 
A pairwise Dali
50
 structure based alignment of the three primase CTD structures 
shows the S. aureus structure is similar to the G. stearothermophilus structure with a loop 
region separating the two sub-domains.  The Z-scores for the pairwise structure 
similarities of the three structures are S. aureus-G. stearothermophilus 8.0, S. aureus –E. 
coli 6.5 and G. stearothermophilus - E. coli 5.3.  The structure overlays are found in 
figure 5.7. Structure similarity between the three proteins is limited the N-terminal (C1) 
sub-domain. E. coli and G. stearothermophilus have the same overall fold with a 
backbone rmsd of 3.2 Å observed for the alignment of the first 6 helices that form an N-
terminal helical bundle (C1).
4, 7
 The same comparison for S. aureus to E. coli gives a 
backbone rmsd of 3.4 Å and the comparison between S. aureus and G. 
stearothermophilus gives a backbone rmsd of 2.8 Å.    
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Figure 5.6. Three bacterial primase CTD structures.  The three bacterial primase CTD 
structures are reported showing the two different sub-domains and the residue responsible 
for the flexible linker. (A) Solution structure of S. aureus primase CTD, (B) solution 
structure of G. stearothermophilus primase CTD, and (C) solution structure of E. coli 
primase CTD.  In both A and B, the two sub-domains are separated by a loop region 
linker.  In E. coli, the loop region forms a ridged, continuous helix with a methionine 
residue in the structurally similar site to S. aureus and G. stearothermophilus.     
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Figure 5.7.  Structure similarities between the three primase CTD structures.  (A). 
Comparison between S. aureus (blue) and G. sterarothermophilus (green) primase CTD 
gave a Z-score of 8.0and sequence identity of 20%. (B) Comparison between S. aureus 
(blue) and E. coli (red) primase CTD gave a Z-score of 6.5 and a sequence identity of 
10%. (C) Comparison between G. sterarothermophilus (green) and E. coli (red) primase 
CTD gave a Z-score of 5.3 and sequence identity of 14%.  (D) Multiple structure 
alignment of all three structures shows the conservation in the N-terminal bundle. The E. 
coli structure has an extend helix 6, which is broken into two helices in the two 
Firmicutes structures. The long helix 6 of E. coli is highlighted to show the primary 
difference in the structures. 
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As described previously, the only known structure similarity for the two 
previously solved primase CTD structures is the N-terminus of the replicateive 
helicases.
4, 7
 The S. aureus primase CTD structure is also similar to the N-terminal 
domain of the replicative helicases. As with E. coli and G. stearothermophilus, the 
similarity is limited to the N-terminal helical bundle (C1).  A comparison of S. aureus 
primase CTD with the Dali
51, 52
 database identified the N-terminal domain of the G. 
stearothermophilus helicase as having the highest similarity (Z-score of 8.4) to S. aureus 
primase CTD. The remaining significant hits included the 3 previously solved primase 
CTD structures (1Z8S, 1T3W, and 2HAJ) from G. stearothermophilus and E. coli 
respectively. Additionally, the N-terminal domains of DnaB helicase from E. coli (1B79), 
H. pylori (3GXV) T. aquaticus (2Q6T) and Bacillus phage spp1 (3BGW)  were identified 
as structurally similar to S. aureus primase CTD. 
5.3.4 Phylum dependency of the helix 6 structure. Similar to G. 
stearothermophilus, the S. aureus primase CTD structure also has a loop between helix 6 
and 7. Examining the 3 non-redundant structures currently solved for the C-terminal 
domain of primase suggests a phylum dependency on the helix 6 loop structure. The 
difference in this helix is the primary reason the two Firmicutes structures are more 
similar to each other than to the Proteobacteria primase CTD structure. In G. 
stearothermophilus, the loop between helix 6 and 7 is composed of the amino acids 
Asn554, Arg555, and Pro556.  Conversely, in the S. aureus structure, the loop is 
composed of the amino acids Gly125, Gln126, and Glu127.  A multiple sequence 
alignment suggests the helix breaking proline appears to be limited to bacillus 
organisms.
7
  Correspondingly, the glycine that forms the loop region between helix 6 and 
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7 in S. aureus appears to be limited to other Staphylococcus organisms. Thus, the loop 
that forms the C1 and C2 sub-domains in the G. stearothermophilus and S. aureus 
primase CTD structures appears to be phylum dependent and the sequence appears to be 
species dependent.   
To follow this hypothesis further, the secondary structure of primase CTD for 6 
different organisms was completed using NetSurfP.
40
  The NetSurfP
40
 accurately 
predicted the secondary structure for S. aureus primase CTD (figure 5.2B), supporting its 
reliable for accurately predicting secondary structures. In all three Firmicutes sequences 
(G. stearothermophilus, S. aureus and B. anthracis), a loop is predicted between helix 6 
and 7 that forms two independent sub-domains (figure 5.8).  Interestingly, the residues 
that form the loop are not highly conserved (figure 5.9).  In all three Proteobacteria 
sequences (E. coli, Y. pestis and P. aeruginosa), the loop is not present and a long ridged 
helix 6 remains (figure 5.8). Again, the residues that make up the ridged portion of helix 
6 and are structurally aligned with the loop region in the Firmicutes are not highly 
conserved (figure 5.10).  My hypothesis is that primase CTD regulates binding to 
helicase in a phylum dependent manner based on structure. Secondly, primase CTD 
binding to DnaB helicase is sequentially regulated in a species-specific manner.   
The helicase interaction with the CTD of primase is essential for primer synthesis 
during DNA replication.
2, 53, 54
 It has been previously shown that S. aureus helicase will 
only stimulate primer synthesis when incubated with the cognate primase
6
 suggesting a 
species-specific interaction. The observed difference in Firmicutes and Proteobacteria 
primase CTD structures reported here could explain the observed species-specific results 
of primer synthesis.   
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Figure 5.8 Secondary structure prediction of 6 primase CTD sequences. The 
secondary structures for 6 primase CTD domains were predicted using NetSurfP.
40
  The 
probability index ranges from 0-1 with 0 indicating a loop and 1 indicating a helix. Three 
Firmicutes sequences (S. aureus Sau, G. stearothermophilus Gst, and B. anthracis Ban) 
all predict 8 helices with a loop region between helix 6 and 7 based on lower probablilty 
indices forming two sub-domains (C1 and C2).  Three Proteobacteria sequences (E. coli 
Eco, P. aeruginosa Pae and Y. pestis Ype) all show 7 helices with a ridged helix 6. The 
Sau, Eco and Gst structures have all been solved confirming secondary structure 
prediction.   
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Ban             -------PKLTGFERAEREIIYHMLQSPEVAVRMESHIED--FHTEEHKGILYELYAYYE 51 
Gst             -------KLLPAFQNAERLLLAHMMRSRDVALVVQERIGGR-FNIEEHRALAAYIYAFYE 52 
Sau             PIGMAQFDNLSRQEKAERAFLKHLMRDKDTFLNYYESVDKDNFTNQHFKYVFEVLHDFYA 60 
                         *.  :.*** :: *:::. :. :   . :    *  :..: :   :: :*  
 
Ban             KGNEPSVGTFLSWLSDEKLKNIITDISTDEFINPEYTEEVLQSHLETLRRHQEKLEKMEI 111 
Gst             EGHEADPGALISRIPG-ELQPLASDVSLLLIADDVSEQELEDYIRHVLNRPKWLMLKVKE 111 
Sau             ENDQYNISDAVQYVNSNELRETLISLEQYNLNDEPYENEIDDYVNVINEKGQETIESLN- 119 
                :..: . .  :. : . :*:    .:.   : :    :*: :      .: :  : .::  
 
Ban             IFKIKQMEKTDPVEAAKYYVAYLQNQKARK-- 141 
Gst             QEKTEAERRKDFLTAARIAKEMIEMKKMLSSS 143 
Sau             -HKLREATRIGDVELQKYYLQQIVAKNKERM- 149 
                  * .   : . :   :     :  ::      
 
 
Figure 5.9. Multiple sequence alignment of 3 Firmicutes primase CTD sequences.  A multiple sequence alignment was completed 
using ClustlW for 3 Firmicutes sequences (Ban, B. anthracis, Gst, G. stearothermophilus, Sau, S. aureus).  The residue found in the 
loop region predicted by NetSurfP is highlighted yellow.  In all 3 sequences a loop is predicted between helix 6 and 7.  However, the 
amino acid that forms the loop is not conserved.  This suggests a structural and sequence method to regulate primer synthesis through 
interaction of DnaB helicase. 
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Eco             QLKRTTMRILIGLLVQNPELATLVPPLENLDENKLPGLGLFRELVNTCLSQPGLTTGQLL 60 
Ype             QLKRTTMRILIGLLVQNPQLATLIPSLQGLEQAKLAGLPLFIELVETCLAQPGLTTGQLL 60 
Pae             SVESTTLNALR-TLLHHPQLALKVDDAGTLAREQDTYAQLLVSLLEALQKNPRQSSMQLI 59 
                .:: **:. *   *:::*:**  :     * . : .   *: .*:::   :*  :: **: 
 
Eco             EHYRGTNNAATLEKLSMWDDIADKNIAEQTFTDSLNHMFDS-LLELRQEEL--IARERTH 117 
Ype             ELYRDNKFSQQLETLATWNHMIVEDMVEPTFVDTLASLYDS-ILEQRQETL--IARDRTH 117 
Pae             ARWHGTPQGRLLQALGEKEWLIVQENLEKQFFDTITKLSESQRFGEREERLRSVMQKSYS 119 
                  ::..  .  *: *.  : :  ::  *  * *::  : :*  :  *:* *  : :.    
 
Eco             GLSNEERLELWTLNQELAKK---- 137 
Ype             GLNAEERKELWSLNLALARKK--- 138 
Pae             ELTDEEKALLREHYSVAASSPSQS 143 
                 *. **:  *       * .   
 
Figure 5.10. Multiple sequence alignment of 3 Proteobacteria primase CTD sequences.  A multiple sequence alignment was 
completed using ClustlW for 3 Proteobacteria sequences (Eco, E. coli, Ype, Y. pestis, Pae, P. aeruginosa).  The residues found in 
helix 6 that correspond to the residues of the loop region predicted by NetSurfP
40
 are highlighted yellow.  In all 3 sequences helix 6 is 
predicted to be ridged.  However, the amino acids that form the helix are not highly conserved.  This suggests a structural and 
sequence method to regulate primer synthesis through interaction of DnaB helicase. 
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5.3.5 Dynamics of the primase C-terminal domain from S. aureus.  The 
flexibility of the C2 sub-domain in the G. stearothermophilus structure is thought to play 
an important role in the structural differences with the E. coli structure.  To determine if 
the same flexibility is seen in the S. aureus structure, the dynamics of the protein was 
measured using NMR relaxation parameters T1, T2 and the relative ratio of NOE 
enhancement.   All T1, T2 and NOE values were measured on a per residue basis by eq 
5.1 and 5.2 respectively and imported into the program FASTModel Free
20
 to measure 
the Lapri-Szabo order parameters
19
 (figure 5.11 D), which show relative local motions in 
the structure compared to the complete structure.   
Generally, S
2
 values are near 1.0 for well folded and ridged structures with S
2
 
values below 0.8 indicative of local motion within a structure.  For S. aureus primase 
CTD, the overall model free analysis was very noisy with an average S
2
 of 0.83 ± 0.13 
for all residues except the his-tag.  The large amount of noise in the S
2
 data makes 
identifying significant local motions within the structure challenging based on order 
parameters alone.  The C1 sub-domain (residues 21-124) order-parameters were nosier 
than the C2 domain (residues 128-163) suggesting more flexibility within the C1 sub-
domain.  The increased flexibility apparently played a significant role in the lower 
resolution of the S. aureus primase CTD structure due to exchange broadening and a lack 
of NOE build up, reducing the total number of long range NOEs.  
The raw relaxation data provides further support regarding the overall dynamics 
of the structure.  The average T1 relaxation rate excluding the flexible his-tag residues 
was 657.7 ± 115.5 ms (figure 5.11A) and the average T2 relaxation rate was 64.2 ±17.8 
ms (Figure 5.8B).   The large standard deviations of the relaxation measurements appear 
192 
 
 
  
to be caused by a difference in relaxation rates between the two sub-domains of the 
protein.  Individually each sub-domain has an average T1 of 716 ± 93.5 ms for C1 and 
545.2 ± 53.4 ms for C2.  The average T2 for each sub-domain was 55.5 ±7.3 ms for C1 
and 78.0 ±12.6 ms for C2.  Residue 146 was excluded in these measurements because of 
the increased local motion of the residues in the loop region between helix 7 and 8.   
The difference in the average relaxation times for the two sub-domains and the 
overall noise associated with the T1 data suggest the structure is undergoing significant 
motions.   Each sub-domain of the primase CTD is stable and structured as indicated by 
the average relative ratios of peak intensities between a NOE enhanced and non-enhanced 
spectra (figure 5.11C).  For the C1 sub-domain the average ratio excluding loop regions 
was 0.96 ±0.13 and the C2 sub-domain was 0.95 ±0.17.   
The loop region between helix 6 and 7 (specifically G125) appears to be a pivot 
point for a change in average relaxation rates. The change in relaxation rates, the lack of 
distance restraints and the in ability to simultaneously overlay the two sub-domains 
suggest the two sub-domains act independently of each other on a larger time scale than 
the model free analysis.  The residues of sub-domain C1 fit model 3, which includes both 
S
2
 , a generalized order parameter that reflects the amplitude of internal motions and Rex, 
which accounts for chemical exchange in T2 measurements.  Proteins that fit model three 
generally have internal motions on the ms timescale. The observation that sub-domain C1 
has a significant Rex contribution accounts for the noise in the S
2
 plot (figure 5.11D) and 
the reduced resolution of the structure.  Rex contributions are plotted in figure 5.12.  The 
residues of domain C2 generally fit model 1, which only contributes S
2
 order parameter.   
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 If the two sub-domains exhibit independent motion relative to each other, this 
would result in a separate total correlation times for each sub-domain and contribute to 
the overall noise observed in the model free analysis.  The measured correlation time ( m) 
from the NMR relaxation data for the full protein is 9.8 ns. This is slightly larger than the 
predicted 8.2 ns based on molecular weight of 19.6 kDa where m ≈ MW/24000.
55
  The 
predicted correlation time for the protein based on HYDRONMR
56, 57
 is 15.8 ns.  
HYDRONMR uses the structure of the protein to back calculate the relaxation parameters 
and predict a correlation time.  The predicted correlation time is much larger than 
predicted based on molecular weight.  As described in chapter 2, the molecular weight 
approximation is for spherical, globular proteins.   Having both measured and predicted 
correlation times larger than the approximation value further suggest internal motion 
between the two sub-domains (C1, C2).  Each sub-domain has a predicted correlation 
time using HYDRONMR
56, 57
 of 10.0 ns for C1 and 3.9 ns for C2.  Both predictions are 
longer than the predicted correlation times based on the molecular weight approximation, 
5.5 ns and 1.9 ns for C1 and C2 respectively. 
The dynamic nature of the primase CTD structure could play a role in helicase 
binding.  It was shown the loop region of G. stearothermophilus becomes more extended 
upon binding DnaB helicase N-terminal domain.
9
  This could also be true for S. aureus 
primase CTD, but further analysis will be needed to confirm this hypothesis.  The 
difference in dynamics between bound and free G. stearothermophilus coupled with the 
phylum specific dependency on the loop region further suggest the primase C-terminal 
domain is involved in species-specific regulation of DNA replication.  
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Figure 5.11. Dynamics of S. aureus primase CTD.  The NMR relaxation parameters T1 (A) 
and T2 (B), NOE enhancements (C) and S
2
 order parameters (D) are plotted per residue. The 
graphs show the relative flexibility between the two sub-domains of S. aureus primase CTD. The 
C2 sub-domain (residues 129-163) has different relaxation rates relative to the N-terminal bundle 
suggesting dynamic motion between the two sub-domains on a longer time scale than standard 
Lapri-Szabo Modelfree
19
 measurements ( > ps-ns).   
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Figure 5.12. Contribution of Rex to dynamics of S. aureus primase CTD.  The Rex term in 
model free analysis contributes to chemical exchange due to ms timescale motions of the protein.  
The majority of the C1 sub-domain has a large value for Rex indicating large degree of flexibility.  
This increase in chemical exchange caused an increase in overall linewidth leading to large peak 
overlap, which can account for the lower resolution of the structure.   
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 5.3.6 Identification of binding ligands to S. aureus primase CTD.  A high-
throughput NMR ligand affinity screen of the S. aureus primase CTD was completed to 
identify potential inhibitors of the DnaG - DnaB interaction.  A total of 12 compounds 
(table 5.2) were shown to bind S. aureus primase CTD using the 1D 
1
H NMR screening 
methods described in this dissertation (see chapters 3 & 4).  Two of the ligands, 
acycloguanosine and mitoxantrone dihydrochloride were previously identified as 
inhibitors of the DnaG - DnaB interaction in herpes simplex virus.
58, 59
  Additionally, the 
compound myricetin was shown to inhibit the bacterial helicases with an IC50 of 10 M.
60
 
These three compounds were further analyzed for their binding with primase CTD from 
S. aureus.   
A 2D 
1
H-
15
N HSQC spectrum was collected for ligand free primase CTD and a 
bound primase CTD-ligand complex for acycloguanosine, mitoxantrone, and myricetin 
(figure 5.13). The buffer used for the ligand affinity screen was different from the 
structural work, but did not significantly change the 2D 
1
H-
15
N HSQC spectrum depicted 
in Figure 5.9A.   All three compounds showed primase CTD binding based on chemical 
shift perturbations in the 2D 
1
H-
15
N HSQC spectrum with the addition of the compounds. 
Acycloguanosine showed the most promising specific interaction based on the magnitude 
and clustering of chemical shift changes (figure 5.13C). Conversely, myricetin showed a 
mix of specific and non-specific interactions (figure 5.13B) and mitoxantrone 
dihydrochloride induced the formation of large molecular weight aggregates (figure 
5.13D). 
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Table 5.2 Ligands identified to bind S. aureus primase CTD from a high-throughput 
NMR ligand  affinity screen.   
 
Binding ligand 
(±)-a-Lipoamide 
L-Histidine (His) 
Acycloguanosine 
Sodium DL-lactate    
3-Aminopropionitrile fumarate salt 
Sodium creatine phosphate dibasic tetrahydrate 
mitoxantrone dihydrochloride 
Chelerythrine chloride 
5,5-Diphenylhydantoin 
 1-Methylimidazole 
Didecyldimethylammonium bromide 
(±)-Propranolol hydrochloride 
Myricetin 
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Figure 5.13. 2D 
1
H-
15
N HSQC ligand affinity screen for S. aureus primase CTD inhibitors.  
Ligands identified from the 1D 
1
H NMR line-broadening screen were added to a 100 M 
solution of primase CTD to a final concentration of 500 M (black free primase CTD, blue 
bound primase CTD).  The screening buffer had no effect on the structure or the 2D 
1
H-
15
N 
HSQC spectrum (A).  Myricetin showed a mix of specific and non-specific binding to primase 
CTD indicated by a decrease in peak intensity (B). Acycloguanosine bound specifically to 
primase CTD (C). Residues corresponding to the acycloguanosine binding site are boxed and 
labeled. Mitoxantrone dihydrochloride induced large MW aggregates upon binding to primase 
CTD as indicated by a complete loss of primase CTD signal (D).     
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The residues in primase CTD showing the largest change upon addition of 
myricetin (figure 5.13B) were GLY 16, ASP 17, ASP 19, ASP 20, PHE 21, and LEU 24.  
The corresponding HSQC peaks show a decrease in signal intensity upon binding 
myricetin, which suggests an exchange broadened non-specific interaction.  These 
residues are primarily found in the his-tag and the extreme N-terminus of the primase 
CTD structure. In addition to the decrease in intensity of the N-terminus, residues S51, 
D53, D55, and F57 also showed a significant change in chemical shift as calculated by 
the weighting equation (eq 5.1 see chapter 3 for discussion). 
                                                                       [5.3] 
The change in chemical shift upon addition of myricetin to primase CTD suggests 
a specific interaction between the protein and the ligand.  If the ligand specifically binds 
to residues 51, 53, 55, and 57, the non-specific binding of the his-tag can be explained by 
a transient effect due to the mobility of the his-tag residues and the proximity of the 
ligand bound to helix 51, 53, 55 and 57. 
 Acycloguanosine was shown to specifically and significantly interact with 
primase CTD residues R32, V52, D53, F72, V85, N106, E113, N122, G125, I142, G143, 
Q154, V156, E161, R161 and M163. These residues exhibited chemical shift changes 
above 1 standard deviation from the average of all residues (figure 5.13C).  Importantly, 
no decrease in peak intensity was observed, implying a specific interaction.    
 Mitoxantrone dihydrochloride induced the formation of large molecular weight 
aggregates upon addition to primase CTD.  This is apparent from the complete 
disappearance of NMR signals in the primase CTD 2D 
1
H-
15
N HSQC spectrum, 
presumably caused by molecular-weight induced peak broadening (figure 5.13D).   
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5.3.7 Comparison between primase CTD ligand binding site and helicase 
binding site.  The chemical shift differences between free and acycloguanosine bound 
primase CTD were mapped to the surface of the average water refined structure (figure 
5.14A).  The largest chemical shift differences were found on the last two helices of the 
structure.  This region has been shown to be required for primase CTD binding to the N-
terminal domain of the helicase in E. coli and G. steraothermophilus.
3, 9, 53, 61
  As shown 
by Bailey et. al, 
9
 both the C1 and C2 sub-domains of primase CTD interact with the N-
terminus of helicase.  Specifically, the binding of the C2 sub-domain to the N-terminal 
domain of DnaB helicase is essential for binding the helicase and stimulating primer 
synthesis, while interaction of the C1 sub-domain with helicase is essential for correct 
primer synthesis.   
Using inference through homology, the binding sites from the G. 
stearothermophilus structure with helicase were color coded onto the S. aureus primase 
CTD structure (figure 5.14B).   The residues that undergo the largest chemical shift 
change upon addition of acycloguanosine are in the same region of the helicase binding 
sub-domain (C2).  There are differences between the two binding sites.  Particularly, the 
acycloguanosine site appears to be on the opposite face of the C2 sub-domain relative to 
the helicase binding sites.  However, the S. aureus helicase binding site was only 
identified by inference through homology with G. stearothermophilus.  The exact binding 
site for S. aureus may be different enough to encompass the acycloguanosine binding 
site.  This point highlights the challenges of targeting a large protein-protein interaction 
sites for drug development.   
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Conformation of the acycloguanosine binding site and inhibitory activity can be 
achieved through activity assays showing a decrease in primer synthesis, comparative 
dynamic studies between free and bound primase CTD in complex with helicase, and the 
full structure determination of the ligand bound primase CTD structure.  These studies 
are beyond the scope of this work.  However, identifying a ligand that appears to bind the 
C2 sub-domain of S. aureus primase CTD suggests a potential mechanism of inhibiting 
primer-induced helicase activity. Acycloguanosine may be a viable lead compound for a 
structure-based drug discovery since it may target the essential primase CTD C2 sub-
domain mediated DnaG-DnaB interaction. Pending the conformation studies, the results 
described in this chapter suggest the identification of a new antibiotic drug target; the 
interaction between primase CTD and helicase N-terminal domain.       
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Figure 5.14. Comparison between ligand binding and helicase binding sites.   (A) 
The residues that illustrate the largest chemical shift difference upon addition of 
acycloguanosine are colored blue on the S. aureus primase CTD NMR solution structure.  
(B) The residues that interact with the N-terminal domain of DnaB helicase are colored 
based on sub-domain interaction (red C2, blue C1).  The helicase interactions are based 
on homology transfer between the G. stearothermophilus primase CTD structure 
interacting with the N-terminal domain of G. stearothermophilus DnaB helicase.
9
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Appendix 5A: Sequence of the S. aureus primase C-terminal domain used in these 
studies. The CTD of DnaG primase is approximately 17.2kDa protein (without his-tag, 
19.6kDa with his tag). The glycine residue (G125) that is structurally similar to P543  in 
the G. stearothermophilus structure is highlighted. The sequence has an additional N-
terminal his-tag added for purification shown as lower case.   
 
 
 
>S.aureus primaseCTD     
mghnhnhnhn hnhnggdddd FDNLSRQEKA ERAFLKHLMR 
DKDTFLNYYE SVDKDNFTNQ HFKYVFEVLH DFYAENDQYN 
ISDAVQYVNS NELRETLISL EQYNLNDEPY ENEIDDYVNV 
INEKGQETIE SLNHKLREAT RIGDVELQKY YLQQIVAKNK 
ERM
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Appendix 5B.  Relative relaxation parameters for the S. aureus primase CTD 
structure.  Overall, on a per residue basis the T1 and T2 values were measured to a high 
degree of accuracy using eq 5.1 and 5.2 based on the fit quality.  (A) T1 (B) T2.   
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CHAPTER 6:  
 
BACTERIAL PROTEIN STRUCTURES REVEAL PHYLUM DEPENDENT 
DIVERGENCE 
 
6.1 INTRODUCTION 
As highlighted in Chapter 5, selecting the best model protein for a biological 
system can be challenging if limited to sequence and structure information alone.  The 
differences between the primase CTD structures suggest a third constraint, evolution, for 
selecting a correct model protein.  Quantifiable models of protein evolution are useful for 
developing robust tools to identify suitable drug-binding sites, to predict increases in 
susceptibility to a human genetic disease, and to study organism niches.  Some of the 
strongest arguments in favor of evolution draw from studies on  protein sequence 
homology.
1
 Multiple sequence alignments are routinely used to highlight sequence 
similarity and variability between organisms and create phylogenetic relationships.
2, 3
   
Protein evolution is a direct result from changes to the protein‟s gene sequence, which are 
selected and modulated by a number of factors including structure.
4, 5
 
What is the impact on protein structure as its sequence undergoes genetic drift? 
Maintaining the correct protein fold is fundamental to preserving its function,
6
 but 
evolving the sequence would also be expected to result in structural changes.
7, 8
  The 
resulting paradox is that sequence determines a protein‟s structure, but the structure is 
relatively invariant over a large range of sequences. This paradox is highlighted by the 
tremendous difference between the number of known protein structures versus protein 
folds.
9
 Even though the Protein Data Bank (PDB)
10
 contains 67,529 protein structures as 
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of August, 2010, there are only 1,110 unique topologies and 1,195 unique folds in the 
CATH
11
 and SCOP
12
 structure classification databases, respectively. The significant 
reduction in the number of protein folds relative to the number of protein sequences 
implies a strong correlation between structure and function.  
While the explicit reason for the reduction in fold space remains unclear, some 
have suggested that  protein fold space may be more appropriately described as a 
continuum instead of a collection of discreet folds.
13
 In this manner, a protein fold should 
be considered as being plastic, where sequence changes are accommodated by local 
perturbations in the structure while maintaining the general characteristics of a particular 
fold.
14-16
  Correspondingly, the genetic drift in a protein‟s sequence may imply a similar 
gradual divergence in structure instead of a sudden dramatic transition to a new fold. If 
this perspective is accurate, then a comparative analysis of homologous proteins should 
identify correlated rates of structure and sequence divergence.  Previous studies have 
examined structure similarities between homologous proteins, but did not evaluate if 
structure divergence is correlated with phylogeny.
14-16
  In this chapter, I expand on this 
previous work by quantifying a maximum structure/sequence similarity between the two 
bacterial phyla, Proteobacteria and Firmicutes. I will also discuss the viability of 
phylogeny as a suitable constraint for selecting a homology model by showing certain 
protein folds are more sensitive than others to changes in sequence.      
 
6.2 EXPERIMENTAL 
6.2.1 Cluster of Orthologous Groups (COG) assignment of the Protein Data 
Bank (PDB). Assignment of each bacterial protein in the Protein Data Bank (PDB) to a 
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COG number in the clusters of orthologous groups
17
 database required downloading the 
complete sequence lists from both databases and running a pairwise Basic Local 
Alignment Search Tool  (BLAST) comparison. The pairwise protein BLAST search was 
run using the Protein Mapping and Comparison Tool  (PROMPT v. 0.9.2)
18
 that allowed 
for large pairwise BLAST searching and reported the best match between the two 
databases. The BLAST search was run using the BLOSUM62 matrix with a gap penalty 
of 11, gap extension penalty of 1, a word size of 5, and a BLAST expectation threshold 
(E-value) of 10
-9
. This E-value was used to unambiguously match genes in the COG 
database with proteins in the PDB. All PDB-to-COG matches were reported and stored in 
the PROFESS (Protein Function, Evolution, Structure, and Sequence) database 
(http://cse.unl.edu/~profess/).
19
  
After matching structures to their representative COG each PDB entry was 
matched with its source organism and phylum. The data set was then filtered according to 
the number of unique organisms. Specifically, only those COGs with structures from two 
or more different source organisms in both Proteobacteria and Firmicutes were analyzed 
further. 
6.2.2 Pairwise structure comparison. The pairwise structure comparison 
program DaliLite v. 2.4.2
20
 was installed on our 16-node Dual Athlon AMD 2.13 GHz 
with 1 GB of RAM Beowulf cluster running CentrOS 4.4 Linux with a 2.25 TB RAID 
array. A C-shell script matches the PDB files from each Proteobacteria-Proteobacteria 
comparison (-/-), Firmicutes-Firmicutes comparison (+/+) and Proteobacteria-Firmicutes 
comparison (-/+) and then submits the job to the program DaliLite. Each structural 
comparison took approximately 2-10 min, depending on the size and relative similarity of 
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structures. The total time to run all 63,504 comparisons was approximately 7 weeks.  
The shell script extracts all structural comparison information reported by 
DaliLite (comparison files, rmsd, %Sequence ID, Z-score) on a per chain basis. A single 
PDB file may contain multiple protein chains, where each chain may have a separate 
COG assignment. All structure information is stored in the PROFESS database, which is 
parsed to find the largest Z-score for each pairwise structure comparison. The largest Z-
score represents the best structure comparison for a pair of proteins and ensures the 
correct PDB chains were used for the analysis and the correct COG assignments were 
made. All best matches from each COG were used to calculate the Fractional Structure 
Similarity score (FSS) described by eq  6.1.  
,    [6.1] 
where ZAB was the Z-score for comparing proteins A and B, ZAA was the Z-score 
when protein A was compared to itself and ZBB was the Z-score when protein B was 
compared to itself. Thus, ZAA and ZBB represent the Z-score that can be achieved for 
perfect similarity. 
6.2.3 Manual filtering and data analysis. Manual refinement of the dataset 
included verification of each PDB assignment to a COG and filtering out redundantly 
solved structures from the same organism. When multiple structures were reported from 
the same organism (or organism with synonymous name), the structure that gave the 
largest Dali Z-score within the COG was kept while remaining structures were discarded 
from the analysis. This confirmed a single best PDB-to-COG match for each organism. 
Manual refinement was accomplished by opening all PDB IDs within a COG and 
checking biological information against the PDB (http://www.rcsb.org/pdb/home), COG 
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(http://www.ncbi.nlm.nih.gov/COG/) and the NCBI (http://www.ncbi.nlm.nih.gov/) web 
servers. Consistency in functional and structural assignment within a COG coupled with 
very low E-values between COG and PDB confirmed the best PDB-to-COG match was 
made. Additionally, manual refinement was used to verify uniform sample conditions 
(i.e., the same ligand bound to all proteins within a COG or all proteins correspond to 
wild-type sequences) for cases of redundantly solved structures.  
6.2.4 Structure based phylogenetic trees. In addition to pairwise alignment, all 
the protein structures from each COG were simultaneously aligned using the multiple 
structure alignment program MAMMOTH-multi 
(http://ub.cbm.uam.es/mammoth/mult/).
21
 The resulting aligned structures and the 
structure-based sequence alignment was used with in-house software to calculate an all-
versus-all matrix of per-residue C  distances. Standard boot-strapping techniques were 
then applied to the all-versus-all matrix of per-residue C  distances to generate 100 
distance-matrix tables. Columns of structure-based sequence alignments with the 
corresponding C  distances were randomly selected until the total number of columns in 
the original sequence alignment was reached. The resulting set of C  distances were then 
used to calculate a root mean square deviation (rmsd) between each pair of structures in 
the matrix. The 100 distance-matrix tables were imported into PHYLIP 3.68
22
 to generate 
a consensus phylogenetic tree and bootstrap confidence levels.  
Each set of 100 bootstrapped distance matrices were analyzed by the Fitch-
Margoliash method implemented in PHYLIP. Each matrix was jumbled with 100 
replicates using 37 as the random number generator seed. This resulted in 10000 unique 
and random distance matrices for each COG. The best tree was identified with the 
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program Consense implemented in PHYLIP using the extended majority rule 
conservation. Since the bootstrapped trees do not show distance relationship, the original 
distance matrix generated by MAMMOTH-multi was used to generate a distance based 
phylogenetic tree. Each original distance matrix was jumbled with 100 replicates using 
37 as the random number seed. The distance based phylogenetic tree was drawn using the 
program Drawtree implemented in PHYLIP.  
Representative distance based phylogenetic trees are shown in (figure 6.4). Each 
tree was visually inspected and compared with the DaliLite analysis using the bootstrap 
values to determine if a tree fit the split, starburst, or split +1. A “split” means the 
Firmicutes and Proteobacteria proteins were strongly separated from one another, 
“Starburst” means there was little to no evidence for a split according to phyla, and “Split 
+1” means there was strong evidence for a split according to phyla with the exception of 
one protein 
6.2.5 Measuring functional similarity within a COG. Each protein in our 
dataset was annotated with the corresponding Gene Ontology
23
 identification number(s) 
found in the PDB. By definition, a strong consensus requires each protein to share the 
same set of GO terms. Instead, a weak consensus set of GO terms was generated for each 
COG, where only a majority of proteins are required to share the same GO term. A 
distance was measured between the weak consensus set and the set of GO terms assigned 
to each individual protein. An average, normalized distance is reported for each COG, 
where a score of 1 indicates an identical functional classification and a score of 0 
indicates a lack of functional similarity. The distance between each protein‟s GO terms 
and the consensus GO term set was measured as follows:  
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     [6.2] 
where GOsim is the normalized GO functional similarity score, WC denotes the weak 
consensus set of GO terms for the COG, and GOi denotes the set of GO terms set for each 
protein in the COG. 
 
6.3 RESULTS 
6.3.1 Creating the COG structure families. Current functional annotation tools 
available in the PDB include the Gene Ontology (GO)
23
 and Enzyme Classification  
(EC).
24
 Unfortunately, due to potential for convergence of function, these annotation 
tools are not useful for the study of homologous structures. To accurately observe phylum 
dependent structure divergence of proteins, it is important to construct a dataset of 
functionally similar orthologs. Among the 20 resources for structural classification of 
proteins, the clusters of orthologous groups (COGs) scheme is the only one that attempts 
to identify orthology
25
 while providing moderate functional information. Therefore, each 
sequence and structure in the PDB was annotated with one COG number. Additionally, 
each protein was annotated with GO numbers and the relative functional similarity for 
each COG was measured (table 6.1). 
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Table 6.1. COG structure families. 
a
COG Structure Families have two or more 
represented structures from among the Firmicutes and two or more from among the 
Proteobacteria. 
b
Functonal similarities are measured by overlapping consensus GO terms 
(eq 6.2) 
c“Split” means the Firmicutes and Proteobacteria proteins were strongly 
separated from one another, “Starburst” means there was little to no evidence for a split 
according to phyla, and “Split +1” means there was strong evidence for a split according 
to phyla with the exception of one protein. The relative functional similarity of a COG is 
reported by measuring an average distance between a weak consensus set of Gene 
Ontology (GO) annotations and the set of all GO annotations for each protein within a 
COG.  Perfect functional similarity is reported as a 1, while no similarity is reported as a 
0.  See appendix 6B for a list of the PDB files associated with each COG. *No CATH 
value available for reported structures, CATH values were predicted using a sequence 
based search in the CATH database where the best match is reported.  
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COG
a
 
 
COG Function Annotation 
COG Function 
Similarity
b
  
Phylogenetic 
Structure Tree
c
 
    
CATH 
28 Thiamine pyrophosphate requiring 
enzymes 
0.59 Split 3.40.50.970 
39 Malate/lactate dehydrogenases 0.8 Split 3.40.50.720 
394 Protein-tyrosine-phosphatase 0.61 Split 3.40.50.270 
604 NADPH:quinone reductase and 
related Zn-dependent 
oxidoreductases 
0.88 Split 3.40.50.720 
605 Superoxide dismutase 0.76 Split 3.20.20.80* 
742 N6-adenine-specific methylase 0.73 Split 3.40.50.150* 
813 Purine-nucleoside phosphorylase 0.87 Split 3.40.50.1580 
1012 NAD-dependent aldehyde 
dehydrogenases 
0.58 Split 3.40.309.10 
1075 Predicted acetyltransferases and 
hydrolases with the alpha/beta 
hydrolase fold 
0.7 Split 3.40.50.1820 
1607 Acyl-CoA hydrolase 0.87 Split 3.40.0.1820* 
1940 Transcriptional regulator/sugar 
kinase 
0.31 Split 3.30.420.40 
2124 Cytochrome P450 0.8 Split 1.10.630.10 
2188 Transcriptional regulators 0.89 Split 3.40.1410.10 
446 Uncharacterized NAD (FAD) -
dependent dehydrogenases 
0.85 Split  3.30.390.30 
1057 Nicotinic acid mononucleotide 
adenylyltransferase 
0.95 Split  3.40.50.620 
242 N-formylmethionyl-tRNA 
deformylase 
0.87 Split +1    3.90.45.10 
1052 Lactate dehydrogenase and related 
dehydrogenases 
0.89 Split +1 3.40.50.720 
2141 Coenzyme F420-dependent 
N5,N10-methylene 
tetrahydromethanopterin 
0.76 Split +1 3.20.20.30 
2
2
3
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reductase and related flavin-
dependent oxidoreductases 
3832 Uncharacterized conserved 
protein 
1 Split +1 3.30.530.20 
110 Acetyltransferase  (isoleucine 
patch superfamily)  
0.56 Starburst 2.160.10.10 
171 NAD synthase 0.85 Starburst 3.40.50.620 
251 Putative translation initiation 
inhibitor, yjgF family 
0 Starburst 3.30.1330.40 
346 Lactoylglutathione lyase and 
related lyases 
0.11 Starburst 3.10.180.10 
366 Glycosidases 0.51 Starburst 2.60.40.1180 
454 Histone acetyltransferase HPA2 
and related acetyltransferases 
0.83 Starburst  3.40.630.30 
491 Zn-dependent hydrolases, 
including glyoxylases 
0.5 Starburst 3.60.15.10 
500 SAM-dependent 
methyltransferases 
0.59 Starburst 3.40.50.150 
526 Thiol-disulfide isomerase and 
thioredoxins 
0.96 Starburst 3.40.30.10 
590 Cytosine/adenosine deaminases 0.7 Starburst 3.40.140.10 
637 Predicted 
phosphatase/phosphohexomutase 
0.52 Starburst 1.10.164.10 
664 cAMP-binding proteins 0.5 Starburst 1.10.10.10 
745 Response regulators consisting of 
a CheY-like receiver domain and 
a winged-helix DNA-binding 
domain 
0.73 Starburst 3.40.50.2300 
753 Catalase 0.93 Starburst 3.30.63.10* 
778 Nitroreductase 0.64 Starburst 3.40.109.10 
784 FOG: CheY-like receiver 0.48 Starburst 3.40.50.2300 
796 Glutamate racemase 0.92 Starburst 3.40.50.1860 
1028 Dehydrogenases with different 0.84 Starburst 3.40.50.720 
2
2
4
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specificities  (related to short-
chain alcohol dehydrogenases)  
1151 6Fe-6S prismane cluster-
containing protein 
0.71 Starburst 1.20.1270.30 
1309 Transcriptional regulator 0.8 Starburst 1.10.357.10 
1396 Predicted transcriptional 
regulators 
0.54 Starburst 1.10.260.40 
1404 Subtilisin-like serine proteases 0.6 Starburst 3.40.50.200 
1733 Predicted transcriptional 
regulators 
1 Starburst 1.10.510.10* 
1846 Transcriptional regulators 0.85 Starburst 1.10.10.10 
2159 Predicted metal-dependent 
hydrolase of the TIM-barrel fold 
0.83 Starburst 3.20.20.140* 
2367 Beta-lactamase class A 0.93 Starburst 3.40.710.10 
2730 Endoglucanase 0.88 Starburst 3.20.20.80 
3693 Beta-1,4-xylanase 0.89 Starburst 3.20.20.80 
4948 L-alanine-DL-glutamate 
epimerase and related enzymes of 
enolase superfamily  
0.71 Starburst 3.20.20.120 
2
2
5
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The development of the PROFESS (PROtein Function, Evolution Sequence and 
Structure) database (http://cse.unl.edu~profess)
19
 contains all  PDB-to-COG annotations 
along with other biologically relevant information. This includes associating each 
structure with its phyla classification, which allowed for the structures from Firmicutes 
and Proteobacteria to be easily selected for further analysis.  
The most recent COG database was created by finding the genome-specific best-
hit for each gene in 66 unicellular genomes (50 bacteria, 13 archaea, and 3 eukaryota). 
Specifically, the orthologs present in three or more genomes were detected automatically 
and then multidomain proteins were manually split into component domains to eliminate 
artifactual lumping. The online COG database contains 192,987 sequences distributed 
among 4,876 COGs, accounting for 75% of genes in these 66 genomes.  
At the time of our COG-to-PDB annotation, the PDB included 45,368 protein 
structures (August 2008), although many of them were composed of multiple subunits 
(and therefore associated with an even larger number of sequences). The two best-
represented bacterial phyla, which accounts for nearly one-fourth of all structures in the 
PDB, were selected for annotation. The PDB contains 8,298 Proteobacteria protein 
structures and 3,416 Firmicutes structures. The sequences for each of these structures 
were compared to the COG reference sequences using the Basic Local Alignment Search 
Tool (BLAST).
26
 The initial match between the COG and PDB databases was completed 
with an expectation cut-off of 1x10
-9
 to maximize the likelihood of matching each PDB 
with its correct COG. The BLAST similarity matching was required for two reasons, first 
the PDB did not list gene names and secondly to capture structures from organisms that 
were not present in the COG database.  The BLAST comparison matched 82% of the 
227 
 
 
 
Firmicutes and Proteobacteria sequences to specific COGs, resulting in functional 
assignments for 2,728 Firmicutes structures and 6,881 Proteobacteria structures. Of 
these hits, 27% were 100% identical to the COG reference sequence and 97% matched 
with greater than 50% sequence identity. To carry out our comparative study, we selected 
only those COGs that contained a minimum of two Firmicutes organisms and two 
Proteobacteria organisms. This requirement gave 281 unique COGs with a total of 3,047 
bacterial proteins (1,066 Firmicutes and 1,981 Proteobacteria).  
6.3.2 Pairwise structure similarity. The pairwise structure comparison tool 
DaliLite
20
 was used to perform 63,504 pairwise comparisons between all of the proteins 
in our dataset. In total, the backbone structure similarity corresponded to 31,542 
Proteobacteria-Proteobacteria comparisons (-/-), 12,674 Firmicutes-Firmicutes 
comparisons (+/+), and 19,288 Proteobacteria-Firmicutes comparisons (-/+). All 
comparisons were manually filtered within their respective COG to remove all but one 
redundantly solved structure (the largest contributor to the size of the dataset), multiple or 
non-functionally relevant conformations (mutant protein, non-native experimental 
conditions, inhibited ligand complex), and the shorter of two protein structures. The final 
dataset contained 48 COGs (table 6.1) with a total of 1,713 structural comparisons with 
147 Firmicutes proteins from 58 unique organisms and 176 Proteobacteria proteins from 
84 unique organisms (see appendix 6A for complete list of proteins used in this study).  
After manual analysis the resulting dataset was predominantly populated with 
very low E-values further supporting correct annotation of a structure to the correct COG.  
The distribution of E-values is reported in figure 6.1.  The histogram shows only 3 PDB-
to-COG matches with the minimum E-value cutoff, with the majority of the PDB-to-
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COG matches falling below 1.0E
-40
.   The median E-value for each COG is reported in 
appendix 6B with a range between 4E
-16
 and 0.   Where an E-value of 0 indicates all 
structures within a COG were perfectly matched.    
 
 
Figure 6.1. Distribution of E-values within manually filtered dataset. A set of E-
values at each division consisted of the total number of PDB-to-COG matches between 
the upper and lower bounds.  An E-value of 1x10
-9
 approximately relates to a standard 
significance P-value of 1x10
-9
.  
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The resulting Dali Z-scores from the pairwise structure comparisons were plotted 
against sequence identity (figure 6.2) to reveal a saturating relationship as the percent 
identity rose to 100%. The lowest observed Z-score was 5.7 with a corresponding 16% 
sequence identity. This Z-score was still above the minimum cutoff of 2.0 (dashed line) 
for matches that were two standard deviations above a random match. This lowest Z-
score came from the comparison of two Firmicutes proteins in COG0346 
(lactoylglutathione lyase and related lyases): 2QH0 (Clostridium acetobutylicum); and 
2QQZ (Bacillus anthracis). The average Z-score for all comparisons was 27 ± 13, 
indicating that all structural comparisons were significant.  
Since Z-scores increase as a function of the protein length, we normalized this 
effect by calculating the Fractional Structure Similarity (FSS) score as described in eq 
6.1. The pairwise FSS scores plotted against sequence identity (figure 6.3) resulted in a 
hyperbolic curve. All FSS values fell below an upper-limit at each percent identity. In 
fact, 20% sequence identity yielded a maximal FSS of 60%. This FSS limit was observed 
when all of the data were used (figure 6.3A), when only the pairwise comparisons within 
either phyla were used (figure 6.3B and C), or when only the pairwise comparisons 
between the two phyla were used (figure 6.3D). The pairwise comparison plot between 
the two phyla (figure 6.3D) showed an abrupt cutoff at 61% sequence identity and a 0.84 
FSS score. This abrupt cutoff was not an artifact created by culling the dataset, since a 
similar plot prior to the manual filtering also demonstrated the same effect (appendix 6C).  
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Figure 6.2. The relationship between structure similarity and sequence identity for 48 
COGs. Structure similarity is given as the raw Z-score, which increases as the protein length 
increases. The comparisons were for all proteins against all proteins, and include the comparison 
for each protein against itself. The dashed line identifies a Dali Z-score of 2, which is the 
minimal limit for inferring structural similarity.  
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Figure 6.3. The fractional structure similarity (FSS) and sequence identity for 48 
COGs. FSS was calculated using eq  6.1 to normalize the Dali Z-scores for their different 
sizes. The FSS values were plotted against sequence identity for (A) all the pairwise 
comparisons, (B) only Proteobacteria-Proteobacteria comparisons, (C) only Firmicutes-
Firmicutes comparisons and (D) only Proteobacteria-Firmicutes comparisons.  
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The protein structures in COG0028 (thiamine pyrophosphate requiring enzymes) 
provides a useful example of the structural divergence that occurred after the Firmicutes 
and Proteobacteria phyla split. The overall fold is conserved between the phyla while 
there are discrete structural elements that are unique to each phylum. The two Firmicutes 
structures (figure 6.4A) yield a Z score of 59.6 and an FSS of 0.83, indicating very high 
structural conservation. The structure comparison between the 4 representative 
Proteobacteria structures (figure 6.4B) yield an average Z-score of 37.7 ± 1.6 and an 
average FSS of 0.58 ± 0.03. Again, the structures share a similar fold despite the slightly 
lower scores.  
Comparison of the structures between the Firmicutes and Proteobacteria (figure 
6.4C and D, respectively) phyla yield a lower Z-score of 34.8 ± 1.2 and a lower FSS of 
0.49 ± 0.02 then the comparisons within each phylum. This suggests a divergence in 
structural details while conserving the overall fold. A detailed analysis reveals localized 
differences between the structures from the two phyla (see red highlights in figure 6.4C 
and D). In the Firmicutes representative structure, there is a continuous helix compared to 
helical breaks and loop insertions in the Proteobacteria structure. This is similar to the C-
terminal domain of primase, where a long continuous helix found in the E. coli structure 
is broken by a loop region in G. stearothermophilus
27-30
 and S. aureus (chapter 5).  
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Figure 6.4. Comparison of protein structures for COG0028 between two bacterial 
phyla.  The protein structures for COG0028 thiamine pyrophosphsate requiring enzymes 
show (A) the two Firmicutes structures have highly overlapping structures and (B) the 
four Proteobacteria structures are very similar to each another. See also the phylogenetic 
structure tree for COG0028 in (figure 6.5). On the other hand, the major structural 
differences between the Firmicutes and Proteobacteria are highlighted in red on a 
representative Firmicutes  (C) structure from L. plantarum (Lpl) (PDB ID: 1POW)  and 
the representative Proteobacteria structure  (D) from P. fluorescens  (Pfl) (PDB ID: 
2AG0).  
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6.3.3 COG structure phylogenies. Structure based phylogenies were created 
from root-mean square differences (rmsd) in per residue C  positions for optimally 
aligned protein structures using MAMMOTH-multi.
21
 A separate phylogenetic tree was 
generated for each COG, where three distinct patterns were observed (table 6.1): 15 
exhibited a strong split at the phylum level, 29 exhibited a starburst pattern suggesting 
little to no evidence for a split according to phyla, and 4 exhibited a strong split at the 
phylum level but with the exception of a single structure (split +1).  
The 15 COG phylogenies with strong phylum-splitting patterns had two branches, 
one with closely related Firmicutes structures and the other with closely related 
Proteobacteria structures. Two examples are COG0028 (Thiamine pyrophosphate 
requiring enzymes) and COG0446 (Uncharacterized NAD(FAD)-dependent 
dehydrogenases)  (figure 6.5). The structures for both of these COGs are classified in the 
CATH system as  3-layer sandwiches, but differ in that COG0028 proteins have a 
Rossmann fold topology (figure 6.4) and COG0046 proteins have a FAD/NAD (P)-
binding domain topology.  
The 29 COGs with phylogenetic starburst patterns showed no evidence for the 
separation of structures according to phyla (table 6.1). Two examples were COG0491 
(Zn-dependent hydrolases) and COG1309 (Transcriptional regulator) (figure 6.5). The 
CATH classification for COG0491 Bacillus cereus Zinc-dependent beta-lactamase (PDB 
ID: 1BC2) 
31
 describes it as an  4-layer sandwich with metallo-beta-lactamase Chain 
A topology. The large category of beta-lactamases constitutes a collection of enzymes 
that can be derived from any one of a group of proteins that bind, synthesize, or degrade 
peptidoglycans. The protein structures assigned to COG0491 gave FSS scores with large 
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standard deviations, as is evident from the separated clusters within the Proteobacteria 
arm of the phylogenetic tree. 
The COG1309 structural family falls into one of two CATH topologies, Arc 
Repressor Mutant (subunit A) or Tetracycline Repressor (domain 2). Only those 
structures similar to the Arc Repressor Mutant (subunit A) topology were used for the 
pairwise comparison, since it was the dominant fold in this COG. The protein structures 
in the COG1309 structure family gave low FSS scores. However, even with low overall 
FSS the average absolute Z-score was 13 ± 2 indicating that it has significant overall 
structure similarity. The high FSS deviations of COG0491 structural family and the low 
average FSS scores of COG1309 structural family both indicate rapid structural 
divergence following the phyla split, consistent with the observed starburst phylogenetic 
patterns.  
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Figure 6.5. Protein structure based phylogenetic trees highlighting the split and 
starburst patterns. The phylogenetic structure trees showed three different patterns: 
(top) strong split according to phyla; (bottom) starburst with no clear relationship to a 
common ancestor; and (figure 6.6) strong splits with the exception of one outlier. The 
Firmicutes protein structures are in blue and the Proteobacteria in black. The bootstrap 
values from 100 bootstrap replicates are indicated on branches and represent how often a 
branch appeared in the distance matrix. The two examples for the split pattern were from 
COG0028 (thiamine pyrophosphate requiring enzymes) and COG0446 (uncharacterized 
NAD(FAD)-dependent dehydrogenases). In the case of a strong split, the central 
branches were observed more than 95 times out of 100 replicate trials. The two examples 
for starburst pattern were from COG0491 (Zn-dependent hydrolases) and COG1309  
(transcriptional regulator).  For starburst patterns, very few branches were observed in 
more than two-thirds of the 100 replicate trials. The organism abbreviations are: A. 
hydrophila  (Ahy) ; A. tumefaciens (Atu); A. viridians (Avi) ; B. cereus (Bce) ; B. 
japonicum (Bja); B. subtilis (Bsu) ; B. thuriagienes (Bth); E. carotovora (Eca); E. coli 
(Eco); E. faecalis (Efa); F. gormanii (Fgo); K. pneumonia (Kpn); L. lactis (Lla); L. 
sanfranciscens (Lsa); L. plantarum (Lpl); O. formigens (Ofo) ; P. aeruginosa  (Pae); P. 
fluorescens (Pfl); P. pantotrophus (Ppa); P. putida (Ppu); P. species (Psp); S. aureus 
(Sau); S. marcescens (Sma); S. typhimurium  (Sty); and X. maltophilia  (Xma).  
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Four COG structure phylogenies showed a strong split pattern with a single 
outlier (figure 6.6). This result provides further evidence for the observation of phyla split 
based on structure similarity. The presence of the outlier in a clear split pattern suggests a 
horizontally transferred gene (table 6.1) or potential paralog. For all four families 
[COG0242 (N-formylmethionyl-tRNA deformylase) COG1052 (Lactate dehydrogenase 
and related dehydrogenases), COG2141  (Coenzyme F420-dependent N5,N10-methylene 
tetrahydromethanopterin reductase and related flavin-dependent oxidoreductases), and 
COG3832 (Uncharacterized conserved protein)] there was a large and significant average 
absolute Z-score for all comparisons along with strong BLAST E-values indicating the 
correct match was made between COG and PDB. For COG0242, the Bacillus cereus 
gene def that encodes the N-formylmethionyl-tRNA deformylase protein (PDB ID: 
1WS0) has been previously identified as a gene that has undergone horizontal gene 
transfer.
32
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Figure 6.6. Protein structure based phylogenetic trees highlighting the split +1 
pattern.  Protein structure phylogenies of 4 COGs out of 48 had a strong split pattern 
with the exception of one outlier structure. The phylogenies were very reliable because 
the central branches were observed in 100 out of 100 replicate trials. When one 
Firmicutes or Proteobacteria protein structure clusters on a branch with the other 
phylum, its structure diverges from its closest relatives while resembling those of the 
other phyla. The COGs that fit this pattern are from COG0242 (N-formylmethionyl-
tRNA deformylase), COG1052 (lactate dehydrogenase and related dehydrogenases), 
COG2141 (coenzyme F420-dependent N5, N10-methylene tetrahydromethanopterin 
reductase and related flavin-dependent oxidoreductases), and COG3832 (uncharacterized 
conserved protein). The organism abbreviations are: A. fermentans (Afe); A. tumefaciens 
(Atu); B. cereus (Bce); B. halodurans (Bha); B. stearothermophilus (Bst); B. subtilis 
(Bsu); C. violaceum (Cvi); E. coli (Eco); E. faecalis (Efa); H. methylovorum (Hme); H. 
pylori (Hpy); L. delbrueckii (Lde); L. helveticus (Lhe); M. species (Msp); N. europaea 
(Neu); P. aeruginosa (Pae) ; P. species (Psp), S. aureus (Sau); S. pneumoniae (Spn); and 
V. harveyi (Vha).  
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6.3.4 Structure divergence rates across phyla. As a way to quantify the 
relationship between structure difference and sequence difference, each phylogenetic tree 
was reduced to a single coordinate by calculating a structure similarity ratio ( FSS and a 
sequence identity ratio ( SeqID). FSS was determined for all 48 COGs by calculating an 
average FSS score for the Proteobacteria-Firmicutes structure comparisons, Avg(FSS+/-), 
and dividing by the sum of the average Proteobacteria-Proteobacteria, Avg(FSS-/-), and 
Firmicutes-Firmicutes, Avg(FSS+/+), comparisons: 
              [6.3] 
Similarly, a sequence identity ratio ( SeqID) was determined by calculating an 
average sequence identity for the Proteobacteria-Firmicutes structure comparisons,  
Avg(SeqID+/-), and dividing by the sum of the average Proteobacteria-Proteobacteria, 
Avg(SeqID-/-), and Firmicutes-Firmicutes, Avg(SeqID+/+), comparisons: 
                                    [6.4] 
In general, most starburst phylogenies (see representative COG0491 and 
COG1309 in (figure 6.5) had a branch length between members of different phyla that 
was much shorter than the branch lengths between members within the same phyla. That 
is, a starburst phylogeny was expected to have FSS and SeqID values greater than unity. 
Likewise, most split phylogenies had longer branches between phyla than within each 
phyla (see representative COG0028 and COG0446 in (figure 6.5) and were expected to 
yield FSS SeqID of less than unity.  
When FSS and SeqID for all 48 COGs were plotted versus one another (figure 
6.7), the starburst phylogenies clustered around unity for both structure and sequence 
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whereas the split phylogenies clustered around 0.85 for structure and 0.70 for sequence. 
This indicated that split phylogenies occur when the structure differences are 
significantly less than their sequence differences. In addition, the plot of FSS versus SeqID 
conformed to a linear relationship regardless of the shape of the phylogenetic tree 
indicating that all homologous protein structure differences are constant with respect to 
homologous protein sequence differences ( FSS = 0.55 SeqID + 0.45; R
2
 = 0.7). Thus, this 
curve represents the relative structural drift rate for each COG structural family between 
the two phyla. The slope indicates that structure branch lengths change approximately 
half as fast as sequence branch lengths. 
 
 
Figure 6.7. Constant rate of structural drift.  The relationship between structure and 
sequence change was constant regardless of the phylogenetic starburst (x) or split (■) 
pattern. Structure changes measured using a structure similarity ratio ( FSS), where the 
average FSS between members of the two phyla (Firmicutes versus Proteobacteria) was 
divided by the average FSS between members of the same phyla  (see eq  6.3). Sequence 
change was calculated similarly (see eq  6.4). The best-fit line, FSS=0.55 SeqID + 0.45, 
yielded an R
2
 of 0.70. 
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6.3.5 Fold dependency on structure similarity.  A plot of FSS vs. sequence 
identity for the two most populated CATH families in our dataset (figure 6.8) was used to 
investigate if particular protein architectures are more amenable to structural changes. 
The largest portion of our data set, 24 of 48 COGs (50%), is represented by CATH 3.40  
( , 3-layer ( ) sandwich). Within CATH 3.40, 12 of 24 COGs (50%) are 
represented by the starburst phylogenetic tree pattern. The remaining 12 COGs 
correspond to 11 splits and 1 split +1 phylogenetic tree patterns.  
 
 
 
Figure 6.8. Fold dependency on fractional structure similarity (FSS) and sequence 
comparisons.  The FSS between two CATH families, CATH 1.10 (●) CATH 3.40 (◊).  
CATH 1.10 (mainly , orthogonal bundle) family is apparently limited to approximately 
40% sequence identity and 0.6 FSS while CATH 3.40 ( , 3-Layer ( ) sandwich) 
fills in the complete curve. 87.5% of the COGs (7 of 8) represented by CATH 1.10 give a 
starburst structure similarity tree. Contrastingly, only 50% (12 of 24) of the COGs 
represented by CATH 3.40 give a starburst structure similarity tree. The remaining 12 
COGs formed either split (11 of 12) or split +1 (1 of 12).  
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 The second most populous CATH family is CATH 1.10 (mainly , orthogonal 
bundle) with 15% of our COGs belonging to this CATH family. Most (85.7%) of the 
COGs (6 of 7) in the CATH 1.10 family are represented by the starburst phylogenetic tree 
pattern with only 1 COG represented by a split pattern. There appears to be a limit in 
structure similarity at approximately 0.6 FSS and a corresponding sequence identity limit 
at 40% for CATH 1.10  (figure 6.8, solid circles). This limit is not observed in the CATH 
3.40 family (figure 6.8, open diamonds). The sequence and structure similarity limit for 
CATH 1.10 combined with a larger percentage of COGs assigned to the starburst family 
suggests that CATH 1.10 is more susceptible to mutations that affect the protein 
structure. The results suggest a faster evolutionary rate leading to a higher structural 
divergence relative to other CATH architectures.  
  
6.4 DISCUSSION 
There is an inherent challenge in obtaining an accurate functional annotation for a 
large set of proteins from a relatively small number of experimentally determined 
functions.
33-37
 The available functional information is incomplete, ambiguous and error-
prone
38, 39
 and requires multiple sources
35
 to improve the accuracy in the annotation of a 
protein. There is also the complicating factor of correctly distinguishing between 
orthologs and paralogs, where it has been previously noted the COG database does 
include some paralog members
17, 40
. Thus, the accuracy of this analysis is fundamentally 
dependent on a reliable functional assignment for each protein structure.  Given these 
challenges, the independent and separate utilization of both COG and GO terms provides 
a reasonable and robust approach to identify clusters of functionally similar proteins. The 
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overall high sequence (E-value ≤ 10-9, sequence identity ≥ 16%), structure (Z-score > 5.7) 
and GO term similarity (0.72 ± 0.21) within each COG supports this conclusion. The lack 
of identity for the GO term similarity scores should not be interpreted as evidence for 
functional divergence. GO terms are assigned based on a validated source. So, a missing 
GO term for a protein is more likely attributed to the fact the protein has not been 
explicitly tested for the specified activity. Similarly, a protein being assigned a GO term 
does not provide definitive evidence the function is relevant in vivo.
41-44
     
The comparison of homologous protein structures with the same function 
provides quantitative evidence that protein structures diverged following the speciation 
events that created the modern bacterial phyla of Firmicutes and Proteobacteria. The 
abrupt cutoff at 61% sequence identity and 0.84 fractional structure similarity observed 
between Firmicutes and Proteobacteria proteins was mirrored by an approximate 60% 
protein sequence identity between these two phyla observed by 16S rRNA sequence 
similarity.
45, 46
 Thus, this maximum observed sequence identity imparts limits to the 
maximum possible structure similarity between homologus proteins from these two 
phyla. This is consistent with prior observations that sequence identity ≤ 40-50% 
sometimes results in significant structural and functional differences.
7, 8, 47 Furthermore, 
the results imply an inherent allowable structural plasticity that does not perturb function. 
The random drift after speciation inexorably leads to non-identical structures despite 
maintenance of function. There are a number of cases where FSS was below 0.20 
indicating a significant structural change. Proteins with completely different folds but the 
same function are extreme examples of the plasticity of the structure-function 
relationship and include such proteins as peptidyl-tRNA hydrolases (COG1990),
48
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pantothenate kinase (KOG2201).
49
 polypeptide release factors 
50
 and lysyl-tRNA 
synthetases (COG1190),
51
 these proteins are not in our dataset.  
Forty percent of the COGs we examined have evolved slowly enough that it was 
possible to generate phylogenetic trees consistent with this ancient split. The other COGs 
have either evolved too rapidly or are otherwise subject to few evolutionary constraints to 
provide evidence for this split. This distinction between the COGs is clearly apparent 
from the comparison of FSS and SeqID in (figure 6.7). The linear relationship implies a 
fixed relative structure drift rate, where structure changes half as fast as sequence across 
phyla. This correlation in the divergence of protein sequences and protein structures has 
additional ramifications beyond bacterial evolution. Our analysis implies a continuum of 
protein folds that adapt to large sequence changes by incurring local structural 
modifications.
13-16
 This continuum of protein folds makes it challenging to apply protein 
structural classification to identify function, as has been previously noted.
52, 53
  
Does the nature of the protein‟s three-dimensional structure play a role in protein 
structure divergence? Our analysis demonstrates that some proteins evolve slowly and 
maintain high sequence identity (>80%) and structure similarity (> 0.80 FSS) while other 
proteins exhibit rapid evolution rates where sequence identity is ≤ 20% and FSS ≤ 0.40.  
This implies the underlying architecture of a particular protein may be more or less 
amenable to amino-acid substitutions in order to maintain functional activity. A specific 
protein fold may have a higher intrinsic plasticity that enables it to readily accommodate 
sequence changes through local conformational changes without a detrimental impact on 
activity. This is exactly what was observed, structural variations were localized to 
specific regions as illustrated by the comparison of the COG0028 protein structures see 
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(figure 6.4). This is consistent with the observation of different structure divergence rates 
within a protein.
54, 55
 Regions of the protein that do not impact biological activity are 
expected to yield a higher divergence rate and incur larger local structural changes.
56, 57
 
As a result, a fold with a relatively high plasticity would experience an elevated structural 
diversity between phyla, where the rate of change may closely parallel the mutation 
rate.
14
 Conversely, another fold may be extremely sensitive to amino-acid substitutions, 
where minor sequence perturbations may result in a decrease in structural integrity and a 
corresponding loss of activity. As a result, the sequence and structure of this protein class 
would be relatively conserved. This analysis is consistent with the known range of 
protein thermodynamic stabilities,
58
 and the general observation that most mutations 
destabilize protein structures.
59
  
This chapter illustrates the inherent value in solving structures for functionally 
identical proteins from multiple organisms. A major challenge in creating our COG-to-
PDB dataset was the fundamental requirement to have structures from at least two 
Firmicutes organisms and two Proteobacteria organisms. Only 48 (~1%) of the 4,876 
COGs meet this stringent requirement. The limited number of multiple homologous 
structures has partly occurred because structural biology efforts are focused on obtaining 
single representative structures for each functional class or protein fold
60
  and 
understandably biased toward therapeutically relevant proteins.
61
 If we are to achieve a 
more accurate understanding of the relationship between the evolution of protein fold, 
protein sequence, and the organisms in which they function, the fields of bioinformatics 
and structural biology must expand their focus to include efforts to obtain a more diverse 
set of homologous protein structures. 
248 
 
 
 
6.5 REFERENCES 
1. Do, C. B.; Katoh, K., Protein multiple sequence alignment. Methods Mol. Biol. 
(Totowa, NJ, U. S.) 2008, 484, (Functional Proteomics), 379-413. 
2. Feng, J.-a., Improving pairwise sequence alignment between distantly related 
proteins. Methods Mol. Biol. (Totowa, NJ, U. S.) 2007, 395, (Comparative 
Genomics, Volume 1), 255-268. 
3. Chang, G. S.; Hong, Y.; Dae Ko, K.; Bhardwaj, G.; Holmes, E. C.; Patterson, R. 
L.; van Rossum, D. B., Phylogenetic profiles reveal evolutionary relationships 
within the "twilight zone" of sequence similarity. Proc Natl Acad Sci USA 2008, 
105, (36), 13474-13479, S13474/1-S13474/14. 
4. Pal, C.; Papp, B.; Lercher, M. J., An integrated view of protein evolution. Nat Rev 
Genet 2006, 7, (5), 337-48. 
5. Rocha, E. P. C., The quest for the universals of protein evolution. Trends in 
Genetics 2006, 22, (8), 412-416. 
6. Forouhar, F.; Kuzin, A.; Seetharaman, J.; Lee, I.; Zhou, W.; Abashidze, M.; Chen, 
Y.; Yong, W.; Janjua, H.; Fang, Y.; Wang, D.; Cunningham, K.; Xiao, R.; Acton, 
T. B.; Pichersky, E.; Klessig, D. F.; Porter, C. W.; Montelione, G. T.; Tong, L., 
Functional insights from structural genomics. J Struct Funct Genomics 2007, 8, 
(2-3), 37-44. 
7. Chothia, C.; Lesk, A. M., The relation between the divergence of sequence and 
structure in proteins. Embo J 1986, 5, (4), 823-6. 
8. Rost, B., Twilight zone of protein sequence alignments. Protein Engineering 
1999, 12, (2), 85-94. 
249 
 
 
 
9. Sadreyev, R. I.; Grishin, N. V., Exploring dynamics of protein structure 
determination and homology-based prediction to estimate the number of 
superfamilies and folds. BMC Struct Biol 2006, 6, 6. 
10. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; 
Shindyalov, I. N.; Bourne, P. E., The Protein Data Bank. Nucleic Acids Res 2000, 
28, (1), 235-42. 
11. Orengo, C. A.; Michie, A. D.; Jones, S.; Jones, D. T.; Swindells, M. B.; Thornton, 
J. M., CATH--a hierarchic classification of protein domain structures. Structure 
1997, 5, (8), 1093-108. 
12. Murzin, A. G.; Brenner, S. E.; Hubbard, T.; Chothia, C., SCOP: a structural 
classification of proteins database for the investigation of sequences and 
structures. J Mol Biol 1995, 247, (4), 536-40. 
13. Kolodny, R.; Petrey, D.; Honig, B., Protein structure comparison: Implications for 
the nature of 'fold space', and structure and function prediction. Curr. Opin. 
Struct. Biol. 2006, 16, (3), 393-398. 
14. Illergard, K.; Ardell, D. H.; Elofsson, A., Structure is three to ten times more 
conserved than sequence-A study of structural response in protein cores. Proteins 
2009, 77, (3), 499-508. 
15. Panchenko, A. R.; Wolf, Y. I.; Panchenko, L. A.; Madej, T., Evolutionary 
plasticity of protein families: coupling between sequence and structure variation. 
Proteins 2005, 61, (3), 535-44. 
16. Williams, S. G.; Lovell, S. C., The effect of sequence evolution on protein 
structural divergence. Mol Biol Evol 2009, 26, (5), 1055-65. 
250 
 
 
 
17. Tatusov, R. L.; Fedorova, N. D.; Jackson, J. D.; Jacobs, A. R.; Kiryutin, B.; 
Koonin, E. V.; Krylov, D. M.; Mazumder, R.; Mekhedov, S. L.; Nikolskaya, A. 
N.; Rao, B. S.; Smirnov, S.; Sverdlov, A. V.; Vasudevan, S.; Wolf, Y. I.; Yin, J. 
J.; Natale, D. A., The COG database: an updated version includes eukaryotes. 
BMC Bioinformatics 2003, 4, 41. 
18. Schmidt, T.; Frishman, D., PROMPT: a protein mapping and comparison tool. 
BMC Bioinformatics 2006, 7, 331. 
19. Triplet, T.; Shortridge, M. D.; Griep, M. A.; Stark, J. L.; Powers, R.; Revesz, P., 
PROFESS: a PROtein function, evolution, structure and sequence database. 
Database (Oxford) 2010, baq011. 
20. Holm, L.; Park, J., DaliLite workbench for protein structure comparison. 
Bioinformatics 2000, 16, (6), 566-7. 
21. Lupyan, D.; Leo-Macias, A.; Ortiz, A. R., A new progressive-iterative algorithm 
for multiple structure alignment. Bioinformatics 2005, 21, (15), 3255-63. 
22. Felsenstein, J., PHYLIP- Phylogeny Inference Package (Version 3.2). Cladistics 
1989, 5, 164-166. 
23. Ashburner, M.; Ball, C. A.; Blake, J. A.; Botstein, D.; Butler, H.; Cherry, J. M.; 
Davis, A. P.; Dolinski, K.; Dwight, S. S.; Eppig, J. T.; Harris, M. A.; Hill, D. P.; 
Issel-Tarver, L.; Kasarskis, A.; Lewis, S.; Matese, J. C.; Richardson, J. E.; 
Ringwald, M.; Rubin, G. M.; Sherlock, G., Gene ontology: tool for the unification 
of biology. The Gene Ontology Consortium. Nat Genet 2000, 25, (1), 25-9. 
251 
 
 
 
24. Schomburg, I.; Chang, A.; Ebeling, C.; Gremse, M.; Heldt, C.; Huhn, G.; 
Schomburg, D., BRENDA, the enzyme database: updates and major new 
developments. Nucleic Acids Res 2004, 32, (Database issue), D431-3. 
25. Ouzounis, C. A.; Coulson, R. M.; Enright, A. J.; Kunin, V.; Pereira-Leal, J. B., 
Classification schemes for protein structure and function. Nat Rev Genet 2003, 4, 
(7), 508-19. 
26. Altschul, S. F.; Gish, W.; Miller, W.; Myers, E. W.; Lipman, D. J., Basic local 
alignment search tool. J Mol Biol 1990, 215, (3), 403-10. 
27. Bailey, S.; Eliason, W. K.; Steitz, T. A., Structure of hexameric DnaB helicase 
and its complex with a domain of DnaG primase. Science 2007, 318, (5849), 459-
463. 
28. Oakley, A. J.; Loscha, K. V.; Schaeffer, P. M.; Liepinsh, E.; Pintacuda, G.; Wilce, 
M. C.; Otting, G.; Dixon, N. E., Crystal and solution structures of the helicase-
binding domain of Escherichia coli primase. Journal of Biological Chemistry 
2005, 280, (12), 11495-11504. 
29. Su, X. C.; Schaeffer, P. M.; Loscha, K. V.; Gan, P. H.; Dixon, N. E.; Otting, G., 
Monomeric solution structure of the helicase-binding domain of Escherichia coli 
DnaG primase. Febs J 2006, 273, (21), 4997-5009. 
30. Syson, K.; Thirlway, J.; Hounslow, A. M.; Soultanas, P.; Waltho, J. P., Solution 
structure of the helicase-interaction domain of the primase DnaG: A model for 
helicase activation. Structure 2005, 13, (4), 609-616. 
31. Fabiane, S. M.; Sohi, M. K.; Wan, T.; Payne, D. J.; Bateson, J. H.; Mitchell, T.; 
Sutton, B. J., Crystal structure of the zinc-dependent beta-lactamase from Bacillus 
252 
 
 
 
cereus at 1.9 A resolution: binuclear active site with features of a mononuclear 
enzyme. Biochemistry 1998, 37, (36), 12404-11. 
32. Garcia-Vallve, S.; Romeu, A.; Palau, J., Horizontal gene transfer in bacterial and 
archaeal complete genomes. Genome Res. 2000, 10, (11), 1719-1725. 
33. Andrade, M. A. In Automatic genome annotation and the status of sequence 
databases, 2003; Horizon Scientific Press: 2003; pp 107-121. 
34. Frishman, D., Protein Annotation at Genomic Scale: The Current Status. Chem. 
Rev. (Washington, DC, U. S.) 2007, 107, (8), 3448-3466. 
35. Rentzsch, R.; Orengo, C. A., Protein function prediction - the power of 
multiplicity. Trends Biotechnol. 2009, 27, (4), 210-219. 
36. Valencia, A., Automatic annotation of protein function. Curr. Opin. Struct. Biol. 
2005, 15, (3), 267-274. 
37. Karp, P. D.; Paley, S.; Zhu, J., Database verification studies of SWISS-PROT and 
GenBank. Bioinformatics 2001, 17, (6), 526-532. 
38. Schnoes, A. M.; Brown, S. D.; Dodevski, I.; Babbitt, P. C., Annotation Error in 
Public Databases: Misannotation of Molecular Function in Enzyme 
Superfamilies. PLoS Comput Biol 2009, 5, (12), e1000605. 
39. Benitez-Paez, A., Considerations to improve functional annotations in biological 
databases. OMICS 2009, 13, (6), 527-532. 
40. Dessimoz, C.; Boeckmann, B.; Roth, A. C. J.; Gonnet, G. H., Detecting non-
orthology in the COGs database and other approaches grouping orthologs using 
genome-specific best hits. Nucleic Acids Res. 2006, 34, (11), 3309-3316. 
253 
 
 
 
41. Canevascini, S.; Caderas, D.; Mandel, t.; Fleming, A. J.; Dupuis, I.; Kuhlemeier, 
C., Tissue-specific expression and promoter analysis of the tobacco Itp1 gene. 
Plant Physiol. 1996, 112, (2), 513-524. 
42. Lindorff-Larsen, K.; Lerche, M. H.; Poulsen, F. M.; Roepstorff, P.; Winther, J. R., 
Barley lipid transfer protein, LTP1, contains a new type of lipid-like post-
translational modification. J. Biol. Chem. 2001, 276, (36), 33547-33553. 
43. Otsuka, T.; Takagi, H.; Horiguchi, N.; Toyoda, M.; Sato, K.; Takayama, H.; Mori, 
M., CCl4-induced acute liver injury in mice is inhibited by hepatocyte growth 
factor overexpression but stimulated by NK2 overexpression. FEBS Lett. 2002, 
532, (3), 391-395. 
44. West, G.; Nymalm, Y.; Airenne, T. T.; Kidron, H.; Mattjus, P.; Salminen, T. T., 
Crystallization and x-ray analysis of bovine glycolipid transfer protein. Acta 
Crystallogr., Sect. D: Biol. Crystallogr. 2004, D60, (4), 703-705. 
45. Konstantinidis, K. T.; Tiedje, J. M., Towards a genome-based taxonomy for 
prokaryotes. J Bacteriol 2005, 187, (18), 6258-64. 
46. Konstantinidis, K. T.; Tiedje, J. M., Genomic insights that advance the species 
definition for prokaryotes. Proc Natl Acad Sci U S A 2005, 102, (7), 2567-72. 
47. Rost, B., Enzyme function less conserved than anticipated. Journal of Molecular 
Biology 2002, 318, (2), 595-608. 
48. Powers, R.; Mirkovic, N.; Goldsmith-Fischman, S.; Acton, T. B.; Chiang, Y.; 
Huang, Y. J.; Ma, L.; Rajan, P. K.; Cort, J. R.; Kennedy, M. A.; Liu, J.; Rost, B.; 
Honig, B.; Murray, D.; Montelione, G. T., Solution structure of Archaeglobus 
fulgidis peptidyl-tRNA hydrolase (Pth2) provides evidence for an extensive 
254 
 
 
 
conserved family of Pth2 enzymes in archea, bacteria, and eukaryotes. Protein Sci 
2005, 14, (11), 2849-61. 
49. Yang, K.; Eyobo, Y.; Brand, L. A.; Martynowski, D.; Tomchick, D.; Strauss, E.; 
Zhang, H., Crystal structure of a type III pantothenate kinase: insight into the 
mechanism of an essential coenzyme A biosynthetic enzyme universally 
distributed in bacteria. J Bacteriol 2006, 188, (15), 5532-40. 
50. Kisselev, L., Polypeptide release factors in prokaryotes and eukaryotes: same 
function, different structure. Structure 2002, 10, (1), 8-9. 
51. Ibba, M.; Morgan, S.; Curnow, A. W.; Pridmore, D. R.; Vothknecht, U. C.; 
Gardner, W.; Lin, W.; Woese, C. R.; Soll, D., A euryarchaeal lysyl-tRNA 
synthetase: resemblance to class I synthetases. Science 1997, 278, (5340), 1119-
22. 
52. Hadley, C.; Jones, D. T., A systematic comparison of protein structure 
classifications: SCOP, CATH and FSSP. Structure 1999, 7, (9), 1099-112. 
53. Pascual-Garcia, A.; Abia, D.; Ortiz, A. R.; Bastolla, U., Cross-over between 
discrete and continuous protein structure space: Insights into automatic 
classification and networks of protein structures. PLoS Comput. Biol. 2009, 5, (3), 
No pp given. 
54. Lin, Y.-S.; Hsu, W.-L.; Hwang, J.-K.; Li, W.-H., Proportion of solvent-exposed 
amino acids in a protein and rate of protein evolution. Molecular Biology and 
Evolution 2007, 24, (4), 1005-1011. 
55. Chirpich, T. P., Rates of protein evolution. Function of amino acid composition. 
Science (Washington, DC, United States) 1975, 188, (4192), 1022-3. 
255 
 
 
 
56. Chothia, C.; Lesk, A. M., The relation between the divergence of sequence and 
structure in proteins. EMBO Journal 1986, 5, (4), 823-6. 
57. Lesk, A. M.; Chothia, C., How different amino acid sequences determine similar 
protein structures: the structure and evolutionary dynamics of the globins. Journal 
of Molecular Biology 1980, 136, (3), 225-70. 
58. Robertson, A. D.; Murphy, K. P., Protein Structure and the Energetics of Protein 
Stability. Chem Rev 1997, 97, (5), 1251-1268. 
59. Sanchez, I. E.; Tejero, J.; Gomez-Moreno, C.; Medina, M.; Serrano, L., Point 
mutations in protein globular domains: contributions from function, stability and 
misfolding. J Mol Biol 2006, 363, (2), 422-32. 
60. Chandonia, J. M.; Brenner, S. E., Implications of structural genomics target 
selection strategies: Pfam5000, whole genome, and random approaches. Proteins 
2005, 58, (1), 166-79. 
61. Mestres, J., Representativity of target families in the Protein Data Bank: impact 
for family-directed structure-based drug discovery. Drug Discovery Today 2005, 
10, (23/24), 1629-1637. 
 
 
 
 
 
 
 
256 
 
 
 
Appendix 6A. A table of all manually curated proteins used in chapter 6 with their 
associated COG annotation, phylogenetic pattern, phylum classification and source 
organism. 
 
Split 
   COG PDB Phylum Source 
28  2JI7 Proteobacteria OXALOBACTER FORMIGENES 
28  2AG0 Proteobacteria PSEUDOMONAS FLUORESCENS 
28  1YNO Proteobacteria PSEUDOMONAS PUTIDA 
28  1OZF Proteobacteria KLEBSIELLA PNEUMONIAE 
28  1V5E Firmicutes AEROCOCCUS VIRIDANS 
28  1POW Firmicutes LACTOBACILLUS PLANTARUM 
    39  2PWZ Proteobacteria ESCHERICHIA COLI 
39  1B8P Proteobacteria AQUASPIRILLUM ARCTICUM 
39  1Y6J Firmicutes CLOSTRIDIUM THERMOCELLUM 
39  1LDN Firmicutes BACILLUS STEAROTHERMOPHILUS 
39  1EZ4 Firmicutes LACTOBACILLUS PENTOSUS 
    394  2GI4 Proteobacteria CAMPYLOBACTER JEJUNI 
394  2FEK Proteobacteria ESCHERICHIA COLI 
394  1LJL Firmicutes STAPHYLOCOCCUS AUREUS 
394  1JL3 Firmicutes BACILLUS SUBTILIS 
    446  2V3A Proteobacteria PSEUDOMONAS AERUGINOSA 
446  1Q1R Proteobacteria PSEUDOMONAS PUTIDA 
446  1D7Y Proteobacteria PARACOCCUS PANTOTROPHUS 
446  2CDU Firmicutes LACTOBACILLUS SANFRANCISCENSIS 
446  2BC0 Firmicutes STREPTOCOCCUS PYOGENES 
446  1YQZ Firmicutes STAPHYLOCOCCUS AUREUS 
446  1F8W Firmicutes ENTEROCOCCUS FAECALIS 
    604  1WLY Proteobacteria BURKHOLDERIA SP. WS 
604  1QOR Proteobacteria ESCHERICHIA COLI 
604  1XA0 Firmicutes BACILLUS STEAROTHERMOPHILUS 
604  1TT7 Firmicutes BACILLUS SUBTILIS 
    605  2BKB Proteobacteria ESCHERICHIA COLI 
605  1DT0 Proteobacteria PSEUDOMONAS PUTIDA 
605  1XRE Firmicutes BACILLUS ANTHRACIS 
605  1JR9 Firmicutes BACILLUS HALODENITRIFICANS 
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742  2IFT Proteobacteria HAEMOPHILUS INFLUENZAE 
742  2FPO Proteobacteria ESCHERICHIA COLI 
742  2FHP Firmicutes ENTEROCOCCUS FAECALIS 
742  2ESR Firmicutes STREPTOCOCCUS PYOGENES 
    813  1VHJ Proteobacteria VIBRIO CHOLERAE 
813  1ECP Proteobacteria ESCHERICHIA COLI 
813  2AC7 Firmicutes BACILLUS CEREUS G9241 
813  1XE3 Firmicutes BACILLUS ANTHRACIS 
    1012  2HG2 Proteobacteria ESCHERICHIA COLI 
1012  1EYY Proteobacteria VIBRIO HARVEYI 
1012  1T90 Firmicutes BACILLUS SUBTILIS 
1012  1EUH Firmicutes STREPTOCOCCUS MUTANS 
    1057  1YUM Proteobacteria PSEUDOMONAS AERUGINOSA 
1057  1K4M Proteobacteria ESCHERICHIA COLI 
1057  2H2A Firmicutes STAPHYLOCOCCUS AUREUS 
1057  1KAQ Firmicutes BACILLUS SUBTILIS 
    1075  1TAH Proteobacteria BURKHOLDERIA GLUMAE 
1075  1OIL Proteobacteria BURKHOLDERIA CEPACIA 
1075  1EX9 Proteobacteria PSEUDOMONAS AERUGINOSA 
1075  2HIH Firmicutes STAPHYLOCOCCUS HYICUS 
1075  1KU0 Firmicutes BACILLUS STEAROTHERMOPHILUS 
    1607  2GVH Proteobacteria AGROBACTERIUM TUMEFACIENS STR. C58 
1607  1YLI Proteobacteria HAEMOPHILUS INFLUENZAE 
1607  1Y7U Firmicutes BACILLUS CEREUS 
1607  1VPM Firmicutes BACILLUS HALODURANS CProteobacteria25 
    1940  1Z6R Proteobacteria ESCHERICHIA COLI 
1940  1Z05 Proteobacteria VIBRIO CHOLERAE O1 BIOVAR ELTOR 
1940  2QM1 Firmicutes ENTEROCOCCUS FAECALIS V583 
1940  2GUP Firmicutes STREPTOCOCCUS PNEUMONIAE 
1940  1XC3 Firmicutes BACILLUS SUBTILIS 
    2124  1YRD Proteobacteria PSEUDOMONAS PUTIDA 
2124  1T2B Proteobacteria CITROBACTER BRAAKII 
2124  1Q5E Proteobacteria POLYANGIUM CELLULOSUM 
2124  1IZO Firmicutes BACILLUS SUBTILIS 
2124  1FAG Firmicutes BACILLUS MEGATERIUM 
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2188  2PKH Proteobacteria PSEUDOMONAS SYRINGAE PV. TOMATO STR. DC3000 
2188  2FA1 Proteobacteria ESCHERICHIA COLI 
2188  2OOI Firmicutes STAPHYLOCOCCUS AUREUS 
2188  2OGG Firmicutes BACILLUS SUBTILIS 
    
    Split with HGT 
  COG PDB Phylum Source 
242  2EW7 Proteobacteria HELICOBACTER PYLORI 
242  1IX1 Proteobacteria PSEUDOMONAS AERUGINOSA 
242  1ICJ Proteobacteria ESCHERICHIA COLI 
242  2AI9 Firmicutes STAPHYLOCOCCUS AUREUS 
242  1WS0 Firmicutes BACILLUS CEREUS 
242  1LQY Firmicutes BACILLUS STEAROTHERMOPHILUS 
242  1LM6 Firmicutes STREPTOCOCCUS PNEUMONIAE 
    1052  2GSD Proteobacteria MORAXELLA SP. 
1052  2GO1 Proteobacteria PSEUDOMONAS SP. 
1052  1GDH Proteobacteria HYPHOMICROBIUM METHYLOVORUM 
1052  2DLD Firmicutes LACTOBACILLUS HELVETICUS 
1052  1XDW Firmicutes ACIDAMINOCOCCUS FERMENTANS 
1052  1J4A Firmicutes LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS 
    2141  2I7G Proteobacteria AGROBACTERIUM TUMEFACIENS 
2141  1M41 Proteobacteria ESCHERICHIA COLI 
2141  1BRL Proteobacteria VIBRIO HARVEYI 
2141  2B81 Firmicutes BACILLUS CEREUS 
2141  1TVL Firmicutes BACILLUS SUBTILIS 
    3832  1Z94 Proteobacteria CHROMOBACTERIUM VIOLACEUM ATCC 12472 
3832  1XFS Proteobacteria NITROSOMONAS EUROPAEA 
3832  2NN5 Firmicutes ENTEROCOCCUS FAECALIS 
3832  2IL5 Firmicutes STAPHYLOCOCCUS AUREUS 
3832  1XN6 Firmicutes BACILLUS CEREUS 
3832  1XN5 Firmicutes BACILLUS HALODURANS 
    Starburst 
  COG PDB Phylum Source 
110  2NPO Proteobacteria CAMPYLOBACTER JEJUNI 
110  1KRR Proteobacteria ESCHERICHIA COLI 
110  2IC7 Firmicutes GEOBACILLUS KAUSTOPHILUS 
110  1KK5 Firmicutes ENTEROCOCCUS FAECIUM 
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171  1XNG Proteobacteria HELICOBACTER PYLORI 
171  1WXE Proteobacteria ESCHERICHIA COLI 
171  2PZB Firmicutes BACILLUS ANTHRACIS 
171  1KQP Firmicutes BACILLUS SUBTILIS 
    251  2IG8 Proteobacteria PSEUDOMONAS AERUGINOSA 
251  1QU9 Proteobacteria ESCHERICHIA COLI 
251  1J7H Proteobacteria HAEMOPHILUS INFLUENZAE 
251  2EWC Firmicutes STREPTOCOCCUS PYOGENES 
251  1XRG Firmicutes CLOSTRIDIUM THERMOCELLUM 
251  1QD9 Firmicutes BACILLUS SUBTILIS 
    346  2PJS Proteobacteria AGROBACTERIUM TUMEFACIENS 
346  1R9C Proteobacteria RHIZOBIUM LOTI 
346  1NPB Proteobacteria SERRATIA MARCESCENS 
346  1MPY Proteobacteria PSEUDOMONAS PUTIDA 
346  1LQK Proteobacteria PSEUDOMONAS AERUGINOSA 
346  1LGT Proteobacteria BURKHOLDERIA SP. 
346  1KMY Proteobacteria BURKHOLDERIA CEPACIA 
346  1F9Z Proteobacteria ESCHERICHIA COLI 
346  1EIL Proteobacteria PSEUDOMONAS SP. 
346  1ECS Proteobacteria KLEBSIELLA PNEUMONIAE 
346  2QQZ Firmicutes BACILLUS ANTHRACIS STR. AMES 
346  2QH0 Firmicutes CLOSTRIDIUM ACETOBUTYLICUM 
346  2P7K Firmicutes LISTERIA MONOCYTOGENES 
346  2P25 Firmicutes ENTEROCOCCUS FAECALIS 
346  2I7R Firmicutes STREPTOCOCCUS PNEUMONIAE 
346  1ZSW Firmicutes BACILLUS CEREUS 
346  1SS4 Firmicutes BACILLUS CEREUS 
    366  1ZJA Proteobacteria PSEUDOMONAS MESOACIDOPHILA 
366  1M53 Proteobacteria KLEBSIELLA SP. LX3 
366  1G5A Proteobacteria NEISSERIA POLYSACCHAREA 
366  1B0I Proteobacteria PSEUDOALTEROMONAS HALOPLANKTIS 
366  1WZA Firmicutes HALOTHERMOTHRIX ORENII 
366  1W9X Firmicutes BACILLUS HALMAPALUS 
366  1UA7 Firmicutes BACILLUS SUBTILIS 
366  1PAM Firmicutes BACILLUS SP. 
366  1OT2 Firmicutes BACILLUS CIRCULANS 
366  1JI1 Firmicutes THERMOACTINOMYCES VULGARIS 
366  1HVX Firmicutes BACILLUS STEAROTHERMOPHILUS 
366  1E3X Firmicutes BACILLUS AMYLOLIQUEFACIENS 
366  1BPL Firmicutes BACILLUS LICHENIFORMIS 
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    454  2Q0Y Proteobacteria RALSTONIA EUTROPHA JMP134 
454  2OZH Proteobacteria XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS 
454  2GE3 Proteobacteria AGROBACTERIUM TUMEFACIENS 
454  2FT0 Proteobacteria ESCHERICHIA COLI 
454  2FIW Proteobacteria RHODOPSEUDOMONAS PALUSTRIS CGA009 
454  2EUI Proteobacteria PSEUDOMONAS AERUGINOSA 
454  1S3Z Proteobacteria SALMONELLA ENTERITIDIS 
454  1GHE Proteobacteria PSEUDOMONAS SYRINGAE PV. TABACI 
454  2PC1 Firmicutes STREPTOCOCCUS AGALACTIAE 2603V/R 
454  2OH1 Firmicutes LISTERIA MONOCYTOGENES STR. 4B F2365 
454  2JDC Firmicutes BACILLUS LICHENIFORMIS 
454  2ATR Firmicutes STREPTOCOCCUS PNEUMONIAE TIGR4 
454  2AJ6 Firmicutes STAPHYLOCOCCUS AUREUS 
454  1Z4E Firmicutes BACILLUS HALODURANS 
454  1Y9K Firmicutes BACILLUS CEREUS 
454  1U6M Firmicutes ENTEROCOCCUS FAECALIS 
454  1TIQ Firmicutes BACILLUS SUBTILIS 
    491  2OBW Proteobacteria SALMONELLA TYPHIMURIUM 
491  2GMN Proteobacteria BRADYRHIZOBIUM JAPONICUM 
491  2FM6 Proteobacteria XANTHOMONAS MALTOPHILIA 
491  2FHX Proteobacteria PSEUDOMONAS AERUGINOSA 
491  1X8G Proteobacteria AEROMONAS HYDROPHILA 
491  1WUO Proteobacteria SERRATIA MARCESCENS 
491  1P9E Proteobacteria PSEUDOMONAS SP. 
491  1K07 Proteobacteria FLUORIBACTER GORMANII 
491  2BTN Firmicutes BACILLUS THURINGIENSIS 
491  1BC2 Firmicutes BACILLUS CEREUS 
    500  2PKW Proteobacteria SALMONELLA TYPHIMURIUM 
500  2P7I Proteobacteria ERWINIA CAROTOVORA SUBSP. ATROSEPTICA SCRI1043 
500  2OYR Proteobacteria SHIGELLA FLEXNERI 2A 
500  2IP2 Proteobacteria PSEUDOMONAS AERUGINOSA 
500  1PJZ Proteobacteria PSEUDOMONAS SYRINGAE PV. PISI 
500  1NKV Proteobacteria ESCHERICHIA COLI 
500  1IM8 Proteobacteria HAEMOPHILUS INFLUENZAE 
500  2P8J Firmicutes CLOSTRIDIUM ACETOBUTYLICUM 
500  2GH1 Firmicutes BACILLUS CEREUS 
500  1XXL Firmicutes BACILLUS SUBTILIS 
500  1VL5 Firmicutes BACILLUS HALODURANS CProteobacteria25 
    526  2TRX Proteobacteria ESCHERICHIA COLI 
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526  2I4A Proteobacteria ACETOBACTER ACETI 
526  2O7K Firmicutes STAPHYLOCOCCUS AUREUS 
526  2GZY Firmicutes BACILLUS SUBTILIS 
526  1NW2 Firmicutes ALICYCLOBACILLUS ACIDOCALDARIUS 
    590  2G84 Proteobacteria NITROSOMONAS EUROPAEA 
590  2A8N Proteobacteria AGROBACTERIUM TUMEFACIENS 
590  1Z3A Proteobacteria ESCHERICHIA COLI 
590  2NX8 Firmicutes STREPTOCOCCUS PYOGENES SEROTYPE M6 
590  1WKQ Firmicutes BACILLUS SUBTILIS 
    637  2FDR Proteobacteria AGROBACTERIUM TUMEFACIENS 
637  1TE2 Proteobacteria ESCHERICHIA COLI O157:H7 
637  1RQN Firmicutes BACILLUS CEREUS 
637  1LVH Firmicutes LACTOCOCCUS LACTIS 
    664  1VP6 Proteobacteria RHIZOBIUM LOTI 
664  1U12 Proteobacteria MESORHIZOBIUM LOTI MAFF303099 
664  1G6N Proteobacteria ESCHERICHIA COLI 
664  1FT9 Proteobacteria RHODOSPIRILLUM RUBRUM 
664  2HKX Firmicutes CARBOXYDOTHERMUS HYDROGENOFORMANS 
664  1OMI Firmicutes LISTERIA MONOCYTOGENES 
    745  2PLN Proteobacteria HELICOBACTER PYLORI 
745  1XHF Proteobacteria ESCHERICHIA COLI 
745  2A9O Firmicutes STREPTOCOCCUS PNEUMONIAE 
745  1MVO Firmicutes BACILLUS SUBTILIS 
    753  2ISA Proteobacteria VIBRIO SALMONICIDA 
753  1QWL Proteobacteria HELICOBACTER PYLORI 
753  1M85 Proteobacteria PROTEUS MIRABILIS 
753  1GGE Proteobacteria ESCHERICHIA COLI 
753  2J2M Firmicutes EXIGUOBACTERIUM OXIDOTOLERANS 
753  1SI8 Firmicutes ENTEROCOCCUS FAECALIS 
    778  1VFR Proteobacteria VIBRIO FISCHERI 
778  2ISJ Proteobacteria SINORHIZOBIUM MELILOTI 
778  1KQD Proteobacteria ENTEROBACTER CLOACAE 
778  1F5V Proteobacteria ESCHERICHIA COLI 
778  2H0U Proteobacteria HELICOBACTER PYLORI 
778  2HAY Firmicutes STREPTOCOCCUS PYOGENES SEROTYPE M1 
778  2B67 Firmicutes STREPTOCOCCUS PNEUMONIAE TIGR4 
778  1ZCH Firmicutes BACILLUS SUBTILIS 
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778  2I7H Firmicutes BACILLUS CEREUS 
    
784  2FKA Proteobacteria 
SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR 
TYPHIMURIUM 
784  1P6Q Proteobacteria RHIZOBIUM MELILOTI 
784  1M5T Proteobacteria CAULOBACTER CRESCENTUS 
784  6CHY Proteobacteria ESCHERICHIA COLI 
784  2I6F Proteobacteria MYXOCOCCUS XANTHUS 
784  1F51 Firmicutes BACILLUS SUBTILIS 
784  1QMP Firmicutes BACILLUS STEAROTHERMOPHILUS 
    796  2JFN Proteobacteria ESCHERICHIA COLI 
796  2JFX Proteobacteria HELICOBACTER PYLORI 
796  2JFO Firmicutes ENTEROCOCCUS FAECALIS 
796  2JFQ Firmicutes STAPHYLOCOCCUS AUREUS 
796  2GZM Firmicutes BACILLUS ANTHRACIS 
    
1028 2EWM Proteobacteria AZOARCUS 
1028  2DKN Proteobacteria PSEUDOMONAS SP. 
1028  2CFC Proteobacteria XANTHOBACTER AUTOTROPHICUS 
1028  2B4Q Proteobacteria PSEUDOMONAS AERUGINOSA 
1028  1ZEM Proteobacteria GLUCONOBACTER OXYDANS 
1028 
 
1WMB Proteobacteria PSEUDOMONAS FRAGI 
1028  1PWX Proteobacteria AGROBACTERIUM TUMEFACIENS 
1028  1K2W Proteobacteria RHODOBACTER SPHAEROIDES 
1028  1GEG Proteobacteria KLEBSIELLA PNEUMONIAE 
1028  1FJH Proteobacteria COMAMONAS TESTOSTERONI 
1028  1AHH Proteobacteria ESCHERICHIA COLI 
1028  2UVD Firmicutes BACILLUS ANTHRACIS 
1028  2HQ1 Firmicutes CLOSTRIDIUM THERMOCELLUM 
1028  1NXQ Firmicutes LACTOBACILLUS BREVIS 
1028  1G6K Firmicutes BACILLUS MEGATERIUM 
    1151  1JQK Proteobacteria RHODOSPIRILLUM RUBRUM 
1151  1E2U Proteobacteria DESULFOVIBRIO VULGARIS 
1151  1OA0 Proteobacteria DESULFOVIBRIO DESULFURICANS 
1151  1SU6 Firmicutes CARBOXYDOTHERMUS HYDROGENOFORMANS 
1151  1OAO Firmicutes MOORELLA THERMOACETICA 
    1309  2UXH Proteobacteria PSEUDOMONAS PUTIDA 
1309  2HYT Proteobacteria ERWINIA CAROTOVORA SUBSP. ATROSEPTICA 
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1309  2G7S Proteobacteria AGROBACTERIUM TUMEFACIENS 
1309  2FBQ Proteobacteria PSEUDOMONAS AERUGINOSA 
1309  1T33 Proteobacteria SALMONELLA TYPHIMURIUM 
1309  1PB6 Proteobacteria ESCHERICHIA COLI 
1309  2IU5 Firmicutes LACTOCOCCUS LACTIS SUBSP. LACTIS IL1403 
1309  2FX0 Firmicutes BACILLUS CEREUS 
1309  1Z0X Firmicutes ENTEROCOCCUS FAECALIS V583 
1309  1VI0 Firmicutes BACILLUS SUBTILIS 
    1396  1Y9Q Proteobacteria VIBRIO CHOLERAE 
1396  1Y7Y Proteobacteria AEROMONAS HYDROPHILA 
1396  2P5T Firmicutes STREPTOCOCCUS PNEUMONIAE 
1396  2B5A Firmicutes BACILLUS CALDOLYTICUS 
1396  1B0N Firmicutes BACILLUS SUBTILIS 
    1404  2B6N Proteobacteria SERRATIA SP. 
1404  1V6C Proteobacteria PSEUDOALTEROMONAS SP. ASProteobacteria1 
1404  1S2N Proteobacteria VIBRIO SP. PA-44 
1404  3TEC Firmicutes HIRUDINARIA MANILLENSIS 
1404  2SIC Firmicutes BACILLUS AMYLOLIQUEFACIENS 
1404  2IXT Firmicutes BACILLUS SPHAERICUS 
1404  1YU6 Firmicutes MELEAGRIS GALLOPAVO 
1404  1XF1 Firmicutes STREPTOCOCCUS PYOGENES 
1404  1V5I Firmicutes PLEUROTUS OSTREATUS 
1404  1TEC Firmicutes THERMOACTINOMYCES VULGARIS 
1404  1SEL Firmicutes BACILLUS SUBTILIS 
1404  1SBN Firmicutes HIRUDO MEDICINALIS 
1404  1MEE Firmicutes BACILLUS PUMILUS 
1404  1IAV Firmicutes BACILLUS LENTUS 
1404  1DBI Firmicutes BACILLUS SP. 
1404  1BH6 Firmicutes BACILLUS LICHENIFORMIS 
    1733  2F2E Proteobacteria PSEUDOMONAS AERUGINOSA 
1733  1YYV Proteobacteria SALMONELLA TYPHIMURIUM 
1733  2HZT Firmicutes BACILLUS SUBTILIS 
1733  1Z7U Firmicutes ENTEROCOCCUS FAECALIS V583 
    1846  2FBH Proteobacteria PSEUDOMONAS AERUGINOSA 
1846  2FA5 Proteobacteria XANTHOMONAS CAMPESTRIS 
1846  1JGS Proteobacteria ESCHERICHIA COLI 
1846 
 
2QWW Firmicutes LISTERIA MONOCYTOGENES STR. 4B F2365 
1846  2BV6 Firmicutes STAPHYLOCOCCUS AUREUS 
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1846  1Z91 Firmicutes BACILLUS SUBTILIS 
1846  1LJ9 Firmicutes ENTEROCOCCUS FAECALIS 
    2159  2HBV Proteobacteria PSEUDOMONAS FLUORESCENS 
2159  2DVT Proteobacteria RHIZOBIUM SP. 
2159  2QPX Firmicutes LACTOBACILLUS CASEI ATCC 334 
2159  2F6K Firmicutes LACTOBACILLUS PLANTARUM 
    2367  1N4O Proteobacteria XANTHOMONAS MALTOPHILIA 
2367  1JTG Proteobacteria STREPTOMYCES CLAVULIGERUS 
2367  1JTD Proteobacteria STREPTOMYCES EXFOLIATUS 
2367  1HZO Proteobacteria PROTEUS VULGARIS 
2367  1HTZ Proteobacteria KLEBSIELLA PNEUMONIAE 
2367  1G68 Proteobacteria PSEUDOMONAS AERUGINOSA 
2367  1FQG Proteobacteria ESCHERICHIA COLI 
2367  1DY6 Proteobacteria SERRATIA MARCESCENS 
2367  1BUE Proteobacteria ENTEROBACTER CLOACAE 
2367  1KGG Firmicutes STAPHYLOCOCCUS AUREUS 
2367  1I2S Firmicutes BACILLUS LICHENIFORMIS 
    2730  1TVN Proteobacteria PSEUDOALTEROMONAS HALOPLANKTIS 
2730  1EGZ Proteobacteria ERWINIA CHRYSANTHEMI 
2730  2JEP Firmicutes PAENIBACILLUS PABULI 
2730  1QHZ Firmicutes BACILLUS AGARADHAERENS 
2730  1LF1 Firmicutes BACILLUS SUBTILIS 
2730  1G01 Firmicutes BACILLUS SP. 
    Starburst 
  COG PDB Phylum Source 
3693  2CNC Proteobacteria CELLVIBRIO MIXTUS 
3693  1US3 Proteobacteria CELLVIBRIO JAPONICUS 
3693  1E5N Proteobacteria PSEUDOMONAS FLUORESCENS 
3693  2F8Q Firmicutes BACILLUS SP. NG-27 
3693  2DEP Firmicutes CLOSTRIDIUM STERCORARIUM 
3693  1R85 Firmicutes BACILLUS STEAROTHERMOPHILUS 
    4948  2QDE Proteobacteria AZOARCUS SP. EBN1 
4948  2PPG Proteobacteria SINORHIZOBIUM MELILOTI 
4948  2PMQ Proteobacteria ROSEOVARIUS SP. HTCC2601 
4948  2PGE Proteobacteria DESULFOTALEA PSYCHROPHILA LSV54 
4948  2PCE Proteobacteria ROSEOVARIUS NUBINHIBENS ISM 
4948  2OZ8 Proteobacteria MESORHIZOBIUM LOTI 
4948  2OZ3 Proteobacteria AZOTOBACTER VINELANDII AVOP 
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4948  2OX4 Proteobacteria ZYMOMONAS MOBILIS 
4948  2OO6 Proteobacteria BURKHOLDERIA XENOVORANS 
4948  2OG9 Proteobacteria POLAROMONAS SP. JS666 
4948  2NQL Proteobacteria AGROBACTERIUM TUMEFACIENS 
4948  2HZG Proteobacteria RHODOBACTER SPHAEROIDES 
4948  2GSH Proteobacteria SALMONELLA TYPHIMURIUM 
4948  2DW6 Proteobacteria BRADYRHIZOBIUM JAPONICUM 
4948  1YEY Proteobacteria XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS 
4948  1NU5 Proteobacteria PSEUDOMONAS SP. 
4948  1MUC Proteobacteria PSEUDOMONAS PUTIDA 
4948  1EC7 Proteobacteria ESCHERICHIA COLI 
4948  1CHR Proteobacteria RALSTONIA EUTROPHA 
4948  2P88 Firmicutes BACILLUS CEREUS ATCC 14579 
4948  2OQY Firmicutes OCEANOBACILLUS IHEYENSIS 
4948  2OKT Firmicutes STAPHYLOCOCCUS AUREUS 
4948  2GGE Firmicutes BACILLUS SUBTILIS 
4948  2GDQ Firmicutes BACILLUS SUBTILIS SUBSP. SUBTILIS 
4948  1WUF Firmicutes LISTERIA INNOCUA CLIP11262 
4948  1WUE Firmicutes ENTEROCOCCUS FAECALIS 
4948  1JPM Firmicutes BACILLUS SUBTILIS 
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Appendix 6B: The median E-value for each COG.  A median of 0 represents all proteins 
within the COG gave a perfect match to the PDB.   
 
COG Median E-value 
28 1E-175 
39 1E-121 
110 1E-74 
171 2.5E-147 
242 7E-90 
251 4.9E-66 
346 1E-56 
366 1E-138 
394 1.51E-80 
446 5E-96 
454 4E-72 
491 4.5E-26 
500 6E-136 
526 7E-55 
590 8E-78 
604 3.5E-113 
605 5E-91 
637 1E-120 
664 4E-16 
742 2.5E-89 
745 1E-61 
753 0 
778 1E-117 
784 2E-58 
796 7E-128 
813 4.5E-97 
1012 0 
1028 3E-66 
1052 1E-56 
1057 3.5E-109 
1075 1E-96 
1151 1.5E-147 
1309 5E-96 
1396 4E-58 
1404 1.35E-87 
1607 3.5E-72 
1733 3E-52 
1846 1E-69 
1940 4E-155 
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2124 2E-48 
2141 1.5E-58 
2159 1.5E-21 
2188 5.02E-84 
2367 2E-58 
2730 2.1E-59 
3693 2E-48 
3832 3.75E-50 
4948 1E-140 
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Appednix 6C: The complete Fractional Structure Similarity (FSS) compared to sequence 
identity prior to manual filtering.  As in figure 6.3, (A) is all vs. all comparisons, (B) is 
the comparisons of Proteobacteria structure against Proteobacteria structure, (C) is the 
Firmicutes against Firmicutes and (D) is the Proteobacteria against the Firmicutes.  As 
stated in the text above the comparisons between Proteobacteria and Firmicutes show an 
abrupt cutoff at about 65% sequence identity and 0.85 Fraction Structure Similarity.  
Outliers were shown to be comparisons of the same protein from the same organism 
solved under non-uniform conditions. The large density of structures a 100% sequence 
identity illustrates the propensity of solving structures redundantly from the same 
organism and the large spread of data shows the need for manual curation of the dataset 
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CHAPTER 7:  
 
A SEQUENCE AND STRUCTURE INDEPENDENT METHOD TO PREDICT 
PROTEIN FUNCTION 
 
7.1 INTRODUCTION 
The recent explosion in sequenced genomes has revealed a vast number of 
proteins that lack a functional annotation.
1
 Many of these unannotated proteins may play 
an important role in human disease and correspondingly, are critical for developing new 
therapeutics. Protein sequence and structure similarity methods are currently the most 
robust and widely-used tools to annotate a protein of unknown function.
2
 Nevertheless, 
these methods are limited in scope, prone to errors, and based on a small set of 
experimentally characterized proteins.
3
 Only 40 to 60% of sequences suggest a potential 
functional assignment. Moreover, error rates of < 30% occur even with conservative 
sequence identities of > 60%. The accuracy of functional annotations decreases 
substantially in the twilight zone of 20-35% sequence identity. 
Recent attempts to extend functional prediction beyond global sequence and 
structure similarity have led to the development of active-site similarity search methods.
4-
6
   These methods try to identify protein surface structures that interact with biologically 
important compounds or other proteins.  Protein active-sites that share similar sequence, 
structure and bind similar ligands are predicted to be functionally related.  While 
promising, current active-site similarity techniques still rely on high-resolution protein 
structures to identify and measure functional similarity.
7, 8
  The availability of structures 
for the entire proteome remains a significant bottleneck for high-throughput functional 
annotation of hypothetical proteins.  
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In the previous chapters, functional annotation of proteins was discussed in the 
presence of sequence, structure and active site information.  As shown in chapters 1,3 and 
4 these methods are powerful, but have  limitations that prevent complete annotation of a 
specific genome in a high-throughput manner.  Specifically, sequence similarity methods 
often fail below 30% sequence identity
9, 10
 and structure similarity or active site similarity 
methods require a high-resolution protein structure.  Additionally, functional similarity is 
not necessarily dependent on homology.  This can lead to similar sequences having 
different functions or significantly different sequences with similar functions.
9, 11
  The 
issues raised above suggest a new approach to function annotation that is independent of 
sequence or structure is needed.   
 Proteins interact with biological compounds to perform specific yet versatile 
functions.  Identifying and comparing which compounds bind a target protein provides an 
alternative method to predict function. In this chapter I discuss the development of a 
quantifiable and rapidly adaptable model for protein functional analysis using 
experimentally derived ligand binding profiles (LBP). This new approach is independent 
of sequence, structural or evolutionary information; therefore, extending the current 
analysis of novel genes and predicting ligand binding. A ligand binding profile is defined 
as a set of ligands that bind a protein from a high-throughput ligand affinity screen. The 
hypothesis is that proteins with similar function will bind a similar set of compounds 
from the same high-throughput screening library. A general functional similarity is 
identified by clustering proteins similar binding profiles. 
In this chapter, I discuss the theory behind the ligand binding profile method and 
report screening and similarity results from 19 proteins with a range of functions defined 
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by Gene Ontology (GO) terms.
12
 With the availability of GO terms, many studies relate 
functional similarity to protein-protein interactions,
13
 network prediction,
14
 prediction of 
cellular localization,
15
 pathway modeling,
16
 and improving the quality of microarray 
data.
17
 This chapter is the first attempt to relate ligand binding similarity to functional 
similarity.   
 
7.2 THEORY  
7.2.1 Development of a ligand binding profile scoring function. Measuring a 
significant similarity between two ligand binding profiles requires the development or 
adaptation of a robust scoring function. Current similarity scoring methods used for 
sequence analysis, such as the E-value developed by Karlin and Altschul,
18
 are also well-
suited for  measuring a similarity between ligand binding profiles.  
SKmneE                                                        [7.1] 
Here, the E-value is only dependent on the total number of compounds that bind 
each protein (m and n) and the total number of compounds that bind both proteins (S). 
Additionally, the probability of finding a significant similarity is proportional to the 
probability search space (K) and scoring function (λ).  
p
q
ln and
q
)pq(
K
2
                                             [7.2] 
Unlike sequence similarity, a similarity between ligand binding can be thought of 
as a binary system (binding vs. non-binding) therefore the probabilities p and q simply 
become the probability of finding a hit within a library:  
sizelibrary
1
p                                                         [7.3] 
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and the probability of finding a ligand that binds both proteins: 
S
q
mn
                                                              [7.4] 
The standard E-value also provides a robust measure of the probability. This 
shows a significant ligand binding similarity is not due to chance using the standard P-
value. 
Ee1P                                                              [7.5] 
As expected, the ligand binding profile E-value rapidly becomes non-significant 
(P > 0.0001) as the probability of finding a ligand that binds both proteins (q) decreases 
(figure 7.1). Binding profiles that have a P < 0.0001 are significant at the 99.99% 
confidence interval (~E=10
-5
).   
 
 
 
Figure 7.1. E-value response to the probability of finding overlapping ligands 
between two proteins.  A set of 33,207 randomly generated hypothetical binding profiles 
was generated to observe the response of the E-value similarity with probability of 
overlapping ligands (q=S/mn) as the probability of finding an overlapping ligand 
decreases the E-value rapidly becomes non-significant (E>1x10
-5
).  
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7.3 EXPERIMENTAL  
7.3.1 Hypothetical binding profiles. A set of hypothetical binding profiles was 
generated to test the E-value scoring method for the ligand binding profiles.  To generate 
the hypothetical binding profiles, an Excel program was written to generate random 
values for m, n and S for 100,000 hypothetical binding profiles.  The hypothetical library 
size was 437 compounds; random numbers were generated between 0 and 437.  The data 
set was filtered such that S ≤ m and S ≤ n giving 33,207 comparisons.  The data set was 
used to compare the E-value response to probablilty of finding an overlapping ligand 
(figure 7.1).   
7.3.2 Materials. The human serum albumin (HSA) (essentially fatty acid free, ≥ 
96 % pure), bovine serum albumin (BSA) (minimum 98% agarose gel electrophoresis, 
lyophilized), α-amylase from Bacillus lincheniformis (Bli) (500-1,500 units/mg protein, 
93-100% (SDS page)), α-amylase from Aspergillus oryzae (Aor) (powder, ~30 units/mg), 
α-amylase from Bacillus amyloliquefaciens (Bam) (liquid, ≥250 units/g protein), β-
amylase from barley (Hvu) (type II-B 20-80 units/mg protein), and β-amylase from sweet 
potato (Iba) (Type I-B, ammonium sulfate suspension, ≥750 units/mg protein) protein 
samples were all purchased from Sigma (St. Louis, MO). The S. typhimurium PrgI 
protein samples and assigned 2D 
1
H-
15
N HSQC spectrum were generously provided by 
Dr. Roberto DeGuzman (University of Kansas). Staphylococcus aureus primase C-
Terminal domain (CTD) protein sample was purchased from Nature Technologies 
Corporation (Lincoln, NE). H. sapiens diacylglycerol kinase alpha (DGKA), P. 
aeruginosa unannotated protein PA1324, S. aureus unannotated protein SAV1430, S. 
typhimurium unannotated protein STM1790, H. sapiens ubiquitin-fold modifier-
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conjugating enzyme 1 (UFC1), E. coli unannotated protein YjbR, E. coli unannotated 
protein YkfF, B. subtilis unannotated protein YkvR and E. coli unannotated protein YtfP 
protein samples were provided by Dr. Gaetano Montelione, Director of the Northeast 
Structural Genomics Consortium (NESG, www.nesg.org). The S. aureus nuclease was 
over-expressed in house from a cell stock of E. coli Bl21 DE3 codon+ (Stratagene) 
containing the pET28(a)+plasmid with the dnuc gene provided by Dr. Greg Somerville 
(University of Nebraska-Lincoln) grown in LB broth and purified using a Talon cobalt 
affinity resin (Clontech). The deuterium oxide (99.9% D) and the dimethyl sulfoxide-d6 
(99.9% D) were purchased from Aldrich (Milwaukee, WI) The 3-
(trimethylsilyl)propionic acid-2,2,3,3-d4 (TMS) was purchased from Cambridge Isotope 
(Andover, MA). The bis-Tris-d19 (98% D) was purchased from Isotec (Milwaukee, WI). 
The compound library was previously complied as described elsewhere 
19
 .  
7.3.2 Apparatus. All NMR data was collected on a Bruker 500 MHz Avance 
spectrometer (Billercia, MA) equipped with a triple resonance, Z-axis gradient cryoprobe 
and using a Bruker BACS-120 sample changer and IconNMR software for automated 
data collection. The screening data for this study was compiled over a 5 year time span in 
which two different 1D 
1
H solvent suppression pulse sequences were used for the 
measurement of ligand 1D 
1
H NMR line broadening.  High-throughput NMR screening 
spectra for the HSA, BSA, S. aureus primase CTD, PrgI, PA1324, and SAV1430 were 
collected at 298 K using 64 transients with a sweep-width of 6009 Hz with 8 K data 
points and a 2.0 s relaxation delay using the using a presaturation solvent suppression 
pulse sequence (chapter 3 & 5).
4, 20-22
 High-throughput NMR screening spectra for 
DGKA, STM1790, UFC1, YjbR, YkfF, YkvR and YtfP, the 5 amylases and S. aureus 
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nuclease proteins were collected at 298 K using 64 transients with a sweep-width of 6009 
Hz with 8 K data points and a 1.0 sec relaxation delay using the excitation sculpting
23
 
method for solvent suppression of the residual H2O resonance signal (chapter 4).  
7.3.3 Sample preparation.  All NMR ligand affinity assays were completed by 
screening each protein individually with a library of biologically active compounds.  The 
compound library is composed of 113 mixtures with 3-4 ligands per mixture and is 
described in detail elsewhere.
19
  The screens of HSA, BSA, S. aureus primase CTD, PrgI, 
PA1324, and SAV1430 were prepared as previously described.
4, 20-22
 S. aureus nuclease, 
DGKA, STM1790, UFC1, YjbR, YkfF, YkvR, YtfP, and the 5 amylases were screened at 
5 µM protein concentration and 100 µM ligand concentration in a screening buffer of 2% 
DMSO-d6, 20 mM Bis-Tris pH 7.0 (uncorrected), 11.1 M TMSP in “!00%”D2O. 
7.3.4 Binding assay. Ligand binding was identified by a decrease in free ligand 
signal upon the addition of protein.  The methods for data processing and identifying 
binding ligands have been previously discussed in detail in the previous chapters 2, 3, and 
4 and references.
4, 21, 24
  Briefly, data was Fourier transformed, auto-phase and baseline 
corrected. Each 1D 
1
H NMR spectrum were compared to the corresponding free ligand 
mixture reference spectrum and visually analyzed to identify binding ligands.  A binding 
event was identified by the decrease in ligand intensity of the nuclease-mixture relative to 
the free ligand mixture. 
7.3.5 Ligand binding profiles. A ligand binding profile score was measured for 
each protein comparison using equation 7.1.  Overlapping binding ligands (S) for every 
protein were identified in a pairwise manner for a total of 171 comparisons.  The 
probability of finding overlapping ligands between two proteins was calculated using eq  
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7.5 Each pairwise E-value was calculated using a library size of 437 compounds (with p 
= 1/437 = 0.00229).   
7.3.6 Functional similarity measurement. The Uniprot accession number was 
obtained for each protein in the study (http://www.uniprot.org/). The list of Uniprot 
accession numbers was uploaded to the semantic similarity tool FunSimMat.
25
 All 
reported functional similarities are expressed as the funsim score measured as described.
25
 
Briefly, the funsim score is measure of relative functional similarity between GO terms at 
the biological process and molecular function levels of the gene ontology. It ranges from 
0 for no functional similarity to 1 for maximal functional similarity  
 
Where, max(BPscore) and max(MFscore) denote the maximal similarity scores 
for biological process and molecular function, respectively.  The max(BPscore) and 
max(MFscore) scores for the funSim score is computed using simRel. simRel is a 
combination of Resnik's and Lin‟s measure of semantic similarity25-27 
 
Where, c1 and c2 are the semantic similarity terms of a protein, maxS(c1,c2) is 
the set of common terms, p(c) is the relative frequency of occurrence of a term.   
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7.4 RESULTS AND DISCUSSION  
7.4.1 Establishing a set of functionally diverse proteins.  Chapter 1 discussed 
the difficulties with non-uniform methods for functional annotation.  The Gene Ontology 
Annotation project
28, 29
 is becoming the standard representation for functional annotating 
of individual proteins.  The success of the GO method lies in the hierarchical approach to 
protein annotation.  Each protein or gene product is annotated with three levels of 
functional similarity, biological process, molecular function and cellular component.  
This approach annotates a specific GO number for each level of function which allows 
for development of computational functional similarity scoring methods. A number of 
methods have been developed to measure functional similarity with the majority of the 
methods based on semantic similarity of GO terms.
25, 26, 30-32
  In this study the functional 
similarity score from FunSimMat
25, 32
 was used to measure functional similarly between 
19 proteins with a range of functional similarity (appendix 7A).  FunSimMat is a 
composite average method for semantic similarity. The composite methods are generally 
more biologically accurate
33
  
For the 19 proteins screened in the NMR ligand affinity assay, 13 proteins have a 
previously annotated function based on GO terms and 6 proteins have an unknown 
function. As a positive control, two sets of functionally related proteins (2 serum 
albumins and 5 amylases) were evaluated. A functional similarity score between each 
pair of proteins was measured by the semantic similarity tool of GO annotations 
FunSimMat (table 7.1).
25
 The FunSimMat similarity for HSA and BSA was 0.98 and an 
average FunSimMat similarity score of 0.69 ± 0.01 was calculated for the amylases. The 
remaining 12 proteins exhibited no functional relationship to any other protein in the 
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screening set, yielding an average FunSimMat similarity score of 0.1 ± 0.1. A weak 
functional similarity was observed between the two albumins and the human protein 
ubiquitin-fold modifier-conjugating enzyme 1 (UFC1, Uniprot: Q9Y3C8). However, this 
similarity is limited to one overlapping and generic “protein binding” GO number 
(GO:0005515). 
7.4.2 High-throughput ligand screening of a set of functionally diverse 
proteins. To experimentally support the ligand binding profile hypothesis, 19 proteins 
were screened by NMR using a chemical library of biologically active compounds.
19
 
Binding events were identified as previously described by measuring a decrease in ligand 
1
H NMR peak intensities in the presence of a protein (figure 7.4).
4, 21
 As an example, 
figure 7.4 shows the relative responses in binding for HSA and BSA to the non-steroidal 
anti-inflammatory drug naproxen.  Naproxen was identified from a screen of the entire 
ligand library as a binder for both proteins.  The relative change in linewidth for naproxen 
binding HSA was comparable to naproxen binding BSA. The ligand binding profile 
method only uses the identification of binding ligands (hit vs. no hit) to compare 
functional similarities.  The binary mode of measuring ligand binding similarities makes 
the ligand binding profile a high-throughput method for functional annotation.  
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Table 7.1 A diverse set of proteins have been screened by 1D 
1
H NMR line broadening experiments (see methods 7.3.3).  The set of 
19 proteins is comprised of 2 sets of positive controls (set1=albumins, set2=amylases). Functional similarity between each protein was 
measured by the semantic similarity tool FunSimMat.
25
  The 6 unannotated proteins in the data were removed from the table for 
clarity; there was no measured functional similarity due to the lack of Gene Ontology
12
 annotations for the proteins.  The nuclease 
protein was also removed for clarity because there was no functional similarity to any protein in the dataset. 
 
HSA BSA Primase PrgI Aor-A Hvu-B Bam-A Bli-A Iba-B DGKA UFC1 
HSA 
 
0.98 0.07 0.28 0.05 0.02 0.04 0.04 0.03 0.23 0.49 
BSA 
  
0.07 0.28 0.05 0.03 0.04 0.04 0.04 0.25 0.49 
Primase 
   
- 0.2 0.15 0.19 0.19 0.17 0.24 0.15 
PrgI 
  
 
 
0 0 0 0 0 0 0 
Aor-A 
     
0.64 0.68 0.68 0.67 - - 
Hvu-B 
      
0.63 0.63 0.71 - - 
Bam-A 
       
0.68 0.63 - - 
Bli-A 
        
0.63 - - 
Iba-B 
         
0.07 0.22 
STM1790 
         
- - 
DGKA 
          
0.03 
YjbR 
          
- 
UFC1 
           
2
7
9
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Figure 7.4. Proteins with similar function bind similar ligands. Ligand binding is 
identified by a decrease in ligand peak intensity upon addition of a target protein. The 1D 
1
H NMR spectrum of the non-steroidal anti-inflammatory drug naproxen (I) is shown to 
broaden in the presence of H. sapiens serum albumin (HSA) (II) and B. taurus serum 
albumin (BSA) (III) indicating a positive binding event. The NMR line broadening 
experiments used 100 M ligand and 5 M protein as described in the methods section. 
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7.4.3 Ligand binding profiles for a set of functionally diverse proteins. An all-
vs-all pairwise comparison of the 19 proteins gave a total of 171 ligand binding profile 
comparisons with only 11 comparisons giving a significant similarity score (P < 0.0001). 
The comparisons with the highest similarity scores corresponded to the set of albumins 
(E-value 1x10
-58
) and the set of amylases (average E-value ~1x10
-11
). Table 7.2 lists all 
protein pairs with a significant ligand binding similarity score along with the 
corresponding FunSimMat functional similarity score. The complete list of ligand 
binding similarity scores (appendix 7A) shows an abrupt decrease in significance for the 
remaining proteins.  This correlates with the remaining proteins having no functional 
similarity to one another.  
As shown in table 7.2, human serum albumin (HSA) and bovine serum albumin 
(BSA) had a large number of binding ligands (178 and 171, respectively) compared to the 
overall size of the library. The relative hit rate for these two proteins was 40.7% and 
39.1%, respectively. With a large hit rate, false similarities may arise if a second protein 
serendipitously bound to a small subset of compounds that were shown to bind HSA or 
BSA. However, the ligand binding similarity score (eq 7.2) effectively eliminates this 
concern by scaling the score based on both the total number of compounds found to bind 
each protein and by the number of overlapping binding ligands. As an example, the S. 
typhimurium type III secretion system protein PrgI bound to a total of five compounds, 
where each compound was also shown to bind HSA and BSA. The corresponding E-
values for the ligand binding profile comparisons between PrgI and HSA (6.9 x 10
-2
) and 
BSA (6.4 x 10
-2
) were not significant. 
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Table 7.2 The number of hits per protein (m and n), overlapping ligands (S), E-values 
and functional similarity scores (FunSim) are reported for the significant ligand binding 
profiles at 99.99% confidence interval from a comparison of 19 proteins. The set of 
serum albumins from H. sapiens (HSA) and B. taurus (BSA) and amylases (Aor, Bam, 
Bli, Hvu, and Iba) gave significant similarity. The set of amylases was composed of 3 -
amylases from A. oryzae (Aor), B. amyloliquefaciens (Bam), and B. licheniformis (Bli) 
and 2 -amylases H. vulgare (Hvu) and I. batatas (Iba). A complete list of binding 
profiles is reported in the appendix 7A.  
Comparison m/n S E-value Funsim Score 
HSA-BSA 178/171 162 2.16X10
-58
 0.98 
Bam-Aor 35/36 22 6.38X10
-19
 0.68 
Bam -Hvu 35/29 14 1.17X10
-10
 0.63 
Bli- Aor 28/36 18 1.19X10
-15
 0.68 
Bli - Bam 28/35 16 1.42X10
-14
 0.68 
Bli - Hvu 28/29 9 3.86X10
-06
 0.63 
Hvu - Aor 29/36 13 2.98X10
-08
 0.64 
Iba- Aor 29/36 12 2.98X10
-08
 0.67 
Iba - Bam 29/35 15 7.56X10
-12
 0.63 
Iba - Bli 29/28 11 2.43X10
-08
 0.63 
Iba - Hvu 29/29 12 2.45X10
-09
 0.71 
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There was an observed similarity in ligand binding profiles between S. aureus 
nuclease and the -amylases from A. oryzae and B. amyloliquefaciens. However, the 
similarity in the ligand binding profiles was limited to the nucleosides in the library. 
Additionally, the remaining 3 amylases did not bind these ligands or exhibit a significant 
ligand binding similarity to nuclease. The observed ligand binding similarity between the 
nuclease and two of the -amylases is potentially due to trace amounts of a nuclease that 
may be present in the A. oryzae and B. amyloliquefaciens -amylases samples. This is a 
likely occurrence since the samples were purchased as crude mixtures, where size-
exclusion chromatography only yielded a modest improvement in purity. 
   The ligand binding profiles for all 19 proteins is represented as a heat map in 
figure 7.5.  Each binding ligand was colored red while each non-binding ligand was 
colored white.  The heat map shows the overall clustering patterns for each binding 
profile.  The heat map correlates well with table 7.2 showing that functionally similar 
proteins bind a consensus set of ligands from a standardized library of compounds. 
Ligands that are not included in the consensus set could either be due to non-specific 
binding, differences between sample preparation, or potentially unique and specific 
binders.    
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Figure 7.5 Heat map summarizing the NMR ligand affinity screens. For 19 proteins: 
H. sapiens serum albumin (HSA), B. taurus serum albumin (BSA), A. oryzae -amylase 
(Aor), B. amyloliquefaciens -amylase (Bam), B. licheniformis amyloliquefaciens -
amylase (Bli), I. batatas -amylase (Iba), H. vulgare -amylase (Hvu), S. aureus 
nuclease, S. aureus primase C-terminal domain, S. typhimurium type III secretion system 
protein (PrgI), S. aureus unannotated protein SAV1430,  E. coli unannotated protein 
YtfP, P. aeruginosa unannotated protein PA1324, B. subtilis unannotated protein YkvR, 
E. coli unannotated protein YkfF, S. typhimurium  unannotated protein STM1790, H. 
sapiens diacylglycerol kinase alpha (DGKA), E. coli unannotated protein YjbR, H. 
sapiens ubiquitin-fold modifier-conjugating enzyme 1 (UFC1), where the albumins are 
colored red, the amylases cyan and the remainder of the proteins grey. A binding ligand 
is indicated by a red line. The 437 ligands were sorted to maximize the clustering of 
binding ligands for the albumins and amylases. 
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 7.4.4 Future developments to the ligand binding profile method.  Ligand 
binding profiles are independent of sequence and structural information and thus provide 
an experimental-based approach to predict protein function in a relatively robust and 
high-throughput fashion. The results reported herein demonstrate a clear correlation 
between ligand binding similarity scores and FunSimMat functional similarity scores. 
Specifically, only the set of albumins and amylases gave significant ligand binding 
similarity scores. Unfortunately, the ligand binding profile method was unable to 
differentiate between the  and  amylase families. A further refinement of the functional 
annotation would require a second screening step using a focused library to differentiate 
these functional classes. In the case of the amylases, this would involve screening the 
proteins with a carbohydrate library, where a subset of the compounds would selectively 
bind to the - or -amylase proteins.  
The success of the ligand binding profile approach to annotate a protein depends 
on a functionally diverse and modestly sized chemical library that differentiates between 
various functional classes. Importantly, the methodology used to identify binding ligands 
must efficiently eliminate non-specific or irrelevant interactions. This is not the case with 
traditional high-throughput screening (HTS) methods that encounter significant false-
positive and false-negative rates. Applying the ligand binding profile technique to HTS 
data sets from the High Throughput Screening Laboratory at the University of Kansas 
were unsuccessful. Alternatively, NMR ligand-affinity screens provide a direct 
observation of a specific interaction between the ligand and protein. As demonstrated, the 
preponderance of binding ligands identified from the 19 NMR ligand affinity screens was 
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uniquely associated with each functional class and were shown to correlate with the 
protein‟s GO terms.    
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Appendix 7A Complete list of ligand binding profile scores, - marks indicate no 
overlapping binding ligands 
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CHAPTER 8: 
 
 CONCLUSIONS 
 
8.1 SUMMARY OF WORK 
 Protein science has always had a long history intertwined with the advancements 
in chemistry, biology and physics.  Today, with nearly 1350 complete genome sequences 
available, our understanding of biology at the molecular level has never been more 
complete.  While our understanding of biology continues to grow exponentially, we are 
still at the beginning of having a truly systematic understanding of Mother Nature‟s most 
fundamental secrets. This is most evident by the large functionally unannotated segments 
of each organism‟s genome.   
The genes (and proteins they encode) found in these functionally unannotated 
regions are considered “hypothetical proteins”. Current estimates suggest between 12%-
50% of the known gene sequences belong to unannotated proteins.
1-3
 This is true even for 
the most highly studied model organisms Escherichia coli. An estimated 50% of the 
genes found in the E. coli genome have no experimental annotation.
4, 5
  Considering the 
large degree of biodiversity, it was initially suggested that hypothetical proteins were 
adaptations to specific environmental niches and therefore species specific.
6, 7
  However, 
many hypothetical proteins are not species-specific and homologous sequences are found 
in a range of phylogenetic distributions. These evolutionary “conserved hypothetical 
proteins” significantly limits our understanding of biology.8   
From a pragmatic viewpoint, identifying the functions of these proteins could lead 
to new therapeutics; making functional annotation of paramount importance. Considering 
the large number of unannotated proteins (~1.5 million), the most popular tools for 
functional annotation rely on homology transfer of sequences and structures to 
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automatically predict protein function.  However, sequence and structure homology does 
not always imply functional conservation and these automatic methods often lead to 
spurious annotations.  Estimates in the error rates suggested nearly 30% of all automatic 
functional annotations of enzymes are incorrect.
9
  Differences in protein active site 
structures leading to different ligand specificities and enzyme efficiencies are suspected 
to be a major source of errors in automatic functional annotations.
9-11
   
 The large error rate of automatic functional annotation methods strongly supports 
the need for developing new methods that are independent of homology transfer.  In this 
dissertation I thoroughly tested the hypothesis of using ligand-defined active sites for 
functional annotation. In chapter 2, I discussed the theory and experimental validation of 
a method to measure single point binding dissociation constants (KD) from 1D 
1
H NMR. 
The primary goal of the project was to develop a method that would be robust for a broad 
functional library of compounds to a variety of biological target molecules.  The method 
was intended as a qualitative screening tool to provide accurate ranking of target 
molecules for both drug discovery and functional annotation using the Functional 
Annotation Screening Technology by NMR (FAST-NMR) method.  
In chapter 3 I used this single point KD method in concert with the FAST-NMR 
method to select the best binding ligand to the type three-secretion system protein PrgI 
(didecyldimethylammonium bromide, DDAB).  Didecyldimethylammonium bromide 
was identified from a compound library using 1D 
1
H NMR screening techniques and 
used to identify the active site of PrgI. Finding the active site of PrgI facilitated the 
identification of a functional similarity between PrgI and Bcl-xL using the Comparison of 
Protein Active Site Similarities (CPASS) database.
12
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The results from the FAST-NMR screen of S. aureus nuclease in chapter 4 
confirmed the use of NMR screening to identify a protein active site and the use of active 
site similarities to identify protein functional similarities. Additionally, the successful 
identification of a ligand bound S. aureus nuclease structure having the best active site 
similarity validated CPASS and using active site similarity as a functional annotation 
tool.  Finally, the optimization of the initial version of the NMR screening techniques 
utilized by FAST-NMR significantly improved the efficiency of the high-throughput 
screen.  
The rapid rise in community acquired antibiotic resistance, particularly to S. 
aureus, requires the rapid identification of new antibiotic targets and potential drugs.
13
   
The interaction between bacterial primase C-terminal domain and replicative helicase N-
terminal domain is an attractive antibiotic target because it is functionally conserved in 
bacteria, essential for DNA replication and distinctly different from eukaryotes.
14, 15
  
Additionally, the high degree of sequence variability and differences in structure suggest 
a possible means to tailor antibiotic development to a specific organism. In chapter 5, I 
reported the NMR solution structure of S. aureus primase CTD.  I use the structure to 
show a strong phylum dependency for primase CTD structure similarity and reported a 
potential drug lead for further antibiotic development.    
In chapter 6, I expanded upon the work of phylum dependent structure similarity 
by thoroughly analyzing functionally conserved, orthologous structures..  I quantify a 
maximum structure/sequence similarity between the two bacterial phyla, Proteobacteria 
and Firmicutes, and discussed the viability of phylogeny as a suitable constraint for 
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selecting a homology model.  This was supported by showing protein folds are not 
uniformly sensitive changes in sequence.     
The problems with automatic functional annotation were thoroughly discussed in 
this dissertation.  The development of the FAST-NMR method is a significant 
advancement towards high-throughput functional annotation but is limited by the 
availability of a high-resolution protein structure. In chapter 7, I discussed the 
development the ligand binding profile (LBP) method for functional annotation.  A 
ligand binding profile is defined as a set of ligands that bind a protein from a high-
throughput ligand affinity screen. The hypothesis was proteins with similar function will 
bind a similar set of compounds from the same high-throughput screening library. I tested 
the method on a set of 19 proteins with a range of functions and reported only proteins 
with high degree of functional similarity gave significant LBP scores. The ligand binding 
profile method is independent of sequence, structure or evolutionary information and 
therefore not limited by the issues of automatic functional annotation discussed in this 
dissertation.   
 As a final thought, the ligand binding profile is not dependent on screening 
method or chemical library (provided binding profiles are generated from the same 
chemical library). This opens the door for virtual screening methods to identify binding 
ligands and compare ligand binding profiles.  Virtual screens significantly reduce the 
time scale of ligand screening relative to experimental based approaches. The continual 
advancements in virtual screening coupled with the ligand binding profile will help make 
high-throughput functional annotation a reality.  
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